 
Study Title  Multi -center, Randomized, Parallel, Adaptive, 
Controlled Trial in Adult and Pediatric Patients 
with Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at 
Home  
 
NCT Number  [STUDY_ID_REMOVED]  
Document Description  Clinical Investigation  Plan  (Version H) 
Document Date  01-FEB-2024 
 

&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 1 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

&OLQLFDO,QYHVWLJDWLRQ3ODQ 
&OLQLFDO,QYHVWLJDWLRQ3ODQ6WXG\7LWOH Multi-center, Randomized, Parallel, Adaptive, Controlled 
Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home  
&OLQLFDO,QYHVWLJDWLRQ3ODQ,GHQWLILHU CEP304DOC  
6WXG\3URGXFW1DPH xMiniMed¬Æ 670G Pump labeled as MiniMed Insulin 
Pump - referred to as MiniMed Pump throughout the protocol 
xMiniMed 770G Pump labeled as MiniMed Insulin 
Pump - referred to as MiniMed Pump throughout the protocol 
xGuardian
¬ÆLink (3) Transmitter  
xMiniMed Mobile Application referred to as the Mobile 
App in the protocol  
xCareLink Connect Application  
xTransmitter Charger  
xCONTOUR¬Æ NEXT LINK 2.4 by Ascencia Blood Glucose 
Meter  - referred to as the Study Meter throughout this protocol) 
xRoche Accu-Chek Guide Link Meter  -referred to as the 
Accu-Chek Guide Link study meter in this protocol 
xGuardian
¬ÆSensor (3), referred to as Guardian Sensor 
(3) throughout this protocol 
xOne-Press Serter  -referred to as the Serter 
throughout the protocol 
xTester  
6SRQVRU/RFDO6SRQVRUUSA: 
 
Medtronic MiniMe d (‚ÄúMedtronic‚Äù) 
18000 Devonshire St 
Northridge, CA 91325
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 2 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
866.948.6633 
 
Europe: 
  
Medtronic International Trading Sarl. (‚ÄúMedtronic‚Äù)  Route du Molliau 31 Case Postale 
1131 Tolochenaz 
Switzerland (+41) 21 803 80 84 Canada: Medtronic Canada ULC.  99 Hereford St. Brampton, Ontario, Canada  L6Y 0R3 
905 460 37211 
 Australia: 
  
Medtronic Australasia Pty. Ltd 2 Alma Road Macquarie Park, NSW 2113 
Australia 
(+61) 2 9857 9000  New Zealand: 
 
Medtronic New Zealand Limited 
Level 3, Bldg 5, 666 Great South Road 
Penrose, Auckland 1051 
New Zealand 
(+64) 9 9674600
'RFXPHQW9HUVLRQ CEP304DOC, version H (Equivalent to Version H.1)  
9HUVLRQ'DWH )HE  
&RQILGHQWLDOLW\6WDWHPHQW
The information contained in this document is confidential and the proprietary property of Medtronic. Any 
distribution, copying, or disclosure without the prior written authorization of Medtronic is strictly prohibited. 
Persons to whom the information is disclosed must know that it is confidential and that it may not be further 
disclosed by them. PI
PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 3 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

,QYHVWLJDWRU$JUHHPHQWDQG6LJQDWXUH3DJH

6WXG\3URGXFW1DPHMiniMed 670G pump  
MiniMed 770G pump  
6SRQVRU Medtronic MiniMed
&OLQLFDO,QYHVWLJDWLRQ3ODQ,GHQWLILHU CEP304DOC
9HUVLRQ1XPEHU'DWH H/01-FEB-2024
I have read the protocol, including all appendices, and I agree  that it contains all necessary details for me 
and my staff to conduct this study as described. I will conduct  this study as outlined herein and will make a 
reasonable effort to complete the study within the time designa ted. 
I agree to comply with all applicable regulatory guidelines und er which the study is being conducted, i.e., 
International Conference on Harmonization Guidelines on Good Cl inical Practice (US only), United Stated 
Food and Drug Administration regulations (21 CFR Part 50, 21CFR  Part 56, 21 CFR 812, etc.) (US only), United 
Stated Food and Drug Administration regulations (21 CFR Part 54  and part 11) (US and Europe), Health 
Canada Regulations (SOR/98-282 ‚Äì Canada only), International Or ganization for Standardization (ISO 
14155:2011 ‚Äì Europe only). In Australia and New Zealand, the st udy will be carried out in conformity with 
the ethical principles of the Declaration of Helsinki, the requ irements of ISO14155:2011 and with all the 
other local laws and regulations relevant to the use of new and  approved medical devices in the country. 
I agree to ensure that the confidential information contained i n this document will not be used for any 
purpose other than the evaluation and conduct of the clinical i nvestigation without the prior written consent 
of Medtronic. 
I will provide all study personnel under my supervision copies of the protocol and access to all information 
provided by Medtronic. I will discuss this material with them t o ensure that they are fully informed about 
the products and the study.  
,QYHVWLJDWRU¬∂V6LJQDWXUH 
,QYHVWLJDWRU¬∂V1DPH 
,QVWLWXWLRQ 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 4 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
'DWH  
7DEOHRI&RQWHQWV
 ,QYHVWLJDWRU$JUHHPHQWDQG6LJQDWXUH3DJH   
 *ORVVDU\   
 6\QRSVLV   
 ,QWURGXFWLRQ   
 %DFNJURXQG   
 3XUSRVH   
 2EMHFWLYHVDQGRU(QGSRLQWV   
 2EMHFWLYHV   
  3ULPDU\2EMHFWLYHV   
 (QGSRLQWV¬±*HQHUDO&RQVLGHUDWLRQV    
  &R3ULPDU\(IIHFWLYHQHVV(QGSRLQWV   
  6HFRQGDU\(IIHFWLYHQHVV(QGSRLQWV   
  6DIHW\(QGSRLQW   
 'HVFULSWLYH&RPSDULVRQVRI,QWHUHVW   
 6WXG\'HVLJQ   
 'XUDWLRQ   
 5DWLRQDOH   
 3URGXFW'HVFULSWLRQ   
 *HQHUDO   
 ,QWHQGHG3RSXODWLRQ   
 1DPHVDQG,QWHQGHG8VHRI'HYLFHV   
 0LQL0HG*,QVXOLQ3XPS   
 0LQL0HG*,QVXOLQ3XPS   
 *XDUGLDQ¬ä6HQVRU   
 2QH3UHVV6HUWHU   
 *XDUGLDQ/LQN7UDQVPLWWHU   
 7UDQVPLWWHU&KDUJHU   
  7HVWHU   
  &217285¬ä1(;7/,1.E\$VFHQFLD5)(QDEOHG%ORRG*OXFRVH0HWHU   
  $FFX&KHN*XLGH/LQN%OXHWRRWK(QDEOHG0HWHUE\5RFKH   
 &DUH/LQN¬ä3HUVRQDO)RU&OLQLFDO5HVHDUFK6RIWZDUHDQG&DUH/LQN¬ä&OLQLFDO6RIWZDUH
  &DUH/LQN86%*+]   
  %OXH$GDSWHU   
  0HGWURQLF0RELOH$SSOLFDWLRQ   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 5 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
  &DUHOLQN&RQQHFW$SSOLFDWLRQ    
  .HWRQH0HWHU   
  ,QIXVLRQVHWV   
  5HVHUYRLUV   
  ,QIXVLRQ6HW6HUWHU'HYLFHV   
  ,QVXOLQ   
  6XSSOLHV   
  3DFNDJLQJ   
  3URGXFW7UDLQLQJ5HTXLUHPHQWV   
  3URGXFW5HFHLSWDQG7UDFNLQJ   
  'HYLFH'LVEXUVHPHQW   
  3URGXFW6WRUDJH   
  3URGXFW5HWXUQ   
  3URGXFW$FFRXQWDELOLW\    
 6HOHFWLRQRI6XEMHFWV 
 6WXG\3RSXODWLRQ   
 6XEMHFW(QUROOPHQW   
 ,QFOXVLRQ&ULWHULD   
 ([FOXVLRQ&ULWHULD   
 6WXG\6LWH5HTXLUHPHQWV   
 6WXG\6LWH$FWLYDWLRQ   
  6WXG\3URFHGXUHV   
  2YHUYLHZ   
  6FKHGXOHG)ROORZ8S9LVLW:LQGRZV    
  6FKHGXOHRI(YHQWV   
  'DWD&ROOHFWLRQ   
  6XEMHFW&RQVHQW   
  5DQGRPL]DWLRQDQG7UHDWPHQW$VVLJQPHQW    
 $VVHVVPHQWRI6DIHW\   
  $GYHUVH(YHQW   
  &DXVDOLW\$VVHVVPHQW   
  $QWLFLSDWHGRU8QDQWLFLSDWHG   
  5HFRUGLQJ'DWD   
  'HYLDWLRQ+DQGOLQJ   
  6XEMHFW([LW:LWKGUDZDORU'LVFRQWLQXDWLRQ   
  ,QYHVWLJDWLRQDO&HQWHU'LVTXDOLILFDWLRQ   
  6WRSSLQJ5XOHV   
  6XEMHFW6WRSSLQJ5XOHV   
  6WRSSLQJ5XOHVIRU(QWLUH6WXG\    
  6DIHW\6XFFHVV&ULWHULD    
  0HGLFDO2YHUVLJKW   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 6 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
  0HGLFDO6WDII   
  4XDOLILFDWLRQ    
  ([SHULHQFH    
 6DIHW\0RQLWRULQJ5LVN$QDO\VLV 
  *OXFRVH0RQLWRULQJ5LVN   
  +\SRJO\FHPLF+\SHUJO\FHPLF5LVN   
  &DOLEUDWLRQRI&*05LVN   
  5HXVH5LVN   
  6WHULOL]DWLRQ5LVN   
  0LVXVH5LVN   
  5LVNRI%ORRG6DPSOH&ROOHFWLRQ&RQWDPLQDWLRQ)URP6DPSOLQJ7H FKQLTXHV  
  $&5LVN   
  *OXFRVHDQG*O\FHPLD0HDVXUHPHQWV   
  *OXFRVHDQG*O\FHPL D0HDVXUHP HQWV   
  'DLO\%ORRG*OXFRVH   
  %ORRG.HWRQH9DOXHV   
  6HQVRU*OXFRVH9DOXHV   
  $&   
  5LVNVDQG%HQHILWV   
  3RWHQWLDO5LVNV    
  5LVN0LQLPL]DWLRQ    
  3RWHQWLDO%HQHILWV   
  5LVN%HQHILW5DWLRQDOH   
  3D\PHQWVIRU3DUWLFLSDQWV   
  $GYHUVH(YHQW$VVHVVPHQWV   
  'HILQLWLRQV&ODVVLILFDWLRQV   
  $GYHUVH(YHQW$(,6 2   
  $GYHUVH'HYLFH(IIHFW$'(,62   
 6HULRXV$GYHUVH(YHQW6$(,62   
 6HULRXV$GYHUVH'HYLFH(IIHFW6$'(,62 
  8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFW8$'(&)5V   
  8QDQWLFLSDWHG6HULRXV$GYHUVH'HYLFH(IIHFW86$'(,62   
  6LJQLILFDQW6DIHW\,VVXH66,$XVWUDOLD1+05&6DIHW\PRQLWRU LQJDQGUHSRUWLQJLQ
FOLQLFDOWULDOVLQYROYLQJWKHUDSHXWLFJRRGV1RYHPEHU   
  8UJHQW6DIHW\0HDVXUH860$XVWUDOLD1+05&6DIHW\PRQLWRULQJ DQGUHSRUWLQJLQ
FOLQLFDOWULDOVLQYROYLQJWKHUDSHXWLFJRRGV1RYHPEHU   
  5HSRUWLQJRI$GYHUVH(YHQWV   
  'DWD5HYLHZ&RPPLWWHHV   
  &OLQLFDO(YHQWV&RPPLWWHH   
  'DWD0RQLWRULQJ&RPPLWWHH   
  6WDWLVWLFDO'HVLJ QDQG0HWKRGV   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 7 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
  6WDWLVWLFDO0HWKRGVDQG'DWD$QDO\VLV   
  *HQHUDO$VSHFWVRI$QDO\VLV   
  (QGSRLQWVDQG+\SRWKHVHV   
  6DPSOH6L]H&RQVLGHUDWLRQV   
  5DQGRPL]DWLRQ   
  6WXG\3RSXODWLRQV   
  $QDO\VLVRI(QGSRLQWV   
  ,QWHULP$QDO\VLV   
  6XSSRUWLYH$QDO\VLVIRU3ULPDU\(IIHFWLYHQHVV(QGSRLQWV   
  .H\6HFRQGDU\(IIHFWLYHQHVV(QGSRLQWV    
  2WKHU6HFRQGDU\(IIHFW LYHQHVV(QGSRLQWV   
  &RGLQJRI$GYHUVH(YHQWV   
  6XEMHFW)HHGEDFN   
  (WKLFV   
  6WDWHPHQWVRI&RPSOLDQFH   
  'HYLFH'HILFLHQFLHVDQG7URXEOHVKRRWLQJ   
 6WXG\$GPLQLVWUDWLRQ 
  0RQLWRULQJ   
  'DWD0DQDJHPHQW   
  'DWD3UHSDUDWLRQ   
  6WXG\%LQGHUV    
  'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV   
  &RQILGHQWLDOLW\   
  /LDELOLW\   
  &,3$PHQGPHQWV    
  5HFRUG5HWHQWLRQ    
  3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ    
  6XVSHQVLRQRU(DUO\7HUPLQDWLRQ   
  6WXG\&ORVXUH3U RFHGXUHV   
  5HIHUHQFHV   
  $SSHQGLFHV   
  $SSHQGL[$&(3&RKRUW9LVLW7DEOH+&/$UP   
  $SSHQGL[%&(3&RKRUW9LVLW7DEOH&6,,$UP   
  $SSHQGL[&&(3&RKRUW9LVLW7DEOH0',$UP   
  $SSHQGL['&(3&RKRUW9LVLW7DEOH6$3$UP   
 9HUVLRQ+LVWRU\ 

 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 8 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
*ORVVDU\
Term Definition 
A1C Glycosylated hemoglobin  
AE Adverse Event  
ADE Adverse Device Effect  
ASIC  Application Specific Integrated Circuit  
BLE Bluetooth Low Energy 
BMI Body Mass Index  
CEC Clinical Events Committee
CFR Code of Federal Regulations  
CGM  Continuous Glucose Monitoring  
CGMS Continuous Glucose Monitoring System
CL Closed Loop  
CSII Continuous Subcutaneous Insulin Infusion  
CV Coefficient of Variation
DCCT  Diabetes Control and Complications Trial  
DKA  Diabetic Ketoacidosis  
DMC Data Monitoring Committee
eCRF  Electronic Case Report Form  
EC Ethics Committee  
EIS Electrochemical Impedance Spectroscopy  
ER Emergency Room  
EU MDR European Medical Device Regulation 
FDA United States Food and Drug Administration  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 9 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Term Definition 
FST Frequent Sample Testing  
GCRC  General Clinical Research Center  
hCG Human chorionic gonadotropin 
HCL Hybrid Closed Loop  
HCP Health Care Professional 
HFE Human Factors Engineer
HIPAA  Health Insurance Portability and Accountability Act of 1996  
ICF Informed Consent Form  
IDE Investigational Device Exemption
IFU Instructions for Use  
IRB Institutional Review Board  
IV Intravenous
JDRF  Juvenile Diabetes Research Foundation  
LSL Low Suspend Limit  
MAGE  Mean Amplitude of Glycemic Excursions  
MDD  Medical Device Directive  
MDI  Multiple Daily Injections  
MedDRA  Medical Dictionary for Regulatory Activities  
NDC  National Drug Code  
NGSP  National Glycohemoglobin Standardization Program  
OC-RDC  Oracle Clinical Remote Data Capture  
OLS Clinical Online Store  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 10 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Term Definition 
PC Personal Computer  
QC Quality Control  
RF Radio Frequency
SAE Serious Adverse Event  
SADE  Serious Adverse Device Effect  
SAP Sensor Augmented Pump
SG Sensor Glucose  
SGV Sensor Glucose Value  
SMBG Self-Monitoring of Blood Glucose
SR Significant Risk  
Tel-D  Telemetry-Diabetes 
TLS Transport Layer Security
TDD  Total Daily Dose  
TGA Therapeutic Goods Administration 
TS Technical Support 
TSH Thyroid-stimulating hormone  
UADE  Unanticipated Adverse Device Effect  
USADE Unanticipated Serious Adverse Device Effect 
 
¬© 2024 Medtronic. All rights reserved. Medtronic, Medtronic log o and Engineering the extraordinary are 
trademarks of Medtronic.  
‚Ñ¢*Third party brands are trademarks of their respective owners.  All other brands are trademarks of a 
Medtronic company. 
CGMS¬Æ, CareLink¬Æ, Guardian¬Æ, MiniLink¬Æ, MiniMed¬Æ, Paradigm¬Æ and Enlite¬Æ are registered or unregistered 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 11 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
trademarks of Medtronic 
Ascensia, the Ascensia Diabetes Care logo, and Contour are trad emarks and/or registered trademarks of 
Ascensia Diabetes Care.  
  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 12 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
6\QRSVLV
Title Multi-center, Randomized, Parallel, Adaptive Controlled Trial i n Adult and 
Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loo p System and 
Control (CSII, MDI and SAP) at Home  
Clinical Study Type Phase IV; Interventional  
Product Name Hybrid Closed Loop System   
Sponsor  Medtronic MiniMed  
Local Sponsor  
Medtronic MiniMed 18000 Devonshire St Northridge, CA 91325, USA 
 
  
Medtronic International Trading Sarl. (‚ÄúMedtronic‚Äù)  Route du Molliau 31 Case Postale 
1131 Tolochenaz, Switzerland 
 Medtronic Canada ULC 99 Hereford St. 
Brampton, Ontario, Canada L6Y 0R3 
  
Medtronic Australasia Pty. Ltd 2 Alma Road Macquarie Park, NSW 2113 
Australia PI
PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 13 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
(+61) 2 9857 9000 
 
 
Medtronic New Zealand Limited Level 3, Bldg 5, 666 Great South Road 
Penrose, Auckland 1051 
New Zealand (+64) 9 9674600 
Indication under 
investigation  Type 1 Diabetes  
Investigation Purpose The purpose of this study is to evaluate the safety and effecti veness of the 
Hybrid Closed Loop system (HCL) in adult and pediatric patients  with type 1 
diabetes in the home setting. A diverse population of patients with type 1 
diabetes will be studied. The study population will have a larg e range for 
duration of diabetes and glycemic control, as measured by glyco sylated 
hemoglobin (A1C). The following cohorts will be enrolled:  
1) Cohort 1: Continuous Subcutaneous Insulin Infusion (CSII) or  HCL;  
2) Cohort 2: Multiple Daily Injections (MDI) or HCL and  
3) Cohort 3: Sensor-Augmented Pump therapy (SAP) or HCL. 
Product Status Investigational Devices  
 
MiniMed 670G US only ‚Äì Subjects 2-6 years:   
RMiniMed 670G Pump labeled as MiniMed Insulin Pump (MMT-
1780), referred to as MiniMed Pump throughout the protocol 
RGuardian¬ÆLink (3) Transmitter (MMT-7811)
RGuardian¬ÆSensor (3) (MMT-7020), referred to as Guardian Sensor 
(3) throughout this protocol 
RCONTOUR¬Æ NEXT LINK 2.4 by Ascencia Blood Glucose Meter (MMT-
1152 or MMT-1352 in US) - referred to as the Study Meter PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 14 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
throughout this protocol) 
MiniMed 770G Australia ‚Äì Subjects 2-6 years: 
RMiniMed 770G Pump labeled as Min iMed Insulin Pump (MMT-1881, 
MMT-1891), referred to as MiniMed Pump throughout the protocol 
RGuardian¬Æ Link (3) Transmi tter (MMT-7910W5, MMT-7911W) 
RMiniMed Mobile Application (MMT-6103 Android/6104 IOS)- 
referred to as the Mobile App in  this protocol, Medical Device Data 
System exempt device 
RCareLink Connect Application (MMT-6113 Android/6114 IOS), 
Medical Device Data System exempt device 
RRoche Accu-Chek Guide Link Meter (Model 08116113186M) -
referred to as the Accu-Chek Guide Link study meter in this pro tocol 
RBlue adapter (ACC-1003911) 
RMedtronic CareLink¬Æ Clinical Software (MMT-7338)‚Äì referred to a s 
CareLink Clinical Medical Device Data System exempt device 
 
Non-Investigational/Exempt Devices  
MiniMed 670G US - Subjects 7 years and older:  
RMiniMed 670G Pump labeled as MiniMed Insulin Pump (MMT-
1780), referred to as MiniMed Pump throughout the protocol 
RGuardian¬ÆLink (3) Transmitter (MMT-7811)
RTransmitter Charger (MMT-7715) 
RCONTOUR¬Æ NEXT LINK 2.4 by Ascencia Blood Glucose Meter (MMT-
1152 or MMT-1352 in US) - referred to as the Study Meter 
throughout this protocol) 
RGuardian¬ÆSensor (3) (MMT-7020), referred to as Guardian Sensor 
(3) throughout this protocol 
RTester (MMT-7736L) 
RKetone Meter 
ROne-Press Serter (MMT-7512) -referred to as the Serter througho ut 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 15 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
the protocol 
RMedtronic CareLink¬Æ Personal Therapy Management Software for 
Diabetes (MMT-7333) -‚Äì referred to as CareLink Personal for Cli nical 
Research throughout this protocol; Class 1 exempt device  
 
 MiniMed 670G Europe - Subjects 7 years and older: 
RMiniMed 670G Pump* labeled as MiniMed Insulin Pump (MMT-
1781 or MMT-1782), referred to as MiniMed Pump throughout the 
protocol 
RGuardian¬ÆLink (3) Transmitter (MMT-7811)
RGuardian¬ÆSensor 3 (MMT-7020), referred to as Guardian Sensor (3) 
throughout this protocol
RKetone Meter  
RCONTOUR¬Æ NEXT LINK 2.4 by Ascencia Blood Glucose Meter (MMT-
1151 and MMT-1152) - referred to as the Study Meter throughout 
this protocol) 
RTransmitter Charger (MMT-7715) 
RTester (MMT-7736L)* 
RMedtronic CareLink¬ÆPersonal Therapy Management Software for 
Diabetes (MMT-7333) -‚Äì referred to as CareLink Personal for Cli nical 
Research throughout this protocol; CE Marked.  
ROne-Press Serter (MMT-7512)-referred to as the Serter throughou t 
the protocol 
 
MiniMed 670G Canada - Subjects 7 years and older: 
RMiniMed 670G Pump labeled as MiniMed Insulin Pump (MMT-1781 
(pump) and MMT-1762KCN (kit)) , referred to as MiniMed Pump throughout the protocol 
RGuardian
¬ÆLink (3) Transmitter (MMT-7811) 
RGuardian¬ÆSensor (3) (MMT-7020), referred to as Guardian Sensor 
(3) throughout this protocol 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 16 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
RCONTOUR¬Æ NEXT LINK 2.4 by Ascencia Blood Glucose Meter (MMT-
1151 and MMT-1152) - referred to as the Study Meter throughout this protocol)
RKetone Meter  
RMedtronic CareLink
¬Æ Personal Therapy Management Software for 
Diabetes (MMT-7333WW) -‚Äì referred to as CareLink Personal for 
Clinical Research throughout this protocol; Medical Device Data  
System exempt device 
ROne Press Serter (MMT-7512)- referred to as the Serter througho ut 
the protocol 
RTransmitter Charger (MMT-7715) 
RTester (MMT-7736L) 
 
MiniMed 670G All Geographies: 
RCareLink USB 2.4 GHz (MMT-7306)  
 
MiniMed 770G US Only ‚Äì Subjects 2 years and older: 
RMiniMed 770G Pump labeled as MiniMed Insulin Pump (MMT-1880, 
referred to as MiniMed Pump throughout the protocol 
RMiniMed Mobile Application (MMT-6103 Android/6104 IOS)- 
referred to as the Mobile App in this protocol, (when available ). 
RCareLink Connect Application (MMT-6113 Android/6114 IOS), (when  
available) 
RRoche Accu-Chek Guide Link Meter (Model 08116083022) -referred 
to as the Accu-Chek Guide Link study meter in this protocol 
RBlue adapter (ACC-1003911) 
RMedtronic CareLink¬Æ Clinical Software (MMT-7338) ‚Äì referred to as 
CareLink Clinical; Class 1 exempt device
 
MiniMed 770G Canada - Subjects 2 years and older: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 17 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
RMiniMed 770G Pump labeled as Min iMed Insulin Pump (MMT-1881, 
MMT-1891KCN and MMT-1891CRP (kit)), referred to as MiniMed Pump throughout the protocol
RGuardian
¬ÆLink (3) Transmitter (MMT-7911) 
RMiniMed Mobile Application (MMT-6103 Android/6104 IOS)- 
referred to as the Mobile App in this protocol, Medical Device Data 
System exempt device 
RCareLink Connect Application (MMT-6113 Android/6114 IOS), 
Medical Device Data System exempt device 
RRoche Accu-Chek Guide Link Meter (Model 08109222001) -referred 
to as the Accu-Chek Guide Link study meter in this protocol 
RBlue adapter (ACC-1003911)
RMedtronic CareLink¬Æ Clinical Software (MMT-7338)‚Äì referred to as 
CareLink Clinical Medical Device Data System exempt device 
 
MiniMed 770G Australia ‚Äì Subjects 7 years and older: 
RMiniMed 770G Pump labeled as MiniMed Insulin Pump (MMT-1881, 
MMT-1891), referred to as MiniMed Pump throughout the protocol 
RGuardian¬ÆLink (3) Transmitter (MMT-7910W5, MMT-7911W)
RMiniMed Mobile Application (MMT-6103 Android/6104 IOS)- 
referred to as the Mobile App in  this protocol, Medical Device Data 
System exempt device 
RCareLink Connect Application (MMT-6113 Android/6114 IOS), 
Medical Device Data System exempt device 
RRoche Accu-Chek Guide Link Meter (Model 08116113186M) -
referred to as the Accu-Chek Guide Link study meter in this pro tocol 
RBlue adapter (ACC-1003911) 
RMedtronic CareLink¬ÆClinical Software (MMT-7338)‚Äì referred to as 
CareLink Clinical Medical Device Data System exempt device 
 
MiniMed 770G New Zealand‚Äì Subjects 2 years and older: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 18 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
RMiniMed 770G Pump labeled as MiniMed Insulin Pump (MMT-1881, 
MMT-1891), referred to as MiniMed Pump throughout the protocol 
RGuardian¬ÆLink (3) Transmitter (MMT-7910W5, MMT-7911W)
RMiniMed Mobile Application (MMT-6103 Android/6104 IOS)- 
referred to as the Mobile App in  this protocol, Medical Device Data 
System exempt device 
RCareLink Connect Application (MMT-6113 Android/6114 IOS), 
Medical Device Data System exempt device 
RRoche Accu-Chek Guide Link Meter (Model 08116113186M) -
referred to as the Accu-Chek Guide Link study meter in this pro tocol
RBlue adapter (ACC-1003911) 
RMedtronic CareLink¬ÆClinical Software (MMT-7338)‚Äì referred to as 
CareLink Clinical Medical Device Data System exempt device 
Europe Classification of devices by Rules according to Medical Device Directive (MDD)xInfusion set: MDD, Annex IX, Rule 8, Class IIb  
xInsertion devices: MDD, Annex IX, Rule 12, Class I 
xReservoirs: MDD, Annex IX, Rule 2, Class IIa  
xInsulin Pump: MDD, Annex IX, Rule 11, Class IIb 
xTransmitter: MDD, Annex X, Rule 10, Class IIa 
xTransmitter Charger: MDD, Annex IX, Rule 1, Class I 
xSensor: MDD, Annex IX, Rule 8, Class III 
xGlucose Meter (Ascencia): In vitro diagnostic device, Annex II of the 
DIRECTIVE 98/79/EC, List B 
xBlood Glucose and Ketone Monitoring System: In vitro diagnostic  device, 
Annex II of the DIRECTIVE 98/79/EC, List B 
Europe Classification for Biocompatibility 
according to ISO EN 
10993-1  Table 1 and 2 (Type of Body xInfusion sets, Pump reservoirs: In compliance with ISO10993-1 a nd USP 
requirements for the use of insulin in the infusion sets. 
xInsulin Pump: In compliance with ISO10993-1 
xTransmitter: In compliance with ISO10993-1 
xSensor: In compliance with ISO10993-1 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 19 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
contact/duration) 
Europe Device 
Nomenclature: GMDN 
(Global Medical 
Device Nomenclature) xReservoirs: 35838, Ambulatory insulin infusion pump reservoir 
xInfusion sets: 35833, Infusion Pump Administration Set 
xInsulin Pump: 35983, Insulin Infusion Pump 
xTransmitter: 44611, Interstitial-Fluid Glucose Monitoring Syste m 
xSensor: 59016 Subcutaneous Glucose Sensor 
xTransmitter Charger: 44611 Interstitial-Fluid Glucose Monitorin g System  
xSerter: 45449, Injector Reset Device 
xBlood Glucose Meter: 30854 Glucose Meter Self-Testing 
Primary Objective(s) The purpose of this study is to evaluate the safety and effecti veness of the 
Hybrid Closed Loop system (HCL) in adult and pediatric patients  with type 1 
diabetes in the home setting.  
Study Design This is a 6 month, multi-center, randomized, parallel, adaptive  study in type 1 
diabetes with a 6 month continuation period. Up to 1500 subject s will be 
enrolled in order to have 1000 subjects who enter the study per iod. To date, 
959 subjects have enrolled. Up to 70 investigational Centers in  the US, Europe, 
Canada, Australia and New Zealand will be enrolled.  For additi onal information 
on investigational sites and investigators, refer to informatio n listed on public 
databases (e.g., clinicaltrials.gov). 
The study is anticipated to last no longer than 6.5 years from investigational 
center initiation to completion of all data entry and monitorin g procedures. The 
study will target 54 months to complete subject enrollment. Sub jects can expect 
to participate for approximately 7-8 months during the run-in p eriod and study 
period, with a 6 month continuation period. 
The study will have three periods per Cohort:  
1.Run-in Period: The run-in period can be up to 60 days.  
The run-in period will also be used for CGM data collection for  
approximately two weeks. Two consecutive 7-day sensors will be worn.  
If a sensor falls out, a replacement sensor should make up the 
difference for a total of 14 days of sensor wear (i.e. Monday D ay 1 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 20 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
through next Sunday Day 14) 
For example: If a sensor falls out on Day 4, a replacement sens or 
should be inserted.   Once that replacement sensor has been wor n 
for 7 days, a new sensor should then be inserted and worn for 3  
days so that a total of 14 days of sensor wear is completed.  
 
All patients will wear blinded CGM.  Subjects will be expected to 
demonstrate sensor wear for approximately 14 days total between  the 
two 7-day sensor wears (plus replacement sensor if needed). Sub jects 
should be instructed to make 4-6 BG measurements per day. Spons or 
may request a repeat of blinded CGM. Repeat of blinded CGM may 
occur if the following are not met: 
xA minimum of 12 days of sensor wear have been self-reported to 
research staff 
xA minimum of 2 blood glucose checks/day during the blinded CGM 
wear are confirmed on the subject‚Äôs study BG meter.  
If these requirements are not met then patient should repeat th e entire 
2 week blinded CGM data collection unless sponsor has approved that 
there was adequate data collection.   An additional 21 days may  be 
added to the run in visit window schedule if blinded CGM data c ollection 
needs to be repeated.  Additional visits may also be allowed if  needed.  
 
2.Study Period: There will be a 6 month randomized study period w ith 
two arms: HCL system and Control. CSII and MDI control groups w ill 
undergo two blinded CGM collections during the study period.  
The first blinded CGM data collection during the study period w ill occur 
before the month three (see visit schedule) for approximately t wo 
weeks.  Two consecutive 7-day sensors will be worn.  If a senso r falls 
out, a replacement sensor should make up the difference for a t otal of 
14 days of sensor wear.  (i.e. Monday Day 1 through next Sunday  Day 
14) 
For example: If a sensor falls out on Day 4, a replacement sens or 
should be inserted.   Once that replacement sensor has been wor n 
for 7 days, a new sensor should then be inserted and worn for 3  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 21 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
days so that a total of 14 days of sensor wear is completed.  
All patients will wear blinded CGM. Subjects will be expected t o 
demonstrate sensor wear for approximately 14 days total between  the 
two 7-day sensor wears (plus replacement sensor if needed). Sub jects 
should be instructed to make 4-6 BG measurements per day. Spons or 
may request a repeat of blinded CGM. The following should have 
occurred:   
xA minimum of 12 days of sensor wear have been self-reported to 
research staff 
xA minimum of 2 blood glucose checks/day during the blinded CGM 
wear are confirmed on the subject‚Äôs study BG meter.  
If the above requirements are not met then patient should repea t the 
entire 2 week blinded CGM data collection unless the sponsor ap proves 
that there was adequate data collection.    Additional visits m ay also be 
allowed if needed. No changes to the remaining visit schedule a re 
needed.   
The second blinded CGM data collection during the study period will 
occur before the month six (see visit schedule) for approximate ly two 
weeks.  Two consecutive 7-day sensors will be worn.  If a senso r falls 
out, a replacement sensor should make up the difference for a t otal of 
14 days of sensor wear. (i.e. Monday Day 1 through next Sunday Day 14) 
For example: If a sensor falls out on Day 4, a replacement sens or 
should be inserted.   Once that replacement sensor has been wor n 
for 7 days, a new sensor should then be inserted and worn for 3  
days so that a total of 14 days of sensor wear is completed.  
All patients will wear blinded CGM. Subjects will be expected t o 
demonstrate sensor wear for approximately 14 days total between  the 
two 7-day sensor wears (plus replacement sensor if needed). Sub jects 
should be instructed to make 4-6 BG measurements per day.  
 
3.Continuation Period: There will be a 6 month continuation perio d 
during which time all subjects will use the HCL system.   
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 22 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Enrollment Cohorts According to Treatment 
At Enrollment, subjects will be identified according to the typ e of treatment 
regimen they are currently on. Treatment regimen is defined as follows:
xCohort 1: CSII ‚Äì subjects using pump (Medtronic or other pump s ystems) 
for at least 3 months at time of screening without concurrent u se of real 
time CGM in the last 3 months. (Self-report acceptable.) Please  note 
that alternatives to SMBG such as Freestyle Libre are not consi dered 
real time CGM and subjects who are using Freestyle Libre at tim e of 
Screening will be allowed to enroll in the study. During the st udy, 
however, subjects will not be allowed to use Freestyle Libre. 
xCohort 2: Multiple Daily Injections (MDI) - Subjects using MDI with or 
without concurrent use of CGM for at least 3 months prior to Sc reening.  
(Self report is acceptable.)  
xCohort 3: Sensor Augmented Pump (SAP) ‚Äì subjects using pump for  at 
least 3 months at time of screening with real time CGM use (Med tronic 
or other CGM systems) approximately 20% of the time (Self repor t 
acceptable). Subjects will use the Medtronic CGM starting at Vi sit 3, but 
they may use their own CGM until then. Sensor insertion placeme nt will 
be according to User guide. 
Staged enrollment in the post approval study for Subjects 2-6 Y ears of Age: 
xSubjects 2-6 years of age will be allowed to enroll in the post  approval 
study, once DMC has reviewed data from 10 subjects age 2-4 year s who 
have completed participation in the study period of the CEP302 study 
and has given approval to enroll.   
In the US and Canada, subjects 2-80 years of age will be allowe d to transition 
from the 670G system to the 770G system.  
The Run-In Period: Following successful screening, all subjects  (CSII, MDI or SAP) 
will enter the run-in period and collect blinded CGM data while  using their own 
diabetes therapy. Blinded CGM consists of using a Guardian Sens or (3) 
connected to a Guardian Link (3) transmitter. A total period of  2 weeks of CGM 
data will be collected.  
Note: Subjects 2-6 years of age will automatically enter the HC L arm at the end 
of the run-in period 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 23 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
Cohort 1: CSII 
The Study Period: After completion of the run-in period, subjec ts with CSII 
therapy (minimum N= 280) will be randomized and placed into one  of 2 
different arms during the study period: 
1.The HCL Arm will use the MiniMed System (i.e., using Auto Mode)  for 6 
months during the study period. There will be N=140 for the HCL  arm. 
2.The Control Arm will use the MiniMed Pump without CGM 
a.Blinded CGM (Guardian Link (3) Transmitter and Guardian 
Sensor (3)) will only be worn at baseline, 3 months, and 6 
months (two weeks of sensors use). There will be N=140. 
 Cohort 2: MDI The Study Period: After completion of the run-in period, subjec ts with MDI 
therapy (minimum of N=280) will be randomized and placed into o ne of 2 
different arms during the study period: 
1.The HCL Arm will use the MiniMed system (i.e., using Auto Mode)  for 6 
months during the study period. There will be N=140 for the HCL  arm. 
2.The Control Arm will be using their current insulin therapy (MD I).  
The Multiple Daily Injection (MDI) subjects will remain on MDI therapy 
with subjects using their own insulin for 6 months during the s tudy 
period. The Sponsor will not provide insulin. Blinded CGM (Guar dian 
Link (3) Transmitter and Guardian Sensor (3)) will only be worn  at 
baseline, 3 months and 6 months (two weeks of sensors use). The re 
will be N=140. 
MDI subjects who are currently using CGM, i.e. Dexcom or Medtro nic 
Guardian Connect or who are currently using a SMBG alternative,  i.e. 
Libre, will be allowed to enroll in the study and continue usin g their 
own device. There will be N=100 
 
Cohort 3: SAP The Study Period: After completion of the run-in period, subjec ts with SAP 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 24 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
therapy (minimum N=280) will be randomized and placed into one of 2 different 
arms during the study period.  Sensor insertion placement will be according to 
User guide: 
1.The HCL Arm will use the MiniMed system (i.e., using Auto Mode)  for 6 
months during the study period. There will be N=140 for the HCL  arm. 
2.The Control Arm will be using SAP therapy using the MiniMed Sys tem. 
a.The Sensor Augmented Pump (SAP) subjects will use the 
MiniMed System (SAP without Low Management Suspend on Low, Low Management Suspend before low or Auto Mode) with Real Time CGM for the 6 month study period. There will be 
N=140.  
 
The Continuation Period:  All subjects above will enter the continuation period 
for 6 months using the MiniMed system with Auto Mode on.    

&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 25 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 Figure 1.  Study Design 
Cohort1(CSII)
Run-In Period Study  Period Continuation  Period
Screening and 2 weeks of 
blinded CGMRandomizationTreatment (HCL)
Control (CSII)Treatment (HCL) End of Study
Cohort2(MDI)
Run-In Period Study  Period Continuation  Period
Screening and 2 weeks of 
blinded CGMRandomizationTreatment (HCL) Treatment (HCL) End of Study
Cohort3(SAP)
Run-In Period Study  Period Continuation  Period
Screening and 2 weeks of 
blinded CGMRandomizationTreatment (HCL)
Control (SAP)Treatment (HCL) End of StudyControl (MDI) 
 
Subjects may be re-tested as per sponsor discretion.  Per Cohort  (CSII, MDI or SAP ), here are the numbers of subjects expected  to 
enroll: 
xA1C at time of screening:
RN = 70 A1C > 8% for HCL Arm  
RE—Åœ≥œ¨œ≠—áœ¥–πƒ®≈Ω∆å,>∆å≈µ  
RN = 70 A1C > 8% for Control Arm 
RE—Åœ≥œ¨œ≠—áœ¥–πƒ®≈Ω∆å≈Ω≈∂∆ö∆å≈Ω≈Ø∆å≈µ  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 26 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xAge at time of screening:  
N=Minimum number of eligible 
subjects for each age group within 
each treatment cohort N= Minimum number 
of eligible Subjects for each age group and cohort  N= Minimum 
number of eligible 
subjects for 
each age group for study 
Age Group Cohor
t N N N 
2-6 years CSII  
No Minimum No minimum N =120 SAP 
MDI 
7 -13 years CSII 
No Minimum  No minimum N=180 SAP 
MDI 
14-21 
years CSII 
SAP MDI N=45 N=45 N=135 
22-64 
years CSII 
SAP MDI N=120 N=120 N=360 
65-80 
years CSII 
No Minimum   No minimum N=150 SAP 
MDI 
 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 27 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Randomization Table 1. Randomization  
Treatment at 
Baseline Randomization Options Continuation 
CSII CSII 
HCL 
HCL 
MDI MDI 
HCL 
HCL 
SAP SAP 
HCL 
HCL 
Note: Subjects 2-6 years of age will automatically enter the HC L arm at the end 
of the run-in period 
   
 
 
 
  
 
 
  
 
 
 
 
 
  
 
  
  

  
  PI PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 28 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
   
   
  
 
 
Inclusion/
Exclusion Criteria  Inclusion Criteria:
Subjects will be considered for enrollment in the study if they  meet all of the 
following criteria: 
1.Subject is age 2-80 years at time of screening  
a.US, Canada, Australia and New Zealand: Subjects 2-80 years of a ge 
will be allowed to enroll in the post approval study.  
b.Europe: Only s ∆µƒè≈©ƒûƒê∆ö∆ê—àœ≥«áƒûƒÇ∆å∆ê≈Ωƒ®ƒÇ≈êƒûƒÇ∆åƒûƒÇ≈Ø≈Ø≈Ω«Åƒûƒö∆ö≈Ωƒû≈∂∆å≈Ω≈Ø≈Ø≈ù≈∂∆ö≈öƒû
post-market study. 
2.Subjects who are 2-21 years are determined by the investigator to have the 
appropriate, requisite support (family, caregiver or social net work) to 
successfully participate in this study 
3.Subject must have a minimum daily insulin requirement (Total Da ily Dose) of 
equal to or greater than 8 units/day  
4.Subjects who are determined by the investigator to be psycholog ically sound 
in order to successfully participate in this study 
5.Subject has been diagnosed with type 1 diabetes for at least th ree months   
Note: Determination of classification for diabetes will be base d on 
American Diabetes Association Clinical Practice Guidelines acco unting 
for several patient characterist ics such as:  age of onset, pat ient‚Äôs 
weight or BMI, history of diabetic ketoacidosis, history of the rapy 
management, if available in the medical records.   
6.Subject must be on one of the following management therapies:  
a.Multiple daily injections defined by use of rapid analogue with  meals 
and approved long acting analogue (e.g. detemir or glargine) wi th or 
without CGM 
b.Insulin pump therapy with or without CGM 
7.^∆µƒè≈©ƒûƒê∆ö≈ù∆ê«Å≈ù≈Ø≈Ø≈ù≈∂≈ê∆ö≈Ω∆âƒû∆åƒ®≈Ω∆å≈µ—àœ∞ƒ®≈ù≈∂≈êƒû∆å∆ê∆ö≈ùƒê≈¨ƒè≈Ø≈Ω≈Ωƒö≈ê≈Ø∆µƒê≈Ω∆êƒû≈µƒû ƒÇ∆ê∆µ∆åƒû≈µƒû≈∂∆ö∆ê
daily  PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 29 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
8.Subject is willing to perform required study procedures 
9.Subject is willing to wear the system continuously throughout t he study for 
at least 80% of the time. 
10.Subject is willing to upload data at least weekly from the stud y pump/meter, 
must have Internet access and a computer system that meets the requirements for uploading the study pump/meter for data collec tion 
11.Subject must be willing to use the study glucose meter system ( i.e. along 
with study meter strips).     
12.If subject has celiac disease, it has been adequately treated a s determined 
by the investigator
13.Subject with the diagnosis of myocardial infarction, unstable a ngina, 
coronary artery bypass surgery, coronary artery stenting, trans ient ischemic 
attack, cerebrovascular accident, angina, congestive heart fail ure, ventricular 
rhythm disturbances or thromboembolic disease, within 1 year of  screening, 
will be included in the study with the consent of the Investiga tor  
14.Subject is willing to take one of the following insulins and ca n financially 
afford to use either of the 2 insulin preparations throughout t he course of 
the study (i.e. co-payments for insulin with insurance or able to pay full 
amount) 
a. Humalog
¬Æ (insulin lispro injection) 
b. NovoLog¬Æ (insulin aspart) 
 
Exclusion Criteria: 
1.Subject participated in any Closed Loop study in the past. 
2.Subject is unable to tolerate tape adhesive in the area of sens or placement  
3.Subject has any unresolved adverse skin condition in the area o f sensor 
placement (e.g., psoriasis, rash, Staphylococcus  infection) or area of infusion 
set placement 
4.Women of child-bearing potential who have a positive pregnancy test at 
screening or plan to become pregnant during the course of the s tudy  
5.Subject is being treated for hyperthyroidism at time of screeni ng 
6.Subject has an abnormality (out of reference range) in thyroid- stimulating 
hormone (TSH) at time of screening visit. TSH is not required f or subjects 2-
13 years of age. 
7.Subject has taken any oral, injectable, or IV glucocorticoids w ithin 8 weeks 
from time of screening visit, or plans to take any oral, inject able, or IV 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 30 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
glucocorticoids during the course of the study. 
8.Subject is actively participating in an investigational study ( drug or device) 
wherein he/she has received treatment from an investigational s tudy drug 
or investigational study device in the last 2 weeks 
9.Subject is currently abusing illicit drugs or marijuana 
10.Subject is currently abusing prescription drugs   
11.Subject is currently abusing alcohol 
12.Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP ag onists, 
biguanides, DPP-4 inhibitors or sulfonylureas at time of screen ing 
13.Subject is using hydroxyurea at the time of screening or plans to use it 
during the study.     
14.Subject has a history of visual impairment which would not allo w subject to 
participate in the study and perform all study procedures safel y, as 
determined by the investigator 
15.Subject has a sickle cell disease, hemoglobinopathy; or has rec eived red 
blood cell transfusion or erythropoietin within 3 months prior to time of 
screening  
16.Subject plans to receive red blood cell transfusion or erythrop oietin over the 
course of study participation     
17.Subject diagnosed with current moderate to severe eating disord er such as 
anorexia or bulimia 
18.Subject has been diagnosed with chronic kidney disease requirin g dialysis or 
resulting in chronic anemia  
19.Subjects who are currently being actively treated for cancer.   
20.Subject who is designated as a research staff member for this s tudy 
Study Procedures and 
Assessments  Each subject‚Äôs participation will be comprised of the following  scheduled visits 
listed below over the course of approximately 8 months during t he run-in period 
and study period, and for 6 months during the continuation peri od.   
xTelemedicine visits will be allowed to replace office visits if  they do not 
involve collection of blood samples and device related procedur es that 
require staff assistance 
 
 
(DUO\:LWKGUDZDO
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 31 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
6XEMHFWVZKRH[LWWKHVWXG\EHIRUHWKHODVWVFKHGXOHGVWXG\YLV LWZLOOFRPSOHWH
DOOUHTXLUHPHQWVWKDWDUHOLVWHGIRU 9LVLW ZLWKWKHH[FHSWLRQRIFSHSWLGHODE
WHVWLQJ  
 
 The schedule is planned as follows:  
Screening and Run-In Period 
All subjects will complete screening and the run-in period. Thi s period must be 
completed in 60 days.  
Visit 1:  Screening Visit ‚Äì Consent and Screening 
Patients may re-screen once with Sponsor approval  
Visit 2:  Begin Run-in Period 
RPlacement of blinded sensor to be worn for 2 Weeks (each sensor  
is worn for 7 days) 
RStudy training, including instruction on procedures for wearing  
blinded CGM (i.e., insertion of sensor)  
Visit 3:  Begin MiniMed Pump (Except MDI Control) 
ROccurs after 2-week blinded sensor wear, either immediately at 
the end of sensor wear or suggested to be within 14 days.  
RThe run-in period may be repeated a second time with Sponsor 
approval  
 
Randomization  
At Visit 3  subjects (CSII, MDI or SAP Cohort) will be randomized into one  of 2 
arms: 
xHCL Arm 
Note: Patients who are on SAP at baseline will start Medtronic CGM at 
this visit.  
xControl Arm  
Note: Patients in SAP will receive and be trained on Medtronic CGM if 
they are randomized to the Control arm to ensure continuity wit h use of 
real time CGM.   
Note: Subjects 2-6 years of age will automatically enter the HC L arm at the end 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 32 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
of the run-in period
 
To schedule Visit 4 :  
xFor subjects who have been on insulin pump therapy prior to scr eening 
for at least 3 months, Visit 4 should occur 3-30 days after Vis it 3  
xFor subjects without pump therapy experience, the following sho uld 
occur: 
xIf randomized to the HCL arm, Visit 4 should occur 14-30 days a fter Visit 
3 
xIf randomized to the MDI Control arm, Visit 4 should occur 1-7 days after 
Visit 3 
The visit schedules for each of these Arms are as follows: 
HCL Arm:  
Visit 4: Start CGM - Day 0  
Start CGM with Guardian Sensor (3) (Note: SAP subjects  will ha ve 
already started CGM with Guardian Sensor (3) at Visit 3) 
Visit 4A: Follow up Telephone visit - 2-3  days after Visit 4  
Visit 5: Follow up Office Visit - 7-21 days after Visit 4   
Auto Mode is enabled and activated. Investigator sets carbohydr ate to 
insulin ratios and active insulin time, and basal rates for ope n loop 
periods  
Visit 6A: Follow-up Telephone Visit (option of office visit) ‚Äì 1  Day after 
Visit 5 
Visit 6B: Follow-up Telephone Visit (option of office visit) - 2  Days after 
Visit 5  
Visit 6C:  Follow-up Telephone Visit - 5  Days (¬± 1 day) after Visit 5 
Visit 7A: Follow up Office Visit - 14  Days (¬± 3 days)   after Visit 5  
Visit 7B: Follow-up Telephone Visit - 21 Days (¬± 3 days) after Visit 5
Visit 7C: Follow up Office Visit - 30  Days after Visit 5 (¬± 5 days) 
Visit 7D: Follow-up Telephone Visit - 45  Days (¬± 7 days) after Visit 5    
Visit 8: Follow up Office Visit - 90 Days after Randomization (¬± 10 days )  
Visit 9: Follow up Office Visit - 180 Days after Randomization (¬± 10 day s)   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 33 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
REnd of Study Period and Start of Continuation period  
Control Arm:  
a.CSII Cohort 
Visit 4:  Day 0:  
RReview pump settings 
 Visit 5:  Follow up Office Visit 7-21 days after Visit 4 
RInsulin Pump adjustments 
Visit 6A: Follow up Telephone Visit - 1 Day after Visit 5   
Visit 6B: Follow up Telephone Visit - 2 Days after Visit 5   
Visit 6C:  Follow up Telephone Visit - 14 Days (¬± 7 days)  after Visit 5  
Visit 6D: Follow up Office Visit - 30 Days after Visit 5 (¬± 7 days) 
Visit 6E: Follow-up Telephone Visit - 45  Days (¬± 7 days) after Visit 5    
Visit 7:  Follow up Office Visit - 76 days after Randomization (-14 days ) 
RBlinded CGM Start 
R14 days of sensor wear before 90 Day study period visit. 
Transmitter is not connected to study pump 
Visit 8A:  Follow up Office Visit ‚Äì 90 Days after Randomization (+14 days ) 
RBlinded CGM Return 
Visit 8B:  Follow up Office Visit - 166 days after Randomization (-14 day s) 
RBlinded CGM Start 
R14 days of sensor wear before 180 Day study period visit. 
Transmitter is not connected to study pump 
Visit 9:  Follow up Office Visit ‚Äì 180 Days after Randomization (+14 day s) 
RBlinded CGM Return 
REnd of Study Period and Start of Continuation period. 
RStart CGM with Guardian Sensor (3) 
 
b.MDI Cohort 
Visit 4: Day 0    
Visit 5:  Follow up Office Visit 7-21 days after Visit 4 
Visit 6A: Follow up Telephone Visit - 1 Day after Visit 5    
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 34 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Visit 6B: Follow up Telephone Visit - 2 Days after Visit 5
Visit 6C:  Follow up Telephone Visit - 14 Days (¬± 7 days)  after Visit 5  
Visit 6D: Follow up Office Visit - 25 Days after Visit 5 (¬± 5 days) 
Visit 6E: Follow-up Telephone Visit - 35  Days (+1 days) after Visit 5    
Visit 7:  Follow up Office Visit - 76 days after Randomization (-2 days)  
RBlinded CGM Start  
R14 days of sensor wear before 90 Day study period visit.  
Visit 8A:  Follow up Office Visit ‚Äì 90 Days after Randomization (+14 days ) 
RBlinded CGM Return 
Visit 8B:  Follow up Office Visit - 166 days after Randomization (-14 day s) 
RBlinded CGM Start  
R14 days of sensor wear before 180 Day study period visit.  
Visit 9:  Follow up Office Visit ‚Äì 180 Days after Randomization (+14 day s) 
RBlinded CGM Return 
REnd of Study Period and Start of Continuation period. 
RStart study pump  
c.SAP Cohort: 
Visit 4:   Day 0  
Visit 4A:  Follow up Telephone visit - 2-3 days after Visit 4 
Visit 5:  Follow-up Office Visit - 7-21 days after Visit 4 
RPump and Sensor adjustments 
Visit 6A: Follow-up Telephone Visit (option of office visit) ‚Äì  1 Day after 
Visit 5  
Visit 6B: Follow-up Telephone Visit (option of office visit) - 2 Days aft er 
Visit 5   
Visit 6C: Follow-up Telephone Visit 7 days after Visit 5 (+3 days )  
Visit 7A: Follow-up Telephone Visit - 14 Days after Visit 5 (¬± 3 days)   
Visit 7B: Follow-up Telephone Visit - 21 Days after Visit 5 (¬± 3 days) 
Visit 7C: Follow-up Office Visit - 30 Days after Visit 5 (¬± 5 days) 
Visit 7D: Follow-up Telephone Visit - 45  Days (¬± 7 days) after Visit 5  
Visit 8: Follow-up Office Visit - 90 Days after Randomization (¬± 10 days )  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 35 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Visit 9: Follow-up Office Visit - 180 Days after Randomization (¬± 10 days )   
REnd of Study Period and Start of Continuation period 
RAuto Mode is enabled and activated. 
Continuation Period: 
HCL Arm:  
Visit 10: Follow up Office Visit ‚Äì 1 to 14 days after Visit 9  
Visit 11: Follow up Office Visit ‚Äì 15 to 30 days after Visit 9  
Visit 12: Follow up Office Visit - 270 Days after Randomization (+/- 21 
days)  
Visit 13: Follow up Office Visit - 365 Days after Randomization (+/- 21 
days)  
REnd of Continuation Period and End of Study 
Control Arm 
 
a.CSII Cohort: 
Visit 10A: Follow up Telephone visit - 2-3 days after sensor start  
Visit 10B: Follow up Office Visit 7-21 days after Visit 9   
RAuto Mode is enabled and activated. 
Visit 10C: Follow up Telephone Visit  (option  of office visit) ‚Äì 1 Day aft er 
Visit 10B  
Visit 10D: Follow up Telephone Visit  (option of office visit) ‚Äì 2 Days af ter 
Visit 10B   
Visit 10E: Follow-up Telephone Visit ‚Äì 5  Days (¬± 1 day) after Visit 10B 
Visit 11A: Follow up Office Visit - 14 Days after Visit 10B (¬±3 days )  
Visit 11B: Follow-up Telephone Visit - 21  Days (¬±3 days ) after Visit 10B   
Visit 11C: Follow up Office Visit - 30 Days after Visit 10B (¬±5 days) 
Visit 11D: Follow-up Telephone Visit - 45  Days (¬±7 days ) after Visit 10B   
Visit 12: Follow up Office Visit - 270 Days after Randomization (+/- 21 
days)  
Visit 13:  Follow up Office Visit - 365 Days after Randomization (+/- 21 
days)  
REnd of Continuation Period and End of Study 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 36 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
b. MDI Cohort: 
Visit 9A: Follow up Office Visit ‚Äì 14-30 days after Visit 9  
RStart CGM with Guardian Sensor (3)  
RThis visit should occur between 14 and 30 days after pump 
start.  
Visit 10A: Follow up Telephone visit - 2-3 days after sensor start  
Visit 10B: Follow up Office Visit 7-21 days after Visit 9A  
RPatient has been wearing CGM for at least 4 days before 
enabling Auto Mode 
RAuto Mode is enabled and activated.  
Visit 10C: Follow up Telephone Visit (option  of office visit) ‚Äì 1 Day afte r 
Visit 10B  
Visit 10D: Follow up Telephone Visit (option of office visit) ‚Äì 2 Days aft er 
Visit 10B   
Visit 10E: Follow-up Telephone Visit ‚Äì 5  Days (¬± 1 day) after Visit 10B  
Visit 11A: Follow up Office Visit - 14 Days after Visit 10B (¬±3 days) 
Visit 11B: Follow-up Telephone Visit ‚Äì 21  Days (¬± 3 day) after Visit 10B    
Visit 11C: Follow up Office Visit - 30 Days after Visit 10B (¬± 5 days)  
Visit 11D: Follow-up Telephone Visit ‚Äì 45  Days (¬± 7 day) after Visit 10B 
Visit 12: Follow up Office Visit - 270 Days after Randomization (+/- 21 
days)   
Visit 13: Follow up Office Visit - 365 Days after Randomization (+/- 21 
days)  
REnd of Continuation Period and End of Study 
 
c.SAP Cohort: 
Visit 10A: Follow up Telephone Visit (option of office visit) ‚Äì 1 Day afte r 
Visit 9  
Visit 10B:  Follow up Telephone Visit (option of office visit) ‚Äì 2 Days af ter 
Visit 9  
Visit 10C: Follow-up Telephone Visit ‚Äì 5  Days (¬± 1 day) after Visit 9  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 37 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Visit 11A: Follow up Office Visit - 14 Days after Visit 9 (¬±3 days)  
Visit 11B:   Follow-up Telephone Visit ‚Äì 21  Days (¬± 3 day) after Visit 9  
Visit 11C: Follow up Office Visit - 30 Days after Visit 9 (¬±5 days)   
Visit 11D: Follow-up Telephone Visit ‚Äì 45  Days (¬± 5  day) after Visit 9  
Visit 12:  Follow up Office Visit - 270 Days after Randomization (+/- 21 
days)  
Visit 13: Follow up Office Visit - 365 Days after Randomization (+/- 21 
days)  
REnd of Continuation Period and End of Study 
 
6DIHW\6XFFHVV
&ULWHULDIn order to achieve safety success, the following study success  criteria must be met for 
the HCL Arm by the end of the study: 
 
Table 2. Safety Success Criteria
Adverse Event Reference Reference 
Rate > 25 
years oldReference 
Rate 
15-25 years 
old Reference 
Rate <15 
years oldStudy Success 
Criteria 
 
DKA events 
per 100 patient years STAR 3 
Bergenstal et. al  SAP arm: 
0.68 Control arm: 0SAP arm:  
2.7Control arm: 3.6 SAP arm: 
2.2Control arm: 0
< 4 events 
per 100 
patient years with HCL arm 530 G Adult inhome 
study CEP 266 
(MDT on file)  1.27 3.4 N/A 
530 G Pediatric  
inhome study CEP 287(MDT on file)N/A N/A 0 
Type 1 exchange 
Weinstock et. al4.8 N/A N/A
Type 1 exchange 
Cengiz et. al N/A 9.9 9.9
 
 
Severe 
hypoglycemi
a per 100 
patient years STAR 3 
Bergenstal et. al   
SAP  arm: 
16.5  
Control 
arm: 20.9  
SAP arm:  
5.4 
Control 
arm: 3.9 
SAP arm:  
10.2 
Control 
arm: 3.6 < 8 events 
per 100 
patient 
years with HCL arm 530 G Adult inhome 
study CEP 266 (MDT on file) 0.85 0 N/A 
530 G Pediatric  
inhome study CEP 287N/A N/A 1.42 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 38 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
(MDT on file) 
Type 1 exchange 
Weinstock et. al11.8     N/A N/A 
Type 1 exchange 
Cengiz et. al N/A 6.2  6.2  
Descriptive summary (i.e. not statistically powered) for severe  hypoglycemia and DKA 
events rates will be performed between the HCL and control arms  for each age group (< 
15 years, 15-25 years, and > 25 years), as well as the overall event rates.  
Severe hypoglycemia and DKA event rates were taken from the fol lowing
1.Richard Bergenstal et.al: Effectiveness of Sensor-Augmented Ins ulin-Pump Therapy 
in Type 1Diabetes.New England Journal of Medicine, 2010; 363:31 1-20 
2.Weinstock et. al: Severe hypoglycemia and diabetic ketoacidosis  in adults with type 
1 diabetes: results from the T1D Exchange clinic registry. J Cl in Endocrinol Metab. 
2013 Aug;98(8):3411-9. 
3.Cengiz et. al: Severe hypoglycemia and diabetic ketoacidosis am ong youth with type 
1 diabetes in the T1D Exchange clinic registry. Pediatr Diabete s. 2013 Sep;14(6):447-
54. 
4.MDT on file : Statistical Analysis Plan (SAP) for CEP304, 056-F286 
 
Safety monitoring/risk analysis details are outlined in Section  14. 
 
6WXG\6WRSSLQJ
5XOHVIRU(QWLUH
6WXG\The study will be stopped if DMC determines that there are sign ificant safety 
issues. (See DMC section.) 
Note: If it is decided to withdraw patients from participation in the study or if 
the study is stopped, subjects will be followed-up in accordanc e with standard 
practice. 
 
6XEMHFW6WRSSLQJ
5XOHV1.One episode of DKA or 2 episodes of severe hypoglycemia will re sult in 
withdrawal of subject from study, regardless of which arm or pe riod 
they are in. 
2.The first episode of Severe Hypoglycemia may lead to withdrawal , if it is 
secondary to subject non-compliance or other individual safety concerns:   
RSubject is not using the bolus wizard 
RSubject is not checking blood glucose using finger sticks  
RSubject is non-compliant with sensor wear 
RSubject is not following protocol procedures  
 
Statistics Effectiveness endpoints will be evaluated during the 6 month st udy period by 
individual Cohort (CSII, MDI or SAP), stratified by A1C; 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 39 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xGroup 1: Baseline A1C > 8%  
x'∆å≈Ω∆µ∆âœÆÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π  
The comparison of HCL arm vs. Control arm will be performed.  For SG-based 
comparison between HCL vs Control analyses, two weeks of CGM da ta collected 
at 3 month visit and 6 month visits will be used.  
 Primary Effectiveness Endpoints ‚Äì Co-Primary Endpoints: 
 
xGroup œ≠ÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—Öœ¥–πÕó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø  
The primary effectiveness endpoint  for the baseline A1C > 8% i s the change in 
A1C from baseline to the end of the six-month treatment period,  defined as A1C 
measured at the six-month treatment visit minus A1C measured at  the 
randomization visit. The goal is to show superiority of the HCL  Arm compared to 
the Control Arm in reducing A1C from baseline to end of six-mon th treatment 
period. 
xGroup 2: ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π : Time in Hypoglycemic Range  
 
The primary effectiveness endpoint ƒ®≈Ω∆å∆ö≈öƒûƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π  is the time with 
sensor glucose (SG) below 70 mg/dL (3.9 mmol/L) during the six- month study 
period. The goal is to show superiority of the HCL Arm compared  to the Control 
Arm in reducing time in hypoglycemic range. : 
 
Key Secondary Effectiveness Endpoints 
xGroup 1: Baseline A1C > 8%: Time in Hypoglycemic Range 
The key secondary effectiveness endpoint for the baseline A1C >  8% is the time 
with SG below 70mg/dL (3.9 mmol/L) during the six-month study p eriod. The 
goal is to show non-inferiority of the HCL Arm compared to the Control Arm in 
reducing time in hypoglycemic range.  
xGroup 2ÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–πÕó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø  
The key secondary effectiveness endpoint ƒ®≈Ω∆å∆ö≈öƒûƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π  is the 
change in A1C from baseline to end of six-month treatment perio d, defined as 
A1C measured at the six-month treatment visit minus A1C measure d at the 
randomization visit. The goal is to show non-inferiority of the  HCL Arm compared 
to the Control Arm in reducing A1C from baseline to end of six- month treatment 
period.  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 40 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
Other Secondary Effectiveness Endpoints 
 The other secondary effectiveness endpoints are hierarchically ordered and will 
be evaluated in the fixed sequence from endpoint 1 to 5 during the first 6 
months of study phase. 
xGroup 1 + Group 2: Time in Hypoglycemic Range during Night 
The first secondary effectiveness endpoint is the time with SG below 70 mg/dL 
(3.9mmol/L) during Night. The goal is to show superiority of th e HCL Arm 
compared to the Control Arm reducing time in hypoglycemic range  during night. 
xGroup 1 + Group 2: Time in Hypoglycemic Range during Day and Ni ght 
The endpoint of time in hypoglycemic range below 70 mg/dL (3.9m mol/L) will be 
evaluated for superiority in the combined Groups. The goal is t o show 
superiority of the HCL Arm compared to the Control Arm in reduc ing time in 
hypoglycemic range. 
xGroup 1 + Group 2: Time in Target Range 70mg/dL (3.9mmol/L) ‚Äì 1 80 
mg/dL  (10.0mmol/L) during Night 
The endpoint of time in target range measures the time with SG in target range 
70mg/dL (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) during Night. The goal is to 
show superiority of the HCL Arm compared to the Control Arm in improving the 
time in target range  
xGroup 1 + Group 2: Time in Target Range 70mg/dL (3.9mmol/L)‚Äì 18 0 
mg/dL (10.0mmol/L) during Day and Night 
 
The endpoint of time in target range measures the time with SG in target range 
70mg/dL (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) during Day and Nig ht. The goal 
is to show superiority of the HCL Arm compared to the Control A rm in improving 
the time in target range  
xGroup 1 + Group 2: Change in A1C 
 
The endpoint of change in A1C will be evaluated for superiority  in the combined 
Groups. The goal is to show superiority of the HCL Arm compared  to the Control 
Arm in reducing A1C from baseline to end of six-month treatment  period.  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 41 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Primary Safety Endpoints:  
The primary safety endpoint is the event rate of severe hypogly cemia and DKA 
from both Groups (1 & 2) during the first 6 months of study pha se and second 6 
months of continuation phase. The descriptive summary statistic s will be 
presented by number of event and event rate (100 patient years)  for severe 
hypoglycemia and DKA separately .  
The safety of the study will be evaluated and summarized per ar m, including but 
not limited to the following: 
xDiabetic ketoacidosis (DKA) 
xSevere hypoglycemia 
xSevere hyperglycemia  
xSerious adverse events (SAEs) 
xUnanticipated adverse device effects (UADEs) 
 
 
  
  
 
  
  
 
 
  
 
 
  
  
 
  
  
  
  PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 42 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
  
  
 
 
  
 
 
  
 
 
 
  
 
 
  
 
  
 
 
 
  
 
  
 
 
  
 
 
 
 
 
 PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 43 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
  
 
 
 
 
  
 
 
 
 
   
  
 
 
 
 
 
  
  
 PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 44 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
,QWURGXFWLRQ
 %DFNJURXQG
Provisional studies employing closed loop technology have shown  a reduction in both hypoglycemia and 
hyperglycemia, as well as glycemic variability. Previous studie s have evaluated prototype versions of the 
Medtronic closed-loop insulin delivery systems in pediatric pat ients, as well as adolescents and young adults.  
Researchers at the Yale University School of Medicine studied t he performance of both a hybrid closed-loop 
algorithm and a fully closed loop algorithm using the Medtronic  MMT-715 insulin pump, the Medtronic Sof-
sensor and MiniLink transmitter and a control algorithm running  on a laptop computer [Weinzimer et al, 2008].  
Seventeen subjects between the ages of 13 and 20 years particip ated in the study with eight subjects 
undergoing testing with a fully closed-loop algorithm, and the remaining nine subjects being evaluated using 
the hybrid closed-loop algorithm.  This study demonstrated that  a fully closed loop artificial pancreas using an 
external glucose sensor is feasible and effective in adolescent s with type 1 diabetes. 
The Type 1 Diabetes TrialNet Study Groups used this same system  to evaluate inpatient hybrid closed-loop 
control (HCL) initiated shortly after the diagnosis of type 1 d iabetes [Diabetes Research in Children Network 
Study Group,  2013].  Forty eight subjects between the ages of 7.8 and 37.7 years participated in the intensive 
treatment group and received inpatient HCL followed by outpatie nt sensor augmented pump therapy.  Forty 
six of the 48 subjects were less than 18 years old.  The study found that inpatient HCL safely initiated soon after 
the diagnosis of type 1 diabetes resulted in the rapid decrease  in blood glucose levels within 24 hours of 
initiation and that while using HCL, about 80% of the glucose l evels were in the target range of 71mg/dL -180 
mg/dL, with minimal hypoglycemia. 
Medtronic has completed 7 phases in the HCL Feasibility Study ( CEP 273) with a total of 71 subjects enrolled. In 
this Feasibility study, the closed loop system was stressed by artificially inducing sensor error as well as 
inducing physiologic stress such as exercise and administration  of meals without bolus. The Feasibility study 
provided data which was used to develop the device algorithm th at is being tested in this study. 
A pivotal trial with 120 subjects was completed in February 201 6.  This was a single arm study evaluating the 
safety of the MiniMed 670G HCL system in subjects 14-75 years o f age, for 3 months in the home setting. The 
pediatric pivotal study for the HCL system was conducted as an at-home, multi-center study, which enrolled 
162 participants ages 2-13 years of age. Patients were recruite d at 11 centers (10 in the United States, 1 in 
Israel). The study was identical in design to the young adult/a dult pivotal study.  
Study results in the pediatric study mirrored data from the piv otal trial of the system in adults and adolescents 
(14 and above), showing patients spent more time in euglycemic range, experienced less glycemic variability, 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 45 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
had less exposure to hypoglycemia and hyperglycemia and signifi cantly reduced HbA1c compared to baseline 
data where they used sensor-augmented pumps without SmartGuardTMautomation activated. No episodes of 
severe hypoglycemia or diabetic ketoacidosis and no serious dev ice-related adverse events were reported. 
The MiniMed 770G Insulin Pump is  equivalent in function to the MiniMed 670G insulin pump, with the 
exception of telemetry. While the MiniMed 670G insulin pump com municates on the basis of Tel-D (telemetry-
diabetes) radio frequency (RF) technology, the MiniMed 770G pum p contains BLE (Bluetooth Low Energy) RF 
communication, which allows for connectivity to patients‚Äô smart phones, CGM transmitter and an BLE RF 
enabled blood glucose meter.  For detailed information on the M iniMed 770G pump, see Section 7.5. 
 
3XUSRVH
The purpose of this study is to evaluate the safety and effecti veness of the Hybrid Closed Loop system (HCL) in 
adult and pediatric patients with type 1 diabetes in the home s etting. A diverse population of patients with 
type 1 diabetes will be studied. The study population will have  a large range for duration of diabetes and 
glycemic control, as measured by glycosylated hemoglobin (A1C).  The following cohorts will be enrolled: 
1) Cohort 1: Continuous Subcutaneous Insulin Infusion (CSII) or  HCL;  
2) Cohort 2: Multiple Daily Injections (MDI) or HCL and  
3) Cohort 3: Sensor-Augmented Pump therapy (SAP) or HCL.  
 
 2EMHFWLYHVDQGRU (QGSRLQWV
2EMHFWLYHV

3ULPDU\2EMHFWLYHV
The purpose of this study is to evaluate the safety and effecti veness of the Hybrid Closed Loop system (HCL) in 
adult and pediatric patients with type 1 diabetes in the home s etting.  
(QGSRLQWV¬±*HQHUDO&RQVLGHUDWLRQV
All endpoints are hierarchically ordered and will be evaluated in the fixed sequence from primary endpoints to 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 46 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
secondary endpoints. Unless the primary endpoints hypotheses ar e rejected, secondary endpoints will not be 
tested.   
Effectiveness endpoints will be evaluated during the 6 month st udy period by individual Cohort (CSII, MDI or 
SAP), stratified by A1C; 
 
xGroup 1: Baseline A1C > 8%  
x'∆å≈Ω∆µ∆âœÆÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π  
The comparison of HCL arm vs. Control arm will be performed.  For SG-based comparison between HCL vs 
Control analyses, two weeks of CGM data collected at 3 month vi sit and 6 month visits will be used.   
 
&R3ULPDU\(IIHFWLYHQHVV(QGSRLQWV
The primary effectiveness endpoints consist of one-primary endp oint for each group.
Group 1: Baseline A1C > 8% Õó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø
xThe primary effectiveness endpoints for the baseline A1C > 8% g roup is change in A1C from baseline to 
end of six-month treatment period, defined as A1C measured at t he six-month treatment visit minus 
A1C measured at the randomization visit. The goal is to show su periority of the HCL Arm compared to 
the Control Arm in reducing A1C from baseline to end of six-mon th treatment period.  
xThe hypothesis is mathematically expressed as: 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the mean of change in A1C (%) with the HCL Arm,  Œº(Control) is the mean of change 
in A1C (%) with the Control Arm. 
 
Group œÆÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π : Time in Hypoglycemic Range  
xd≈öƒû∆â∆å≈ù≈µƒÇ∆å«áƒûƒ®ƒ®ƒûƒê∆ö≈ù«Äƒû≈∂ƒû∆ê∆êƒû≈∂ƒö∆â≈Ω≈ù≈∂∆öƒ®≈Ω∆å∆ö≈öƒûƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π≈ê∆å ≈Ω∆µ∆â≈ù∆ê∆ö≈öƒû∆ö≈ù≈µƒû«Å≈ù∆ö≈ö^'ƒèƒû≈Ø≈Ω«Åœ≥œ¨
mg/dL (3.9mmol/L) during the six-month study period, defined as  percentage of SG below 70 mg/dL 
(3.9mmol/L) out of total number of available SG readings. The g oal is to show superiority of the HCL 
Arm compared to the Control Arm in reducing daily time in hypog lycemic range. 
xThe hypothesis is mathematically expressed as: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 47 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø
Ha: Œº(HCL) < Œº(Control) 
 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9 mmol/L) in the HCL Arm, Œº(Control) is 
the subject mean of time with SG below 70 mg/dL (3.9 mmol/L) in  Control Arm  
6HFRQGDU\(IIHFWLYHQHVV(QGSRLQWV
Key Secondary Effectiveness Endpoints 
Group 1: Baseline A1C > 8%: Time in Hypoglycemic Range 
xThe key secondary effectiveness endpoint for the baseline A1C >  8% group is the time with SG below 
70 mg/dL (3.9mmol/L) during the six-month study period, defined  as percentage of SG below 70 mg/dL 
(3.9mmol/L) out of total number of available SG readings. The g oal is to show non-inferiority (with a 
non-inferiority margin of 2%) of the HCL Arm compared to the Co ntrol Arm.  
xThe hypothesis of non-inferiority is mathematically expressed a s: 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø–ΩœÆ–π  
Ha: Œº(HCL) < Œº(Control) + 2% 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9 mmol/L) in the HCL Arm, 
Œº(Control) is the subject mean of time with SG below 70 mg/dL ( 3.9 mmol/L) in the Control Arm  
 
Group œÆÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–πÕó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø  
xThe key secondary ƒûƒ®ƒ®ƒûƒê∆ö≈ù«Äƒû≈∂ƒû∆ê∆êƒû≈∂ƒö∆â≈Ω≈ù≈∂∆öƒ®≈Ω∆å∆ö≈öƒûƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π≈ê∆å≈Ω∆µ∆â≈ù∆êƒê≈öƒÇ≈∂≈ê ƒû≈ù≈∂œ≠ƒ®∆å≈Ω≈µ
baseline to end of six-month treatment period, defined as A1C m easured at the six-month treatment 
visit minus A1C measured at the randomization visit. The goal i s to show non-inferiority (with a non-
inferiority margin of 0.4%) of the HCL Arm compared to the Cont rol Arm in reducing A1C from baseline 
to end of six-month treatment period. 
xThe hypothesis of non-inferiority is mathematically expressed a s: 
x,œ¨Õó—íÕæ,>Õø—à Œº(Control) + 0.4% 
xHa: Œº(HCL) < Œº(Control) + 0.4% 
xwhere Œº(HCL) is the mean of change in A1C (%) with the HCL Arm,  Œº(Control) is the mean of change in 
A1C (%) with the Control Arm.  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 48 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Rest of Secondary Effectiveness Endpoints 
1.Group 1 + Group 2: Time in Hypoglycemic Range during Night 
The secondary effectiveness endpoint is the time with SG below 70 mg/dL (3.9mmol/L) during Night. The goal 
is to show superiority of the HCL Arm compared to the Control A rm reducing time in hypoglycemic range 
during night . The hypothesis is mathematically expressed as:
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9 mmol/L) in the HCL Arm during night, 
Œº(Control) is the subject mean of time with SG below 70 mg/dL ( 3.9 mmol/L) in the Control Arm during the 
night. 
2.Group 1 + Group 2: Time in Hypoglycemic Range during Day and Ni ght 
The endpoint of time in hypoglycemic range below 70 mg/dL (3.9m mol/L) will be evaluated for superiority in 
the combined Groups during day and night. The goal is to show s uperiority of the HCL Arm compared to the 
Control Arm in reducing time in hypoglycemic range. The hypothe sis is mathematically expressed as: 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9 mmol/L) in the HCL Arm, Œº(Control) is 
the subject mean of time with SG below 70 mg/dL (3.9 mmol/L) in  the Control Arm.   
 
3.Group 1 + Group 2: Time in Target Range 70mg/dL (3.9mmol/L) ‚Äì 1 80 mg/dL  (10.0mmol/L) 
during Night 
The endpoint of time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) ‚Äì 180 
mg/dL (10.0mmol/L) during Night. The goal is to show superiorit y of the HCL Arm compared to the Control Arm 
in improving the time in target range. The hypothesis is mathem atically expressed as:
H0: Œº(HCL) ‡µë Œº(Control)   
Ha: Œº(HCL) > Œº(Control) 
where Œº(HCL) is the subject mean of time with SG between 70mg/d L (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) 
range in the HCL Arm during Night, Œº(Control) is the subject me an daily time with SG between 70mg/dL 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 49 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
(3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) range in the Control Arm.
4.Group 1 + Group 2: Time in Target Range 70mg/dL (3.9mmol/L)‚Äì 18 0 mg/dL (10.0mmol/L) 
during Day and Night 
The endpoint of time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) ‚Äì 180 
mg/dL (10.0mmol/L) during Day and Night. The goal is to show su periority of the HCL Arm compared to the 
Combined Control group in improving the time in target range. T he hypothesis is mathematically expressed as:
H0: Œº(HCL) ‡µë Œº(Controls)   
Ha: Œº(HCL) > Œº(Controls) 
where Œº(HCL) is the subject mean of time with SG between 70mg/d L (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) 
range in the HCL Arm during Day and Night, Œº(Control) is the su bject mean daily time with SG between 
70mg/dL (3.9mmol/L)  ‚Äì 180 mg/dL (10.0mmol/L) range in the  Con trol Arm 
5.Group 1 + Group 2: Change in A1C 
The endpoint of change in A1C will be evaluated for superiority  in the combined groups. The goal is to show 
superiority of the HCL Arm compared to the Control Arm in reduc ing A1C from baseline to end of six-month 
treatment period. The hypothesis is mathematically expressed as : 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the mean of change in A1C (%) with the HCL Arm,  Œº(Control) is the mean of change in A1C (%) 
with the Control Arm. 
 
6DIHW\(QGSRLQW
The primary safety endpoint is the event rate of severe hypogly cemia and DKA from both Groups (1 & 2) during 
the first 6 months of study phase and second 6 months of contin uation phase. The descriptive summary 
statistics will be presented by number of event and event rate (100 patient years) for severe hypoglycemia and 
DKA separately . 
The safety of the study will be evaluated and summarized per ar m, including but not limited to the following: 
xDiabetic ketoacidosis (DKA) 
xSevere hypoglycemia 
xSevere hyperglycemia  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 50 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xSerious adverse events (SAEs) 
xUnanticipated adverse device effects (UADEs) 
 
  
  
  
  
 
  
  
 
  
  
  
  
  
 
 
  
 
 
  
 PI
PIPI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 51 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
  
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
x  
 
 
 
   
  
 
 PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 52 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
  
  
  
6WXG\'HVLJQ
This is a 6 month, multi-center, randomized, parallel, adaptive  study in type 1 diabetes with a 6 month 
continuation period. Up to 1500 subjects will be enrolled in or der to have 1000 subjects who enter the study 
period. To date, 959 subjects have enrolled. Up to 70 investiga tional Centers in the US, Europe, Canada, 
Australia and New Zealand will be enrolled. For additional info rmation on investigational sites and 
investigators, refer to information listed on public databases (e.g., clinicaltrials.gov). 
The study will have three periods per Cohort:  
1.Run-in Period: The run-in period can be up to 60 days.  
The run-in period will also be used for CGM data collection for  approximately two weeks. Two consecutive 
7-day sensors will be worn.  If a sensor falls out, a replaceme nt sensor should make up the difference for a 
total of 14 days of sensor wear (i.e. Monday Day 1 through next  Sunday Day 14)  
For example: If a sensor falls out on Day 4, a replacement sens or should be inserted.   Once that 
replacement sensor has been worn for 7 days, a new sensor shoul d then be inserted and worn for 
3 days so that a total of 14 days of sensor wear is completed.  
All patients will wear blinded CGM. Subjects will be expected t o demonstrate sensor wear for 
approximately 14 days total between the two 7-day sensor wears (plus replacement sensor if needed). 
Subjects should be instructed to make 4-6 BG measurements per d ay. Sponsor may request a repeat of 
blinded CGM. Repeat of blinded CGM may occur if the following a re not met: 
xA minimum of 12 days of sensor wear have been self-reported to research staff 
xA minimum of 2 blood glucose checks/day during the blinded CGM wear are confirmed on the 
subject‚Äôs study BG meter.  
If these requirements are not met then patient should repeat th e entire 2 week blinded CGM data 
collection unless sponsor has approved that there was adequate data collection. An additional 21 days may PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 53 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
be added to the run in visit window schedule if blinded CGM dat a collection needs to be repeated.  
Additional visits may also be allowed if needed.  
 
2.Study Period: There will be a 6 month randomized study period w ith two arms: HCL system and Control. 
CSII and MDI control groups will undergo two blinded CGM collec tions during the study period. 
The first blinded CGM data collection during the study period w ill occur before the month three (see visit 
schedule) for approximately two weeks.  Two consecutive 7-day s ensors will be worn.  If a sensor falls out, 
a replacement sensor should make up the difference for a total of 14 days of sensor wear.  (i.e. Monday 
Day 1 through next Sunday Day 14) 
For example: If a sensor falls out on Day 4, a replacement sens or should be inserted.   Once that 
replacement sensor has been worn for 7days, a new sensor should  then be inserted and worn for 3 
days so that a total of 14 days of sensor wear is completed.  
All patients will wear blinded CGM. Subjects will be expected t o demonstrate sensor wear for 
approximately 14 days total between the two 7-day sensor wears (plus replacement sensor if needed). 
Subjects should be instructed to make 4-6 BG measurements per d ay. The following should have occurred:   
xA minimum of 12 days of sensor wear have been self-reported to research staff 
xA minimum of 2 blood glucose checks/day during the blinded CGM wear are confirmed on the 
subject‚Äôs study BG meter.  
If the above requirements are not met then patient should repea t the entire 2 week blinded CGM data 
collection unless the sponsor approves that there was adequate data collection.  Additional visits may also 
be allowed if needed. No changes to the remaining visit schedul e are needed.   
The second blinded CGM data collection during the study period will occur before the month six (see visit 
schedule) for approximately two weeks.  Two consecutive 7-day s ensors will be worn.  If a sensor falls out, 
a replacement sensor should make up the difference for a total of 14 days of sensor wear. (i.e. Monday Day 
1 through next Sunday Day 14). 
For example: If a sensor falls out on Day 4, a replacement sens or should be inserted.   Once that 
replacement sensor has been worn for 7 days, a new sensor shoul d then be inserted and worn for 
3 days so that a total of 14 days of sensor wear is completed.  
All patients will wear blinded CGM. Subjects will be expected t o demonstrate sensor wear for 
approximately 14 days total between the two 7-day sensor wears (plus replacement sensor if needed). 
Subjects should be instructed to make 4-6 BG measurements per d ay.  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 54 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
3. Continuation Period: There will be a 6 month continuation per iod during which time all subjects will use 
the HCL system.  
 
Enrollment Cohorts According to Treatment 
At Enrollment, subjects will be identified according to the typ e of treatment regimen they are currently on. 
Treatment regimen is defined as follows: 
xCohort 1: CSII ‚Äì subjects using pump (Medtronic or other pump s ystems) for at least 3 months at time 
of screening without concurrent use of real time CGM in the las t 3 months. (Self-report acceptable.) 
Please note that alternatives to SMBG such as Freestyle Libre a re not considered real time CGM and 
subjects who are using Freestyle Libre at time of Screening wil l be allowed to enroll in the study.  
During the study, however, subjects will not be allowed to use Freestyle Libre.  
xCohort 2: Multiple Daily Injections (MDI) - Subjects using MDI with or without concurrent use of CGM 
for at least 3 months prior to Screening.  (Self report is acce ptable.)  
xCohort 3: Sensor Augmented Pump (SAP) ‚Äì subjects using pump for  at least 3 months at time of 
screening with real time CGM use (Medtronic or other CGM system s) approximately 20% of the time.  
(Self report acceptable.) Subjects will use the Medtronic CGM s tarting at Visit 3, but they may use their 
own CGM until then. Sensor insertion placement will be accordin g to User guide. 
Staged enrollment for Subjects 2-6 Years of Age: 
xSubjects 2-6 years of age will be allowed to enroll in the post  approval study, once DMC has reviewed  
data from 10 subjects age 2-4 years who have completed particip ation in the study period of the 
CEP302 study and has given approval to enroll   
In the US and Canada, subjects 2-80 years of age will be allowe d to transition from the 670G system to the 
770G system.  
The Run-In Period : Following successful screening, all subjects (CSII, MDI or SA P) will enter the run-in period 
and collect blinded CGM data while using their own diabetes the rapy. Blinded CGM consists of using a 
Guardian Sensor (3) connected to a Guardian Link (3) transmitte r.  A total period of 2 weeks of CGM data will 
be collected.   
Cohort 1: CSII 
The Study Period: After completion of the run-in period, subjec ts with CSII therapy (minimum N= 280) will be 
randomized and placed into one of 2 different arms during the s tudy period: 
1.The HCL Arm will use the MiniMed system (i.e., using Auto Mode)  for 6 months during the study 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 55 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
period. There will be N=140 for the HCL arm.
2.The Control Arm will use the MiniMed Pump without CGM. 
a)Blinded CGM (Guardian Link (3) Transmitter and Guardian Sensor (3)) will only be worn at baseline, 
3 months, and 6 months (two weeks of sensors use). There will b e N=140. 
Cohort 2: MDI The Study Period: After completion of the run-in period, subjec ts with MDI therapy (minimum of N=280) will be 
randomized and placed into one of 2 different arms during the s tudy period: 
1.The HCL Arm will use the MiniMed system (i.e., using Auto Mode)  for 6 months during the study 
period. There will be N=140 for the HCL arm. 
2.The Control Arm will be using their current insulin therapy (MD I) 
 The Multiple Daily Injection (MDI) subjects will remain on MDI therapy with subjects using their own 
insulin for 6 months during the study period. The Sponsor will not provide insulin. Blinded CGM 
(Guardian Link (3) Transmitter and Guardian Sensor (3)) will on ly be worn at baseline, 3 months, and 6 
months (two weeks of sensors use). There will be N=140. 
MDI subjects who are currently using CGM, i.e. Dexcom or Medtro nic Guardian Connect or who are 
currently using a SMBG alternative, i.e. Libre, will be allowed  to enroll in the study and continue using 
their own device. There will be N=100 
Cohort 3: SAP The Study Period: After completion of the run-in period, subjec ts with SAP therapy (minimum N= 280) will be 
randomized and placed into one of 2 different arms during the s tudy period. Sensor insertion placement will be 
according to User guide: 
1.The HCL Arm will use the MiniMed system (i.e., using Auto Mode)  for 6 months during the study 
period. There will be N=140 for the HCL arm. 
2.The Control Arm will be using SAP therapy using the MiniMed Sys tem.  
a)The Sensor Augmented Pump (SAP) subjects will use the MiniMed S ystem (SAP without Low 
Management Suspend on Low, Low Management Suspend before low or  Auto Mode) with Real 
Time CGM for the 6 month study period. There will be N=140.  
The Continuation Period:  All subjects above will enter the continuation period for 6 mo nths using the MiniMed 
system with Auto Mode on. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 56 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Figure 2. Study Design
Cohort1(CSII)
Run-In Period Study  Period Continuation  Period
Screening and 2 weeks of 
blinded CGMRandomizationTreatment (HCL)
Control (CSII)Treatment (HCL) End of Study
Cohort2(MDI)
Run-In Period Study  Period Continuation  Period
Screening and 2 weeks of 
blinded CGMRandomizationTreatment (HCL) Treatment (HCL) End of Study
Cohort3(SAP)
Run-In Period Study  Period Continuation  Period
Screening and 2 weeks of 
blinded CGMRandomizationTreatment (HCL)
Control (SAP)Treatment (HCL) End of StudyControl (MDI) 
 
 
Subjects may be re-tested as per sponsor discretion.  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 57 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Per Cohort (CSII, MDI, or SAP), here is the numbers of subjects expected t o enroll: 
 
xA1C at time of screening: 
RN = 70 A1C > 8% for HCL Arm  
RN = 70 œ≠—áœ¥–πƒ®≈Ω∆å,> Arm 
RN = 70 A1C > 8% for Control Arm 
RN = 70 œ≠—áœ¥–πƒ®≈Ω∆å≈Ω≈∂∆ö∆å≈Ω≈Ø∆å≈µ  
 
xAge at time of screening:  
 
N=Minimum number of eligible subjects for 
each age group within each treatment cohortN= Minimum number of 
eligible Subjects for each age 
group and cohort  N=Minimum number of 
eligible subjects for each 
age group for study 
Age Group Cohort N N N 
2-6 years CSII  
No Minimum No minimum N= 120 SAP 
MDI 
7 -13 years CSII 
No Minimum No minimum 
 N= 180 SAP 
MDI 
14-21 years CSII 
SAP MDI N= 45 N=45 N=135 
22-64 yearsCSII 
SAPMDI N= 120 N=120 N=360
65-80 years CSII 
No Minimum No minimum N=150 SAP 
MDI 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 58 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Table 3. Randomization 
Treatment at Baseline Randomization Options Continuation
CSII CSII 
HCL 
HCL 
MDI MDI 
HCL 
HCL 
SAP SAP 
HCL 
HCL 
Note: Subjects 2-6 years of age will automatically enter the HC L arm at the end of the run-in period 
 
Table 4.  Site Enrollment (approximate schedule from Protocol approval) 
Month 
Enrollment 
TimelinesActual Site Enrollment
(per month) Site 
Enrollment 
Timelines
Month 1-48 April 2017 to March 2021 37 
Month 49-52 April 2021 to July 2021 45 
 
 
Table 5.  Subject Enrollment at 2-3 month intervals (approximate schedule  from first enrollment)  
Month 
Enrollment 
Timelines Actual Month IntervalsSubject 
Enrollment 
Timelines 
Month 1-43 May 2017 to December 2020 930 
Month 44 -50 January 2021 to June 2021 1080 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 59 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Month 
Enrollment 
Timelines Actual Month IntervalsSubject 
Enrollment 
Timelines 
Month 51-56 July 2021 to December 2021 1120* 
*1120 subject enrollment to target 1000 subjects who enter the study period 
Table 6. Milestone Table 
Major Milestone Estimated time required to achieve milestone 
(approximate schedule from study protocol approval)
Protocol Approval / Device Launch
First site enrolled 30 days 
First subject enrolled 70 days 
First subject completed 15 months 
Last site enrolled 52 months 
Last subject enrolled 55 months ‚Äì 57 months (target 54 months) 
Last subject completed 69 months (or sooner based on last subje ct enrolled) 
Final report submitted 75 months 
 
'XUDWLRQ
The study is anticipated to last no longer than 6.5 years from investigational center initiation to completion of 
all data entry and monitoring procedures. The study will target  54 months to complete subject enrollment. 
Subjects can expect to participate for approximately 7-8 months  during the run-in period and study period, 
with a 6 month continuation period. 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 60 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
5DWLRQDOH
As remote monitoring may play an important role in the pediatri c population, we have added this capability 
with the MiniMed 770G system and are introducing this approved device to enhance subject compliance.  In 
the US and Canada subjects 2-80 years of age will be allowed to  transition from the 670G system to the 770G 
system. In Australia, the MiniMed 770G system is investigationa l for 2-6 years of age. 
 
3URGXFW'HVFULSWLRQ
*HQHUDO
None of the devices used in this study contain tissues of anima l origin, nor derivatives rendered non-viable. The 
devices do not incorporate, as an integral part, a substance wh ich if used separately, may be considered to be a 
medicinal product as defined in Annex I point 7.4, 1st paragrap h of Directive 93/42/EEC. 
The sensor contains human serum albumin. The human serum albumi n serves to protect the enzyme in the 
chemistry stack from subsequent processes and layers. Human ser um albumin is immobilized via crosslinking 
and is not liable to act on the human body. 
 
,QWHQGHG3RSXODWLRQ
A diverse population of patients with type 1 diabetes will be s tudied. The study population will have a large 
range for duration of diabetes and glycemic control, as measure d by glycosylated hemoglobin (A1C). They will 
be enrolled in the study regardless of their prior diabetes reg imen, including using Multiple Daily Injections 
(MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Senso r-Augmented Pump therapy (SAP). 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 61 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
1DPHVDQG,QWHQGHG8VHRI'HYLFHV
Table 7. MiniMed 670G System Components* 
Device name MDT Model 
number/ part 
number US Canada Europe 
MiniMed 670G Pump (closed loop 
algorithm)  MMT-1780 
(US) 
 MMT-1781 
(pump) and MMT-1762KCN (kit) (Canada) 
MMT-1781 
and MMT-
1782 (Europe) Age 7-80: Non-
Investigational 
Age 2-6: 
Investigational  Licensed (age 
—àœ≥«áƒûƒÇ∆å∆êÕø   CE marked 
ÕæƒÇ≈êƒû—àœ≥«áƒûƒÇ∆å∆êÕø  
Guardian Link (3) Transmitter  MMT-7811 Age 7-80: Non-
Investigational 
Age 2-6: 
Investigational  Licensed (age 
—àœ≥«áƒûƒÇ∆å∆êÕø  CE marked  
Transmitter Charger MMT-7715 Non-
Investigational Licensed CE marked 
Tester   MMT-7736L Non-
Investigational Licensed CE marked* 
Guardian Sensor (3)  MMT-7020 Age 7-80: Non-
Investigational 
Age 2-6: 
Investigational  Licensed  CE marked  
One-Press Serter  MMT-7512 Non-
Investigational Exempt CE marked 
CareLink USB 2.4 GHz (MMT- 7306)Non-
Investigational Licensed CE marked
Medtronic CareLink¬ÆPersonal 
Therapy Management Software  MMT-7333 Exempt Exempt** CE marked 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 62 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device nameMDT Model 
number/ part 
number US Canada Europe
Paradigm Reservoir  MMT-332A Cleared Licensed  CE marked 
MiniMed Silhouette Infusion Set  e.g. MMT-368 Cleared Licensed  C E  m a r k e d  
MiniMed Sil Serter  MMT-385 Cleared Exempt CE marked 
MiniMed Quick Set Infusion Set e.g. MMT-386 Cleared Licensed CE ma rked
MiniMed Mio Infusion Set e.g. MMT-923 Cleared Licensed CE marked
MiniMed Sure-T Infusion Set e.g. MMT-864 
 Cleared  Licensed CE marked 
 
MiniMed Quick-Serter  MMT-305 Cleared Exempt CE marked 
Ketone Meter   Cleared Licensed CE marked 
Contour Next Link 2.4 by Ascencia 
Meter MMT-1152 or 
MMT-1352 (US) MMT-1151 (Canada)  
MMT-1151 
and MMT-
1152 (Europe) Age 7-80: Non-
Investigational 
Age 2-6: 
Investigational Licensed CE marked 
* For detailed information on the characteristics materials, se e device instructions for use.
** Determined to be a Medical Device Data System by the Medical  Device Directorate and as such not subject 
to the Canadian Medical Device Regulations. 
 Table 8 MiniMed 770G System Components* 
Device nameMDT Model 
number/part number US Canada Australia New Zealand
MiniMed 770G 
Pump (closed 
loop algorithm)  MMT-1890 (US Kit) 
MMT-1880 (US Pump)
MMT-1881 (Canada 
Pump) 
MMT-1891KCN, MMT-Age 2-80: Non-
Investigational  Licensed (age 
2-80 years) Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 63 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device nameMDT Model 
number/part numberUS Canada Australia New Zealand
1891CRP (Canada Kit) 
Guardian Link 
(3) Transmitter  MMT-7911 (US GST5C) 
MMT-7910 (US GST5C 
Kit) 
MMT-7911 (Canada 
Transmitter) 
MMT-7910W4, MMT-
7911WW (Canada Kit) Age 2-80: Non-
Investigational Licensed (age 
2-80 years) Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Accu-Chek Guide Link Meter Blood Glucose 
Monitoring 
System 08116083022 (US) 
08109222001 (Canada) Age 2-80: Non-
Investigational Licensed (age 
2-80 years) Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Transmitter Charger MMT-7715Non-
Investigational Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Tester  MMT-7736LNon-
InvestigationalLicensedAge 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Guardian Sensor (3)  MMT-7020  Non-
Investigational Licensed  Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
One-Press Serter MMT-7512Non-
Investigational  Exempt Age 2-6: 
Investigational
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Blue adapter  ACC-1003911 Not a medical 
device  N/A N/A N/A 
Medtronic 
Mobile ApplicationMT-6104 (iOS) 
MMT-6103 (Android)Class II Exempt  Exempt** Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 64 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device nameMDT Model 
number/part numberUS Canada Australia New Zealand
CareLink 
Connect Application MMT-6114 (iOS) 
MMT-6113 (Android) Class II Exempt  Exempt** Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Medtronic CareLink
¬Æ Clinical 
Software MMT-7338 Class I Exempt Exempt** Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
Paradigm Reservoir  MMT-332A Cleared Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
MiniMed Silhouette Infusion Set  MMT-368 Cleared Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
MiniMed Sil Serter MMT-385 Cleared Exempt Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
MiniMed Quick Set Infusion Set  eMMT-386 Cleared Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
MiniMed Mio 
Infusion Set MMT-923 Cleared Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
MiniMed Sure-T 
Infusion Set MMT-864 Cleared Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
MiniMed Quick-Serter  MMT-305 Cleared Exempt Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 65 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device nameMDT Model 
number/part numberUS Canada Australia New Zealand
Ketone Meter  HMS ‚Äì Ketone Meter Cleared Licensed Age 2-6: 
Investigational 
Age 7-80: Non-
Investigational Age 2-80: Non-
Investigational 
* For detailed information on the characteristics materials, se e device instructions for use. 
** Determined to be a Medical Device Data System by the Medical  Device Directorate and as such not subject 
to the Canadian Medical Device Regulations. 
 
0LQL0HG*,QVXOLQ3XPS
The MiniMed 670G Insulin Pump is capable of continuous insulin delivery, at set and variable rates, for the 
management of diabetes mellitus in persons requiring insulin.  When used with the CGM components 
(Guardian Sensor (3), Guardian Link (3) Transmitter), the pump system is capable of continuous or periodic 
monitoring of glucose levels in the interstitial fluid under th e skin and detection of possible low or high blood 
glucose episodes.  The pump also displays continuous glucose va lues, storing this data so that it can be 
retrospectively analyzed to track patterns and improve diabetes  management. These features are similar to the 
commercially available Medtronic sensor-enabled system (e.g. Mi niMed 530G System (P120010) in the US, 
MiniMed 640G and Veo System OUS, which has the threshold suspen d feature). 
The MiniMed 670G Insulin Pump also  includes the closed loop alg orithm as part of the SmartGuard‚Ñ¢ collection 
of features that may be enabled by the user. SmartGuard is comp rised of Manual Mode Low Management, 
which includes the suspend on low feature (suspends insulin del ivery when a pre-set low SG threshold is 
reached), the suspend before low feature (enables insulin to su spend 30 minutes before a pre-set low SG 
threshold is reached) and Auto Mode (hybrid closed loop) featur e. The Auto Mode and Manual Mode -Low 
Management features will not be active at the same time. 
The pump may also be used as a simple pump without CGM or as a sensor augmented pump without the 
SmartGuard features.   
When Auto Mode is enabled on the MiniMed 670G insulin pump, the  sensor glucose (SG) values received from 
the Guardian Link (3) Transmitter by the insulin pump will be u sed to automatically calculate the insulin 
dose.  It will then deliver insulin to the patient, at five min ute intervals, to achieve glycemic control. 
With the HCL system, subjects must still deliver bolus insulin for meals as calculated by the insulin to 
carbohydrate ratio. This ratio is determined by the Health Care  Professional (HCP)/patient.  In addition, the 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 66 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
setting for active insulin must be programmed.  Basal rates are  set for period of open loop therapy.
When Auto Mode is not enabled, the user may enable the Low Mana gement feature. Here, basal rate delivery 
will be suspended either when the SG reached a programmed low t hreshold (Suspend on Low) or before the 
SGV has reached the programmed low threshold (Suspend before Lo w).  
 
Figure 3. MiniMed 670G Insulin Pump 
 

0LQL0HG*,QVXOLQ3XPS
The MiniMed 770G Insulin Pump is  equivalent in function to the MiniMed 670G insulin pump, with the 
exception of telemetry. While the MiniMed 670G insulin pump com municates on the basis of Tel-D (telemetry-
diabetes) radio frequency (RF) technology, the MiniMed 770G pum p contains BLE (Bluetooth Low Energy) RF 
communication, which allows for connectivity to patients‚Äô smart phones, CGM transmitter and an BLE RF 
enabled blood glucose meter.  
The pump is capable of continuous insulin delivery, at set and variable rates, for the management of diabetes 
mellitus in persons requiring insulin.  When used with the CGM components (Guardian Sensor (3), Guardian 
Link (3) Transmitter), the pump system is capable of continuous  or periodic monitoring of glucose levels in the 
interstitial fluid under the skin and detection of possible low  or high blood glucose episodes. The pump also 
displays continuous glucose values, storing this data so that i t can be retrospectively analyzed to track patterns 
and improve diabetes management. These features are similar to the commercially available Medtronic 
sensor-enabled system (e.g. MiniMed 530G System (P120010) in th e US, MiniMed 640G and Veo System OUS, 
which has the threshold suspend feature). 
The MiniMed 770G Insulin Pump also  includes the closed loop alg orithm as part of the SmartGuard‚Ñ¢ 
technology collection of features that may be enabled by the us er. SmartGuard is comprised of Manual Mode 

&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 67 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Low Management, which includes the suspend on low feature (susp ends insulin delivery when a pre-set low SG 
threshold is reached), the suspend before low feature (enables insulin to suspend 30 minutes before a pre-set 
low SG threshold is reached) and Auto Mode (hybrid closed loop)  feature. The Auto Mode and Manual Mode -
Low Management features will not be active at the same time. 
The pump may also be used as a pump without CGM or as a sensor augmented pump without the SmartGuard 
features.   
When Auto Mode is enabled on the MiniMed 770G insulin pump, the  sensor glucose (SG) values received from 
the Guardian Link (3) Transmitter by the insulin pump will be u sed to automatically calculate the insulin 
dose.  It will then deliver insulin to the patient, at five min ute intervals, to achieve glycemic control. 
With this system, users must still deliver bolus insulin for me als as calculated by the insulin to carbohydrate 
ratio. This ratio is determined by the Health Care Professional  (HCP)/patient.  In addition, the setting for active 
insulin must be programmed.  Basal rates are set for period of open loop therapy. 
When Auto Mode is not enabled, the user may enable the Low Mana gement feature. Here, basal rate delivery 
will be suspended either when the SG reached a programmed low t hreshold (Suspend on Low) or before the 
SG has reached the programmed low threshold (Suspend before Low ). 

*XDUGLDQ¬ä6HQVRU
The Guardian Sensor (3) , referred to as Guardian Sensor (3) in  this protocol, is a product that contains a 
microelectrode with a thin coating of glucose oxidase beneath s everal layers of biocompatible membrane. The 
sensor represents the next generation in the Enlite sensor fami ly with design changes in the engineering 
reports for improved accuracy. It is intended to penetrate the skin at a 90-degree angle and is shorter and 
thinner than the previous generation of MiniMed sensors. An int roducer needle penetrates the skin surface 
and provides support for the sensor microelectrode during inser tion. The electrode tubing maintains the 
electrode structure by providing support during and after subcu taneous insertion. The sensor continuously 
converts small amounts of glucose from the subject‚Äôs interstiti al fluid into an electronic signal that is received 
by a transmitter or recorder, the strength of which is proporti onal to the amount of glucose present in the 
blood. The electrode is composed of embedding, signal-conductin g and insulating layers. 

2QH3UHVV6HUWHU
The One-Press Serter , referred to as the Serter (Figure 4) in this protocol, is an insertion device that is used to 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 68 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
ensure correct placement of the Guardian Sensor (3) into the use r‚Äôs subcutaneous tissue. Insertion is triggered 
when the two spring loaded buttons on the sides of the Serter a re pressed simultaneously. The Serter is 
intended as a single patient, non-sterile, multi-use device.   
 
Figure 4. One-Press Serter and Guardian Sensor (3) 
 
 
*XDUGLDQ/LQN7UDQVPLWWHU
The Guardian Link (3) Transmitter has the same housing and sens or interface as the MiniLink transmitter. 
However, the internal electronics and firmware of the Guardian Link (3) Transmitter are new. Like the MiniLink 
transmitter, the Guardian Link (3) Transmitter reads the electr onic signal generated by the sensor. In addition, 
the transmitter contains a custom Application Specific Integrat ed Circuit (ASIC), which enables Electrochemical 
Impedance Spectroscopy (EIS). The EIS measurements are used as diagnostics for the sensor, which are 
incorporated into the sensor calibration logic.  
In addition, the transmitter also contains the sensor calibrati on algorithm which converts the sensor signal to a 
SGV using calibration blood glucose values from a meter relayed  to the transmitter through the pump. The 
transmitter transmits the calculated glucose data to the pump v ia RF technology.  The new algorithm is 
designed to improve and optimize performance when paired with t he Guardian Sensor (3). Some elements of 
the new calibration logic include prompting the user to calibra te when needed, referred to as ‚ÄúSmart Cal,‚Äù 
instead of strictly scheduled time-based calibration requiremen ts.  
 
 

&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 69 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Figure 5.  Transmitter and Transmitter Charger
  
 
7UDQVPLWWHU&KDUJHU
The Transmitter Charger is used to recharge the Guardian Link (3 ) Transmitter as needed. A fully charged 
battery provides up to 7 days of Guardian Link (3) Transmitter use. The system includes a battery charger that 
will recharge the device according to the user guide.  
 
7HVWHU
The Tester operates as a sensor simulator creating signal curre nt at a level that is within the range of an in-vivo 
sensor during normal operation.
 
&217285¬ä1(;7/,1.E\$VFHQFLD5)(QDEOHG%ORRG*OXFRVH
0HWHU
A CONTOUR Next Link by Ascencia RF-Enabled Blood Glucose Meter,  referred to as the Study Meter 
throughout protocol, will be provided to study participants for  use with the MiniMed 670G Insulin Pump. The 
meter measures a subject‚Äôs capillary blood glucose level using the CONTOUR NEXT Strips by Ascencia, which is 
then used to calibrate the pump. The MiniMed 670G Insulin Pump uses the calibration point in the real-time 
algorithm which calculates the SGVs that are displayed to the s ubject.  The result of the finger stick (capillary 
SMBG) reading performed is entered into the MiniMed 670G Insuli n Pump and can be stored in its memory as 
a glucose point. The MiniMed 670G Insulin Pump asks the user ev ery time if the user wants to use the linked 
meter BG for calibration. If yes is selected, the glucose value  will be stored in memory as a calibration point. 
This meter has a remote bolus feature that will not be operatio nal during the closed loop system.  

&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 70 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 $FFX&KHN*XLGH/LQN%OXHWRRWK(QDEOHG0HWHUE\5RFKH
The Accu-Chek  Guide Link Meter Blood Glucose Monitoring System  for use with the 770G system is comprised 
of the Accu-Chek Guide Link Meter and Accu-Chek Guide Link test  strips. This Blood Glucose Monitoring System 
is intended to quantitatively measure glucose in fresh capillar y whole blood from the fingertip, palm, and 
upper arm as an aid in monitoring the effectiveness of glucose control. The Accu-Chek Guide Blood Glucose 
Monitoring System is intended for in vitro diagnostic single-pa tient use by people with diabetes. Transmission 
of data is via Bluetooth Low Energy. 
 
 &DUH/LQN¬ä3HUVRQDO)RU&OLQLFDO5HVHDUFK6RIWZDUHDQG&DUH/LQN¬ä
&OLQLFDO6RIWZDUH
Medtronic CareLink¬ÆPersonal For Clinical Research Therapy Management Software for Diabetes and CareLink¬Æ 
Clinical are both internet-based software systems which allow t he device data to be viewed and easily 
evaluated by the subject and his/her physician. A PC is used to  access the Medtronic CareLink¬Æ  system via the 
Internet, which then allows subjects and investigational center  staff to upload data from Medtronic MiniMed 
insulin pumps and a range of system-supported, third-party BG m eters. CareLink¬ÆPersonal For Clinical 
Research Therapy Management Software for Diabetes, the clinical  support version of Medtronic CareLink¬Æ 
Personal software, and the CareLink¬ÆClinical allows retrospective review of device data and was dev eloped for 
use by the investigational center staff and subjects. The CareL ink¬Æ  Clinical software allows the investigational 
center staff to manage, create, and link the subject‚Äôs account.  For the purposes of this study, all references to 
CareLink¬Æ  Personal For Clinical Research software in this document rela te to the clinical support version of 
Medtronic CareLink¬ÆPersonal Therapy Management Software for Diabetes. The data con tained in CareLink¬Æ 
Personal For Clinical Research software and CareLink¬Æ Clinical software is accessible to users using a standard 
browser, i.e., Microsoft¬Æ Internet Explorer, on an Internet enabled PC.  
The CareLink¬ÆPersonal For Clinical Research software and CareLink¬ÆClinical software use standard Transport 
Layer Security (TLS) technology. TLS transmission protocol invo kes encryption on both ends of the 
transmissions and is the standard for all security-based system s. The encryption remains in effect whether the 
data is moving to and from the client and server in the United States, or to and from a client in another country 
to the United States. The data is secure behind a three-tier in dustry standard architecture, which places the 
database behind three different firewalls, where each firewall separates a tier: 
xThe internet to the web server; 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 71 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xWeb server to the application server; 
xApplication server to the database server. 
The CareLink¬ÆClinical software supports both Bluetooth¬ÆLow Energy pumps and non- Bluetooth¬ÆLow Energy 
pumps, while the CareLink¬Æ Personal For Clinical Research software only support non- Blue tooth¬Æ Low Energy 
pumps.
 
&DUH/LQN86%*+]
The CareLink USB is an accessory to the CareLink Personal Thera py Management Software that facilitates 
wireless communication between a personal computer and devices employing the Medtronic proprietary RF 
technology. The device is only intended to transfer data, it do es not have any diagnostic or therapeutic 
function/benefit. 
 
%OXH$GDSWHU
The Blue Adapter is an optional accessory with Bluetooth techno logy that facilitates the communication 
between a personal computer and the insulin pump, via BLE wirel ess communication protocol. The Blue 
Adapter is an off-the-shelf non-medical device intended to tran sfer data to CareLink Server. The Blue Adapter 
does not have any computation, diagnostic, monitoring or therap eutic function/benefit. Medtronic will provide 
the Blue Adapter as a convenience to customers as an alternativ e for patients without mobile devices. 
 
 0HGWURQLF0RELOH$SSOLFDWLRQ
The MiniMed Mobile Application is an optional accessory to the MiniMed 770G insulin pump and provides a 
secondary display and passive monitoring of pump data for users  with compatible electronic devices. The 
Mobile App is available for both iOS and Android platforms. 
 
&DUHOLQN&RQQHFW$SSOLFDWLRQ
The CareLink Connect App is an optional accessory which receive s pump data wirelessly from the CareLink 
server. The CareLink Connect App provides a mirroring display o f the MiniMed Mobile App screen, for remote 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 72 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
monitoring by a care partner (e.g., care giver or health care pr ovider). The CareLink Connect App is not 
designed to monitor the performance of the insulin pump nor for  direct monitoring of pump data. As a 
mirroring display, the app can provide notifications to the car e partner via the user interface. 
 
.HWRQH0HWHU
The Ketone Meter measures both blood glucose (sugar) and blood √ü-Ketone. In this study, the meter will only 
be used to collect √ü-Ketone data, which will be collected for r eporting and review (see 
Investigator/Coordinator binder for details) and as described i n the body of this study protocol. This particular 
meter will be used because it is the only commercially availabl e meter which allows quantification of blood √ü-
Ketone levels and is the preferred patient method of testing ov er urine testing. 
Note: In the event the blood ketone meter is not used to collect keto ne values, urine ketones must be 
measured and entered into CareLink instead.   
 
,QIXVLRQVHWV
xQuick Set Infusion sets 
xSilhouette Infusion sets 
xSure-T Infusion sets 
xMio Infusion sets 
 Note: Medtronic may incorporate additional infusion sets into t his clinical study as they become commercially 
available. Instructions for the devices used in this study are provided in their respective manuals. All infusion 
sets provided to subjects must be approved or cleared for use w ith MiniMed Pump for Humalog and Novolog. 
 
 5HVHUYRLUV
Patients are instructed to change their reservoir every 2 to 3 days. All reservoirs provided to subjects must be 
approved or cleared for use with the MiniMed pump for Humalog a nd Novolog. 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 73 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
,QIXVLRQ6HW6HUWHU'HYLFHV
The following infusion set type has a corresponding serter devi ce.
xQuick-Serter‚Ñ¢ (MMT-305)
xSil-Serter‚Ñ¢ (MMT-385)
The devices are indicated for single patient multi use, i.e. a patient uses the same serter every 2 to 3 days to 
insert a new infusion set as described in the IFU. All infusion  set serter devices provided to subjects must be 
approved or cleared for use with the MiniMed pump for Humalog a nd Novolog. 
 
,QVXOLQ
Patients will use their own rapid-acting analogue insulin (novo log, humalog) during this stu dy. 
 
6XSSOLHV
Study pump, study meters and sensors are supplied with addition al, commercially available materials i.e., 
reservoirs, infusion sets, alcohol wipes, meter supplies, tape,  etc. free of charge.   
 
3DFNDJLQJ
In Europe, all devices will be labeled in accordance with local  language requirements.
Labeling for the study devices will be provided under separate cover. Investigational devices will be labeled in 
accordance to their regulatory requirements. 
 
3URGXFW7UDLQLQJ5HTXLUHPHQWV
Training of the investigational center staff on the conduct of the study and system being studied will be 
initiated before the protocol is implemented.  All participatin g physicians and coordinators will be familiarized 
with the system. Specific investigational center staff will be trained on each of the system‚Äôs components. 
Training will contain both lecture and hands-on experience.
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 74 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Trained product support personnel may be present at the trainin g and study follow-up visits to provide technical 
support.  
Trained personnel may also give technical support via the local  support service, e.g. Medtronic 24HR Technical 
Support.  
 
3URGXFW5HFHLSWDQG7UDFNLQJ
Upon receipt of the study devices, investigational center staff  take inventory of the shipment, making sure that 
information on the packing slips/invoices matches exactly the c ontents of the containers, as applicable, 
including: 
xShip To
xReference Number
xDevice Type
xQuantity  
xQuantity per package  
xLot number (where applicable) 
xSerial number (where applicable) 
 Ensure that devices and supplies received have not reached thei r expiration date.  
Sign and date the packing slips/invoices, noting any discrepanc ies, and file in appropriate study binder. 
Notify the study Monitor of any discrepancies. 
Enter the study device information on the appropriate eCRF in t he study database. 
 
'HYLFH'LVEXUVHPHQW
Each time a study device is disbursed to a Subject by the Inves tigator or authorized member of the research 
team, all required eCRF and source documentation will be comple ted (see 7DEOH  for details). Documentation 
may include: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 75 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xDate of disbursement  
xSubject ID 
xLot number(s)  
xSerial Number 
xReference Number 
xAmount dispensed 
 
3URGXFW6WRUDJH
Study devices are to be stored in a secure environment with acc ess limited to authorized research personnel. 
Study devices are to be stored in the proper environmental cond itions, as identified in the user guide/labeling
 
3URGXFW5HWXUQ
After use by the subject, the investigational center is expecte d to accept and retain all devices as described in 
Table and store them in a secure environment. If containers/units/de vices are missing, document the 
reasons in the eCRF. If discrepancies between amounts used by s ubjects and amounts expected to be returned 
exist, document the reasons in the eCRF. 
All devices, as described in Table , will be returned by subjects to the investigational center an d then to the 
Sponsor. Serialized devices provided to the investigational cen ter may be returned as subjects complete the 
study, at the end of study or upon sponsor request. The quantit y received by the investigational center and the 
quantity returned to sponsor should be equal. The investigation al center will provide details of the disposition 
of all unreturned serialized devices (excluding the Study Meter  and Ketone Meter) in the eCRF.  
Used glucose sensors are not expected to be returned by subject s to the investigational center and therefore 
are not expected to be returned to the sponsor.  Other unused c onsumable devices (i.e., infusion sets, alcohol 
wipes, Study Meter supplies, tape, etc.), supplies or materials  may be returned to the sponsor or retained by 
investigational center for educational purposes only, or may be  disposed of properly by the investigational 
center staff.   
Disposable devices and supplies that have been used  by a subject will be disposed of properly by the subject or 
the investigational center staff during the conduct of the stud y. This would include glucose sensors, meter 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 76 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
testing strips and supplies, infusion sets and adhesive tape.  
All study devices that were required to be entered into the stu dy database are required to be accounted for as 
described herein prior to return to sponsor or at the end of th e study. 
 
3URGXFW$FFRXQWDELOLW\
Good clinical research practice requires that investigators and  research teams ensure accurate accountability 
for any investigational device used in a research trial. It is expected that all investigational devices will be used 
in  
the manner intended during the study, that they will be stored under appropriately controlled conditions with 
controlled access and that they will be used only by (on) subje cts who have consented to participate in the 
research study. 
Any investigational device being used in clinical research must  be strictly accounted for and will not be shipped 
to any site unless all of the necessary approvals (e.g. Regulat ory, IRB/EC) have been received. This includes 
keeping records of: 
1.Center receipt and inventory management 
2.Storage  
3.Subject Disbursement   
4.Return (by Subjects and Center) and/or disposal  
During the conduct of the study the investigational center staf f will account for, and document, the following: 
 
Table 9. Device Accountability Requirements (U.S. Sites) 
Device Site Receipt 
(packing slip 
and eCRF) Disbursement to 
Subject (eCRF) Device 
Disposition at 
Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
MiniMed 670G Insulin Pump 
(MMT-1780)Yes Yes Return to Sponsor Yes 
MiniMed 770G Insulin Pump Yes Yes Return to Sponsor Yes 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 77 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device Site Receipt 
(packing slip 
and eCRF) Disbursement to 
Subject (eCRF) Device 
Disposition at 
Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
(MMT-1880)
CONTOUR¬Æ NEXT LINK 2.4 by 
Ascencia Blood Glucose Meter(MMT-1152 or MMT-
1352)   Yes Yes Dispose or return 
unused to Sponsor Yes 
Accu-Chek Guide Link Meter 
Blood Glucose Monitoring System (08116083022) Yes Yes Return to Sponsor Yes 
Guardian Sensor (3) (MMT-
7020) ‚Äì for 670G only Yes Yes Dispose or return 
unused to Sponsor Yes 
Guardian Sensor (3) (MMT-
7020) ‚Äì for 770G only Yes NoDispose or return 
unused to Sponsor No
One-Press Serter (MMT-7512) No No Dispose or return 
unused to SponsorNo 
Guardian Link (3) Transmitter 
(MMT-7811) for 670G only Yes Yes Return to Sponsor Yes 
Guardian Link (3) Transmitter 
(MMT-7910) for 770G only Yes Yes Return to Sponsor Yes
Tester (MMT-7736L) No No Dispose or return 
unused to Sponsor  No 
Transmitter Charger (MMT-
7715) No No Dispose or return 
unused to Sponsor  No 
CareLink USB 2.4 GHz (MMT-
7306)No No Dispose or return 
unused to Sponsor No 
Ketone Meter No No Dispose or return 
unused to Sponsor  No 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 78 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Devices may be combined and distributed in kits. 
 Table 10. Device Accountability Requirements (European Sites) 
Device Site Receipt 
(packing slip 
and eCRF) Disbursement to 
Subject (eCRF)Device Disposition 
at Conclusion of 
Study Record Device 
Disposition 
(eCRF) 
MiniMed 670G Insulin Pump  
(Europe MMT-1781, and 
MMT-1782) Yes Yes Return to Sponsor Yes 
CONTOUR¬Æ NEXT LINK 2.4 by 
Ascencia Blood Glucose 
Meter  
(MMT-1352, Europe: MMT-
1151, MMT-1152)  Yes Yes Dispose or return 
unused to Sponsor Yes 
Guardian Sensor (3) (MMT-
7020) No NoDispose or return 
unused to Sponsor No
Guardian Link (3) 
Transmitter (MMT-7811)Yes Yes Return to Sponsor Yes 
Tester (MMT-7736L) No No Dispose or return 
unused to Sponsor No 
One-Press Serter  
(MMT-7512) No No Dispose or return 
unused to Sponsor No 
Transmitter Charger (MMT-
7715) No No Dispose or return 
unused to Sponsor No 
CareLink USB 2.4 GHz 
(MMT-7306) No No Dispose or return 
unused to Sponsor No 
Ketone Meter No No  Dispose  No 
Devices may be combined and distributed in kits.  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 79 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Table 11. Device Accountability Requirements (Canadian Sites)
Device Site Receipt 
(packing slip and 
eCRF) Disbursement 
to Subject 
(eCRF) Device Disposition 
at Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
MiniMed 670G Insulin Pump 
(Canada MMT-1781 (pump))  Yes Yes Return to Sponsor Yes 
MiniMed 770G Insulin Pump 
(Canada MMT-1881) Yes Yes Return to Sponsor Yes 
CONTOUR¬ÆNEXT LINK 2.4 by 
Ascencia Blood Glucose Meter (Canada MMT-1351 or MMT-1352) Yes Yes Dispose or return 
unused to Sponsor Yes 
Accu-Chek Guide Link Meter 
Blood Glucose Monitoring 
System (08109222001) Yes Yes Return to Sponsor Yes 
Guardian Sensor (3) (MMT-
7020) ‚Äì for 670G only Yes Yes Dispose or return 
unused to Sponsor Yes 
Guardian Sensor (3) (MMT-
7020) ‚Äì for 770G only Yes No Dispose or return 
unused to Sponsor No 
Guardian Link (3) Transmitter 
(MMT-7811WW), 670G only. Yes Yes Return to Sponsor Yes 
Guardian Link (3) Transmitter 
(MMT-7911) 770G only Yes Yes Return to Sponsor Yes 
Tester 
(MMT-7736L)No No Dispose or return 
unused to Sponsor No 
One-Press Serter 
(MMT-7512) No No Dispose or return 
unused to Sponsor No 
Transmitter Charger  
(MMT-7715) No No Dispose or return 
unused to Sponsor No 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 80 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device Site Receipt 
(packing slip and 
eCRF) Disbursement 
to Subject 
(eCRF) Device Disposition 
at Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
CareLink USB 2.4 GHz (MMT-
7306) No No Dispose or return 
unused to Sponsor No 
Ketone Meter No No Dispose No 
Devices may be combined and distributed in kits. 
 Table 12. Device Accountability Requirements (Australian Sites)  
Device Site Receipt 
(packing slip and 
eCRF) Disbursement 
to Subject 
(eCRF) Device Disposition 
at Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
MiniMed 770G Insulin Pump 
(MMT-1881, MMT-1891) Yes Yes Return to Sponsor Yes 
Accu-Chek Guide Link Meter 
Blood Glucose Monitoring System (08116113186M) Yes Yes Return to Sponsor Yes 
Guardian Sensor (3)  
(MMT-7020C5) ‚Äì for 770G only Yes No Dispose or return 
unused to Sponsor No 
Guardian Link (3) Transmitter 
(MMT-7910WS, MMT-7911W) 
770G only Yes Yes Return to Sponsor Yes 
Tester 
(MMT-7736L) No No Dispose or return 
unused to Sponsor No 
One-Press Serter  
(MMT-7512) No No Dispose or return 
unused to Sponsor No 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 81 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device Site Receipt 
(packing slip and 
eCRF) Disbursement 
to Subject 
(eCRF) Device Disposition 
at Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
Transmitter Charger  
(MMT-7715) No No Dispose or return 
unused to Sponsor No 
CareLink USB 2.4 GHz 
(Austalia, New Zealand) No No Dispose or return 
unused to Sponsor No 
Ketone Meter No No Dispose  No 
Devices may be combined and distributed in kits. 
 
Table 13. Device Accountability Requirements (New Zealand Sites ) 
Device Site Receipt 
(packing slip and 
eCRF) Disbursement 
to Subject 
(eCRF) Device Disposition 
at Conclusion of 
Study Record 
Device 
Disposition 
(eCRF) 
MiniMed 770G Insulin Pump 
(MMT-1881, MMT-1891)Yes Yes Return to Sponsor Yes 
Accu-Chek Guide Link Meter 
Blood Glucose Monitoring System (08116113186M) Yes Yes Return to Sponsor Yes 
Guardian Sensor (3)  
(MMT-7020C5) ‚Äì for 770G only Yes No Dispose or return 
unused to Sponsor No 
Guardian Link (3) Transmitter 
(MMT-7910WS, MMT-7911W) 770G only Yes Yes Return to Sponsor Yes 
Tester 
(MMT-7736L) No No Dispose or return 
unused to Sponsor No 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 82 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Device Site Receipt 
(packing slip and 
eCRF)Disbursement 
to Subject 
(eCRF)Device Disposition 
at Conclusion of 
StudyRecord 
Device 
Disposition 
(eCRF) 
One-Press Serter  
(MMT-7512) No No Dispose or return 
unused to Sponsor No 
Transmitter Charger  
(MMT-7715) No No Dispose or return 
unused to Sponsor No 
CareLink USB 2.4 GHz (ACC-
1003911D)No No Dispose or return 
unused to Sponsor No 
Ketone Meter No No Dispose  No 
Devices may be combined and distributed in kits. 
 
6HOHFWLRQRI6XEMHFWV
6WXG\3RSXODWLRQ
A diverse population of patients with type 1 diabetes will be s tudied. The study population will have a large 
range for duration of diabetes and glycemic control, as measure d by glycosylated hemoglobin (A1C). 
 
 6XEMHFW(QUROOPHQW
Subjects will be considered enrolled in the study upon signing the Informed Consent/Assent form(s). 
 
,QFOXVLRQ&ULWHULD
Subjects will be considered for enrollment in the study if they  meet all of the following criteria:
1.Subject is age 2-80 years at time of screening 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 83 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
a. US, Canada, Australia and New Zealand: Subjects 2-80 years of a ge will be allowed to enroll in the 
post approval study.  
b.Europe: Only s ∆µƒè≈©ƒûƒê∆ö∆ê—àœ≥«áƒûƒÇ∆å∆ê≈Ωƒ®ƒÇ≈êƒûƒÇ∆åƒûƒÇ≈Ø≈Ø≈Ω«Åƒûƒö∆ö≈Ωƒû≈∂∆å≈Ω≈Ø≈Ø≈ù≈∂∆ö≈öƒû∆â≈Ω∆ê∆ö -market study. 
2.Subjects who are 2-21 years are determined by the investigator to have the appropriate, requisite 
support (family, caregiver or social network) to successfully p articipate in this study 
3.Subject must have a minimum daily insulin requirement (Total Da ily Dose) of equal to or greater than 8 
units/day  
4.Subjects who are determined by the investigator to be psycholog ically sound in order to successfully 
participate in this study. 
5.Subject has been diagnosed with type 1 diabetes for at least th ree months  
Note: Determination of classification for diabetes will be base d on American Diabetes Association 
Clinical Practice Guidelines accounting for several patient cha racteristics such as:  age of onset, 
patient‚Äôs weight or BMI, history of diabetic ketoacidosis, hist ory of therapy management, if available 
in the medical records.   
6.Subject must be on one of the following management therapies:  
xMultiple daily injections defined by use of rapid analogue with  meals and approved long acting 
analogue (e.g. detemir or glargine) with or without CGM 
xInsulin pump therapy with or without CGM 
7.^∆µƒè≈©ƒûƒê∆ö≈ù∆ê«Å≈ù≈Ø≈Ø≈ù≈∂≈ê∆ö≈Ω∆âƒû∆åƒ®≈Ω∆å≈µ—àœ∞ƒ®≈ù≈∂≈êƒû∆å∆ê∆ö≈ùƒê≈¨ƒè≈Ø≈Ω≈Ωƒö≈ê≈Ø∆µƒê≈Ω∆êƒû≈µƒû ƒÇ∆ê∆µ∆åƒû≈µƒû≈∂∆ö∆êƒöƒÇ≈ù≈Ø«á  
8.Subject is willing to perform required study procedures  
9.Subject is willing to wear the system continuously throughout t he study for at least 80% of the time 
10.Subject is willing to upload data at least weekly from the stud y pump/meter, must have Internet access 
and a computer system that meets the requirements for uploading  the study pump/meter for data 
collection 
11.Subject must be willing to use the study glucose meter system ( i.e. along with study meter strips).    
12.If subject has celiac disease, it has been adequately treated a s determined by the investigator 
13.Subject with the diagnosis of myocardial infarction, unstable a ngina, coronary artery bypass surgery, 
coronary artery stenting, transient ischemic attack, cerebrovas cular accident, angina, congestive heart 
failure, ventricular rhythm disturbances or thromboembolic dise ase, within 1 year of screening, will be 
included in the study with the consent of the Investigator  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 84 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
14. Subject is willing to take one of the following insulins and  can financially afford to use either of the 2 
insulin preparations throughout the course of the study (i.e. c o-payments for insulin with insurance or 
able to pay full amount) 
a.Humalog¬Æ (insulin lispro injection) 
b.NovoLog¬Æ (insulin aspart) 
 
([FOXVLRQ&ULWHULD
1.Subject participated in any Closed Loop study in the past 
2.Subject is unable to tolerate tape adhesive in the area of sens or placement 
3.Subject has any unresolved adverse skin condition in the area o f sensor placement (e.g., psoriasis, rash, 
Staphylococcus  infection) or area of infusion set placement 
4.Women of child-bearing potential who have a positive pregnancy test at screening or plan to become 
pregnant during the course of the study  
5.Subject is being treated for hyperthyroidism at time of screeni ng 
6.Subject has an abnormality (out of reference range) in thyroid- stimulating hormone (TSH) at time of 
screening visit. TSH is not required for subjects 2-13 years of  age.
7.Subject has taken any oral, injectable, or IV glucocorticoids w ithin 8 weeks from time of screening visit, 
or plans to take any oral, injectable, or IV glucocorticoids du ring the course of the study. 
8.Subject is actively participating in an investigational study ( drug or device) wherein he/she has received 
treatment from an investigational study drug or investigational  study device in the last 2 weeks 
9.Subject is currently abusing illicit drugs or marijuana 
10.Subject is currently abusing prescription drugs   
11.Subject is currently abusing alcohol 
12.Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP ag onists, biguanides, DPP-4 inhibitors or 
sulfonylureas at time of screening  
13.  Subject is using hydroxyurea at the time of screening or plan s to use it during the study 
14. Subject has a history of visual impairment which would not allo w subject to participate in the study 
and perform all study procedures safely, as determined by the i nvestigator 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 85 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
15.Subject has a sickle cell disease, hemoglobinopathy; or has rec eived red blood cell transfusion or 
erythropoietin within 3 months prior to time of screening  
16.Subject plans to receive red blood cell transfusion or erythrop oietin over the course of study 
participation  
17.Subject diagnosed with current moderate to severe eating disord er such as anorexia or bulimia 
18.Subject has been diagnosed with chronic kidney disease requirin g dialysis or resulting in chronic 
anemia  
19.Subjects who are currently being actively treated for cancer. 
20.Subject who is designated as a research staff member for this s tudy 
 
 6WXG\6LWH5HTXLUHPHQWV
6WXG\6LWH$FWLYDWLRQ
During the activation process (prior to subject enrollment), Me dtronic will train investigational center staff 
using the sponsor training protocol.  If new members join the s tudy investigational center team, they will 
receive training on the applicable study requirements relevant to their role before contributing to the study. 
Prior to performing study-related activities, all training requ irements shall be fulfilled. 
 
6WXG\3URFHGXUHV
 2YHUYLHZ

Run-In Period Synopsis (Run-in Visits 1-3) 
The purpose of the run-in period is to ensure that study subjec ts are introduced to study devices and to 
provide blinded CGM data. Subjects will be trained on CGM use a nd blinded CGM will be used to collect 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 86 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
data with each subject‚Äôs existing diabetes therapy. There is a window of 60 days from the end of Visit 1 
to the end of Visit 3 during which time subjects should complet e run-in. Subjects will be started on the 
study pump at Visit 3.  
xDevices Worn:   
RMedtronic CGM (blinded) only 
RDepending on age group, sensor is self-inserted by subject or i nserted with assistance 
RExisting Therapy

Study Period Synopsis
Overview:  
 
The study period is  6 months Subjects will be randomized at th e start the study period into 2 arms:  
xHCL Arm: Auto Mode feature on the study pump  turned ON  
xControl Arm: Continue with own therapy for 6 months  
 
RCSII Cohort: The CSII Cohort will use the MiniMed  Pump without  Real Time CGM during 
the 6 month study period. Blinded CGM (Guardian Link (3) Transm itter and Guardian 
Sensor (3)) will only be worn at baseline, 3 months, and 6 mont hs (two weeks of sensors 
use)
RMDI Cohort: The Multiple Daily Injection (MDI) Cohort will rema in on MDI therapy with 
subjects using their own insulin for 6 months during the study period. Blinded CGM 
(Guardian Link (3) transmitter and Guardian Sensor (3)) will on ly be worn at baseline, 3 
months, and 6 months (two weeks of sensors use).  
MDI subjects who are currently using CGM, i.e. Dexcom or Medtro nic Guardian Connect 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 87 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
or who are currently using a SMBG alternative, i.e. Libre, will  be allowed to enroll in the 
study and continue using their own device. There will be N=100 
RSAP Cohort: The Sensor Augmented Pump (SAP) Cohort will use the  MiniMed Pump 
(SAP without Low Management Suspend on Low, Low Management Susp end before low 
or Auto Mode) with Real Time CGM for the 6 month study period  
R
Note: Subjects 2-6 years of age will automatically enter the HC L arm at the end of the 
run-in period
 
Study Period Device Procedures for HCL Arm
 
xDevices Worn:   
RMiniMed Pump 
RDepending on randomization and age group, sensor is self-insert ed by subject or 
inserted with assistance  
xCalibration Requirements with Study Meter:   
RApproximately 30 minutes to 2 hours after the Guardian Sensor ( 3) is initialized, the 
Study Pump will alert the user to enter meter BGs to perform in itial calibration.    
RAfter the first calibration, the user must calibrate the Guardi an Sensor (3) with the study 
meter within 6 hours of the first calibration.   
RThe user must calibrate with the study meter when prompted by t he study pump via the 
Smart Cal feature 
RThe user must calibrate with the study meter every 12 hours aft er last calibration. 
RRecommend 3-4 calibrations per day with the study meter  
RAll BGs used for Auto Mode in the MiniMed Pump system can also be used for sensor 
calibration. However, calibrating during rapid changes (2 or 3 arrows) may temporarily 
decrease sensor accuracy. Best practices should be followed for  each BG measurement 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 88 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
(e.g. clean hands, accepting the calibration on the pump withou t delay) 
ROther recommendations: 
¬ÉAlways have clean dry fingers when you check your blood glucose  
¬ÉOnly use your fingertips to obtain blood samples for calibratio n 
 
xAuto Mode Settings:  
RThe Auto Mode (Closed Loop) target for the closed loop algorith m is set at 120 mg/dL 
(6.7 mmol/L).   
RThe Temp target setting in the pump may be used when subject ex ercises. Temp Target 
Threshold is set to 150 mg/dL (8.3 mmol/L). 
RAlarms that are fixed into system: 
¬ÉSG at or below 50 mg/dL (2.8 mmol/L) 
¬ÉWhen SG at or above 300 mg/dL (16.7 mmol/L) for one hour  
¬ÉWhen SG at or above 250 mg/dL (13.9 mmol/L) for 3 hours  
RHigh Setup limit (i.e. the setting for a high glucose alert thr eshold based on sensor 
reading) is recommended to be set at 300 mg/dL (16.6 mmol/L)
¬ÉAlert setting options may be set per investigator discretion 
RLow Setup limit (i.e. the setting for a low glucose alert thres hold based on sensor 
reading) is recommended to be set at 70 mg/dL (4.0 mmol/L) 
¬ÉAlert setting options may be set per investigator discretion 
¬ÉFor subjects 2-6 years of age, low limit should be set to 80mg/ dL (4.4mmol/L) 
and no lower than 70mg/dL(4.0 mmol/L) 
¬ÉSubjects will be instructed to follow up with an SMBG confirmat ory 
measurement when receiving a low alert  
RInsulin carbohydrate ratios may be adjusted throughout study.  
RActive insulin time may also be adjusted.   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 89 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xManual Mode Settings:  
RHigh Set up Limit recommend to be set at 300 mg/dL (16.6 mmol/L) 
¬ÉAlert Setting Options may be set per investigator discretion 
RLow Set up Limit recommend to be set at 70 mg/dL (4.0 mmol/L) 
¬ÉFor subjects 2-6 years of age, low limit should be set 80 mg/dL  (4.4 mmol/L) and 
no lower than 70 mg/dL(4.0 mmol/L) 
¬ÉSubjects will be instructed to follow up with an SMBG confirmat ory 
measurement when receiving a low alert  
RPredictive alerts and rate of change alerts are optional
RSmartGuard Manual Mode Low Management features may be used when  Auto Mode is 
OFF  
RConsider setting the glucose target in the bolus wizard calcula tor to the same target as 
the closed loop algorithm, i.e. 120 mg/dL (6.7mmol/L) or higher , based on investigator 
discretion. 
xMonitoring Method:   
RStudy Meter 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 90 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Continuation Period Synopsis  
Overview:  
The continuation period is 6 months in duration. Subjects will use MiniMed Pump System and continue 
from the end of the study period as follows: 
 
Continuation Period Device Procedures
   
xDevices Worn:   
RMiniMed  Pump with CGM 
RSensor is self-inserted by subject or inserted with assistance  
xCalibration Requirements with Study Meter:   
RApproximately 30 minutes to 2 hours after the Guardian Sensor ( 3) is initialized, the 
Study Pump will alert the user to enter meter BGs to perform in itial calibration.    
RAfter the first calibration, the user must calibrate the Guardi an Sensor (3) with the study 
meter within 6 hours of the first calibration.   
RThe user must calibrate with the study meter when prompted by t he study pump via the 
Smart Cal feature 
RThe user must calibrate with the study meter every 12 hours aft er last calibration.  
RRecommend 3-4 calibrations per day with the study meter  
RAll BGs used for Auto Mode in the MiniMed Pump system can also be used for sensor 
calibration. However, calibrating during rapid changes (2 or 3 arrows) may temporarily 
decrease sensor accuracy. Best practices should be followed for  each BG measurement 
(e.g. clean hands, accepting the calibration on the pump withou t delay)
ROther recommendations: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 91 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
¬ÉAlways have clean dry fingers when you check your blood glucose  
¬ÉOnly use your fingertips to obtain blood samples for calibratio n 
 
xAuto Mode Settings  
RThe Auto Mode (Closed Loop) target for the closed loop algorith m is set at 120 mg/dL 
(~6.7 mmol/L).   
RThe Temp target setting in the pump may be used when subject ex ercises. Temp Target 
Threshold is set to 150 mg/dL (~8.3 mmol/L). 
RAlarms that are fixed into system:
¬ÉSG at or below 50 mg/dL (~2.8 mmol/L) 
¬ÉWhen SG at or above 300 mg/dL (~16.7 mmol/L) for one hour 
¬ÉWhen SG at or above 250 mg/dL (~13.9 mmol/L) for 3 hours  
RHigh Setup limit (i.e. the setting for a high glucose alert thr eshold based on sensor 
reading) is recommended to be set at 300 mg/dL (16.6 mmol/L) 
¬ÉAlert setting options may be set per investigator discretion 
RLow Setup limit (i.e. the setting for a low glucose alert thres hold based on sensor 
reading) is recommended to be set at 70 mg/dL (4.0 mmol/L) 
¬ÉAlert setting options may be set per investigator discretion
¬ÉFor subjects 2-6 years of age, low limit should be set 80mg/dL (4.4 mmol/L) and 
no lower than 70 mg/dL (4.0 mmol/L) 
¬ÉSubjects will be instructed to follow up with an SMBG confirmat ory 
measurement when receiving a low alert  
RInsulin carbohydrate ratios may be adjusted throughout study.   
RActive insulin time may also be adjusted.   
xManual Mode Settings: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 92 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
RHigh Set up Limit recommend to be set at 300 mg/dL (16.6mmol/L) 
¬ÉAlert Setting Options may be set per investigator discretion 
RLow Set up Limit recommend to be set at 70 mg/dL (4.0mmol/L) 
¬ÉFor subjects 2-6 years of age, low limit should be set 80mg/dL (4.4 mmol/L) and 
no lower than 70 mg/dL(4.0mmol/L) 
¬ÉSubjects will be instructed to follow up with an SMBG confirmat ory 
measurement when receiving a low alert  
RPredictive alerts and rate of change alerts are optional
RSmartGuard Manual Mode Low Management features may be used when  Auto Mode is 
OFF  
RConsider setting the glucose target in the bolus wizard calcula tor to the same target as 
the closed loop algorithm, i.e. 120 mg/dL(6.8mmol/L) or higher,  based on investigator 
discretion. 
 
xMonitoring Method:   
Study Meter
 
 
6FKHGXOHG)ROORZ8S9LVLW:LQGRZV
Refer to the Appendices (Section 24) for the Cohort Visit Table s. 
 
6FKHGXOHRI(YHQWV
Each subject‚Äôs participation will be comprised of the following  scheduled visits listed below over the course of 
approximately 8 months during the run-in period and study perio d, and for 6 months during the continuation 
period.  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 93 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xTelemedicine visits will be allowed to replace office visits if  they do not involve collection of blood test 
samples or device related procedures that require staff assista nce
(DUO\:LWKGUDZDO
6XEMHFWVZKRH[LWWKHVWXG\EHIRUHWKHODVWVFKHGXOHGVWXG\YLV LWZLOOFRPSOHWHDOOUHTXLUHPHQWVWKDWDUHOLVWHG
IRU9LVLW ZLWKWKHH[FHSWLRQRIFSHSWLGHODEWHVWLQJ

The schedule is planned as follows: 
 
Screening and Run-In Period 
All subjects will complete screening and the run-in period. Thi s period must be completed in 60 days.   
Visit 1 : Screening Visit ‚Äì Consent and Screening 
xPatients may re-screened once with Sponsor approval 
Visit 2: Begin Run-in Period  
xPlacement of blinded sensor to be worn for 2 Weeks  (each senso r is worn for 7 days) 
xStudy training, including instruction on procedures for wearing  blinded CGM (i.e., insertion of sensor)         
Visit 3: Begin MiniMed  Pump (Except MDI Control) 
xOccurs after 2 week blinded sensor wear, either immediately at the end of sensor wear or suggested to 
be within 14 days.  
xThe run-in period may be repeated a second time with Sponsor ap proval  
 
Randomization 
At Visit 3 all subjects (CSII, MDI, or SAP Cohort) will be randomized into one of 2 arms:
HCL Arm 
RNote: Patients who are on SAP at baseline will start Medtronic CGM at this visit .  
Control Arm  
RNote: Patients in SAP will receive and be trained on Medtronic CGM if they are randomized to 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 94 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
the Control arm to ensure continuity with use of real time CGM.   
 In the US and Canada, when available, subjects will have the op tion to begin with MiniMed 770G system or 
exchange their MiniMed 670G for a MiniMed 770G system. 
 Note: Subjects 2-6 years of age will automatically enter the HC L arm at the end of the run-in period 
 
To schedule Visit 4:  
RFor subjects who have been on insulin pump therapy prior to scr eening for at least 3 months, Visit 4 
should occur 3-30 days after Visit 3  
RFor subjects without pump therapy experience, the following sho uld occur:  
xIf randomized to HCL Arm, Visit 4 should occur 14-30 days after  Visit 3  
xIf randomized to MDI Control Arm, Visit 4 should occur 1-7 days  after Visit 3  
 
The visit schedules for each of these Arms are as follows:  
HCL Arm: 
 
Visit 4: Start CGM - Day 0  
RStart CGM with Guardian Sensor (3) (Note: SAP subjects will hav e already started CGM with Guardian 
Sensor (3) at Visit 3). 
Visit 4A: Follow up Telephone visit - 2-3 days after Visit 4  
Visit 5: Follow up Office Visit -7-21 days  after Visit 4   
RAuto Mode is enabled and activated. Investigator sets carbohydr ate to insulin ratios and active insulin 
time, and basal rates for open loop periods  
Visit 6A: Follow-up Telephone Visit (option of office visit) ‚Äì 1 Day after Visit 5 
Visit 6B: Follow-up Telephone Visit (option of office visit) - 2 Days after Visit 5 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 95 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Visit 6C: Follow-up Telephone Visit - 5 Days (¬± 1 day) after Visit 5
Visit 7A: Follow up Office Visit - 14 Days (¬± 3 days)  after Visit 5  
Visit 7B: Follow-up Telephone Visit - 21 Days (¬± 3 days) after Visit 5 
Visit 7C: Follow up Office Visit - 30 Days after Visit 5 (¬± 5 d ays)   
Visit 7D: Follow-up Telephone Visit - 45 Days (¬± 7 days) after Visit 5    
Visit 8: Follow up Office Visit - 90 Days after Randomization ( ¬± 10 days)  
Visit 9: Follow up Office Visit - 180 Days after Randomization  (¬± 10 days)    
REnd of Study Period and Start of Continuation period  
 
Control Arm:
 
a.CSII Cohort 
Visit 4: Day 0:  
RReview pump settings 
Visit 5: Follow up Office Visit 7-21  days after Visit 4  
RInsulin Pump adjustments 
Visit 6A: Follow up Telephone Visit - 1  Day after Visit 5   
Visit 6B: Follow up Telephone Visit - 2  Days after Visit  5   
Visit 6C:  Follow up Telephone Visit - 14  Days (¬± 7 days)  after Visit 5  
Visit 6D: Follow up Office Visit - 30  Days after Visit 5 (¬± 7 days) 
Visit 6E: Follow-up Telephone Visit - 45 Days (¬± 7 days) after Visit 5    
Visit 7: Follow up Office Visit - 76 days after Randomization  (-14 days) 
RBlinded CGM Start 
R14 days of sensor wear before 90 Day study period visit. Transm itter is not connected to study pump 
Visit 8A: Follow up Office Visit ‚Äì 90 Days  after  Randomization  (+14 days) 
RBlinded CGM Return 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 96 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Visit 8B: Follow up Office Visit - 166 days after Randomization  (-14 days)
RBlinded CGM Start 
R14 days of sensor wear before 180 Day study period visit. Trans mitter is not connected to study pump 
Visit 9: Follow up Office Visit ‚Äì 180 Days  after  Randomization  (+14 days)  
RBlinded CGM Return 
REnd of Study Period and Start of Continuation period. 
RStart CGM with Guardian Sensor (3) 
 
b.MDI Cohort 
 
Visit 4: Day 0  
Visit 5: Follow up Office Visit 7-21  days after Visit 4  
Visit 6A: Follow up Telephone Visit - 1  Day after Visit 5   
Visit 6B: Follow up Telephone Visit - 2  Days after Visit  5   
Visit 6C:  Follow up Telephone Visit - 14  Days (¬± 5 days)  after Visit 5  
Visit 6D: Follow up Office Visit - 25  Days after Visit 5 (¬± 5 days) 
Visit 6E: Follow-up Telephone Visit - 35 Days (+1 day) after Visit 5    
Visit 7: Follow up Office Visit - 76 days after Randomization  (-2 days) 
RBlinded CGM Start  
R14 days of sensor wear before 90 Day study period visit.  
Visit 8A: Follow up Office Visit ‚Äì 90 Days  after  Randomization  (+14 days) 
RBlinded CGM Return 
Visit 8B: Follow up Office Visit - 166 days after  Randomization  (-14 days)  
RBlinded CGM Start 
R14 days of sensor wear before 180 Day study period visit.  
Visit 9: Follow up Office Visit ‚Äì 180 Days  after  Randomization  (+14 days)  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 97 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
RBlinded CGM Return
REnd of Study Period and Start of Continuation period. 
RStart study pump  
 
c.SAP Cohort: 
 
Visit 4: Day 0    
Visit 4A: Follow up Telephone visit - 2-3 days after Visit 4  
Visit 5: Follow-up Office Visit - 7-21 days after Visit 4  
RPump and Sensor adjustments 
Visit 6A: Follow-up Telephone Visit (option of office visit) ‚Äì 1 Day after Visit 5  
Visit 6B: Follow-up Telephone Visit (option of office visit) - 2 Days after Visit 5   
Visit 6C: Follow-up Telephone Visit 7  days after Visit 5 (+3 days )  
Visit 7A: Follow-up Telephone Visit - 14  Days after Visit 5 (¬± 3 days)   
Visit 7B: Follow-up Telephone Visit - 21  Days after Visit  5 (¬± 3 days)  
Visit 7C: Follow-up Office Visit - 30  Days after Visit 5 (¬± 5 days) 
Visit 7D: Follow-up Telephone Visit - 45 Days (¬± 7 days) after Visit 5  
Visit 8: Follow-up Office Visit - 90  Days after Randomization  (¬± 10 days)   
Visit 9: Follow-up Office Visit - 180  Days after Randomization  (¬± 10 days)   
REnd of Study Period and Start of Continuation period 
RAuto Mode is enabled and activated. 
 
Continuation Period: 
HCL Arm: 
Visit 10: Follow up Office Visit ‚Äì 1 to 14 days after Visit 9  
Visit 11: Follow up Office Visit ‚Äì 15 to 30 days after Visit 9 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 98 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Visit 12: Follow up Office Visit - 270 Days after Randomization (+/- 21 days)
Visit 13: Follow up Office Visit - 365 Days after Randomization  (+/- 21 days)  
REnd of Continuation Period and End of Study 
 
Control Arm 
a.CSII Cohort: 
Visit 10A:  Follow up Telephone visit - 2-3 days after sensor start 
Visit 10B: Follow up Office Visit 7-21 days after Visit 9  
RAuto Mode is enabled and activated. 
Visit 10C: Follow up Telephone Visit  (option of office visit) ‚Äì 1 Day after Visit 10B 
Visit 10D: Follow up Telephone Visit  (option of office visit) ‚Äì 2 Days after Visit 10B  
Visit 10E: Follow-up Telephone Visit ‚Äì 5 Days (¬± 1 day) after Visit 10B  
Visit 11A: Follow up Office Visit - 14 Days after Visit 10B (¬±3 days)    
Visit 11B: Follow-up Telephone Visit - 21 Days (¬±3 days ) after Visit 10B  
Visit 11C: Follow up Office Visit - 30 Days after Visit 10B (¬±5 days)    
Visit 11D: Follow-up Telephone Visit - 45 Days (¬±7 days ) after Visit 10B   
Visit 12: Follow up Office Visit - 270 Days after Randomization  (+/- 21 days)  
Visit 13: Follow up Office Visit - 365 Days after Randomization  (+/- 21 days)  
REnd of Continuation Period and End of Study 
 b.MDI Cohort: 
Visit 9A: Follow up Office Visit ‚Äì 14-30 days after Visit 9 
RStart CGM with Guardian Sensor (3)  
RThis visit should occur between 14 and 30 days after pump start . 
Visit 10A:  Follow up Telephone visit - 2-3 days after sensor start 
Visit 10B: Follow up Office Visit 7-21 days after Visit 9A  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 99 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
RPatient has been wearing CGM for at least 4 days before enablin g Auto Mode
RAuto Mode is enabled and activated. 
Visit 10C: Follow up Telephone Visit  (option of office visit) ‚Äì 1 Day after Visit 10B 
Visit 10D: Follow up Telephone Visit  (option of office visit) ‚Äì 2 Days after Visit 10B  
Visit 10E: Follow-up Telephone Visit ‚Äì 5 Days (¬± 1 day) after Visit 10B  
Visit 11A: Follow up Office Visit - 14 Days after Visit 10B (¬±3 days)  
Visit 11B: Follow-up Telephone Visit ‚Äì 21 Days (¬± 3 day) after Visit 10B     
Visit 11C: Follow up Office Visit - 30 Days after Visit 10B (¬±5 days)    
Visit 11D: Follow-up Telephone Visit ‚Äì 45 Days (¬± 7 day) after Visit 10B  
Visit 12: Follow up Office Visit - 270 Days after Randomization  (+/- 21 days)  
Visit 13: Follow up Office Visit - 365 Days after Randomization  (+/- 21 days)  
REnd of Continuation Period and End of Study 
 
c.SAP Cohort: 
Visit 10A: Follow up Telephone Visit  (option of office visit) ‚Äì 1 Day after Visit 9 
Visit 10B: Follow up Telephone Visit  (option of office visit) ‚Äì 2 Days after Visit 9  
Visit 10C: Follow-up Telephone Visit ‚Äì 5 Days (¬± 1 day) after Visit 9  
Visit 11A: Follow up Office Visit - 14 Days after Visit 9 (¬±3 days)    
Visit 11B:   Follow-up Telephone Visit ‚Äì 21 Days (¬± 3 day) after Visit 9  
Visit 11C: Follow up Office Visit - 30 Days after Visit 9 (¬±5 days)    
Visit 11D: Follow-up Telephone Visit ‚Äì 45 Days (¬± 5  day) after Visit 9  
Visit 12: Follow up Office Visit - 270 Days after Randomization  (+/- 21 days)  
Visit 13: Follow up Office Visit - 365 Days after Randomization  (+/- 21 days)  
REnd of Continuation Period and End of Study 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 100 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
'DWD&ROOHFWLRQ
For detailed data collection and study procedure requirements, see Appendices . 
 6XEMHFW&RQVHQW
Informed Consent/Assent will be obtained in accordance with the  Code of Federal Regulations (CFR) Title 21, 
Part 50 (US only) or ISO14155:2011 (Europe, Australia and New Z ealand only) or Tri-Council Policy Statement, 
Article 3.2 (Canada only), and applicable local regulations. Th e Investigator or designee must obtain written 
informed consent/assent before any clinical study related activ ity takes place. Prior to entry into the study, the 
California Experimental Subject‚Äôs Bill of Rights (if applicable ), the IRB/EC and Medtronic-approved Informed 
Consent Form (ICF)/Assent form, and the Health Insurance Portab ility and Accountability Act (HIPAA) 
Authorization Form (US only) will be given to each subject and legally authorized representative (if applicable). 
The Investigator or designee will fully inform the subject of a ll aspects of the clinical study that are relevant to 
the subject‚Äôs decision to participate in the clinical study (e. g. purpose and duration of the study, requirements 
of the subject during the study, potential risks and possible b enefits associated with participation in this study.  
Subjects will be considered enrolled in the study upon signing the Informed Consent/Assent form(s). 
All items addressed in the Informed Consent/Assent Form must be  explained. The language used shall be as 
non-technical as possible and must be understandable to the sub ject or parent/guardian. 
The subject or parent/guardian must have ample time and opportu nity to read and understand the Informed 
Consent/Assent Forms, to inquire about details of the clinical study, and to decide whether or not to 
participate in the clinical study. All questions about the clin ical study should be answered to the satisfaction of 
the subject. 
Neither the investigator, nor the investigation site staff shal l coerce or unduly influence a subject or 
parent/guardian to participate or to continue to participate in  the clinical study. The informed consent process 
shall not waive or appear to waive the subject‚Äôs rights. 
When the subject decides to participate in the clinical study, the California Experimental Subject‚Äôs Bill of Rights 
(if applicable), the HIPAA Form (US only) and the Informed Cons ent/Assent Form must be signed and 
personally dated by the patient or legally authorized represent ative. In the Europe, Canada, Australia and New 
Zealand the investigator or authorized designee must also count ersign the Informed Consent/Assent Form. The 
consenting process must be documented in each subject‚Äôs source files. 
After all persons have signed and dated the Informed Consent/As sent Form, the investigator must provide the 
subject with a fully signed and dated copy. 
Medtronic will inform the investigators whenever information be comes available that may be relevant to the 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 101 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
subject‚Äôs confirmed participation in the clinical study. The in vestigator or his/her authorized designee should 
inform the subject or parent/guardian in a timely manner.  
Medtronic will revise the written Informed Consent/Assent Form whenever new information becomes 
available that may be relevant to the subject‚Äôs confirmed parti cipation in the clinical study. The revised 
information will be sent to the investigator for approval by th e IRB/EC. After approval by the IRB/EC, a copy of 
this information must be provided to the participating subjects , and the informed consent process as described 
above needs to be repeated. 
If the ICF is amended during the course of the study, the IRB/E C will determine: 
xWhether or not active subjects should be re-consented at their next visit and  
xWhether or not subjects who have completed the study at the tim e of the amendment should repeat 
the informed consent process.  
Subjects will be informed that qualified personnel from the inv estigational center, the sponsor (Medtronic), 
agencies such as the FDA/Health Canada/local regulatory authori ty in Europe, Australia, and New Zealand 
and/or the IRB/EC may have access to clinic records that reveal  their identity.  
The investigational center must report the following violations  to their IRB/EC: 
xFailure to obtain informed consent/assent prior to performing o ne or more study procedures. 
xFailure to maintain ICFs on file for all subjects who have prov ided informed consent.  
xUse of an ICF that has not received approval from the IRB/EC. 
xUse of an incorrect version of the ICF.   
 
 5DQGRPL]DWLRQDQG 7UHDWPHQW$VVLJQPHQW
At the end of the run-in period, subjects are randomized to eit her the HCL or the Control arm. Depending on 
the type of therapy subjects are using at the start of the stud y the randomization will be to participate in the 
Hybrid Closed Loop arm or use their own therapy for the duratio n of the study period. Randomization is 
generated via the RDC study database. 
Note: Subjects 2-6 years of age  will automatically enter the H CL arm at the end of the run-in period.  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 102 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
$VVHVVPHQWRI6DIHW\
$GYHUVH(YHQW
The Medtronic Clinical Research Department, in conjunction with  the Regulatory Affairs Department, will 
monitor and manage adverse event reporting for the study and de termine whether the event requires 
reporting to regulatory agencies. The sponsor will ensure timel y Adverse Event reportin g to meet regulatory 
requirements.  
Throughout the course of the study, investigational centers wil l make all efforts to remain alert to possible 
reportable adverse events or untoward findings. The study perso nnel will elicit reports of adverse events from 
the subject at each visit (including phone calls) documenting t he medical diagnosis, date of event start and end, 
causality (relationship to device or procedure), treatment, res olution and description that includes the details 
of the event.  
&DXVDOLW\$VVHVVPHQW
$QDGYHUVHHYHQWLVQRWDXWRPDWLFDOO\UHODWHGWRWKHVWXG\GHYL FHRUSURFHGXUHVLPSO\EHFDXVHWKHVXEMHFWLV
wearing the device and participating in the study. The event sh ould be reviewed to determine if the device or 
study procedure could have possibly caused the event and theref ore is related to the study device or 
procedure. It should also be noted that should the control arm utilize a non-Medtronic device, these would not 
be considered device related.   
Causality assessment is the determination of the relationship b etween an adverse event and the device being 
studied.  It is expected that the investigational center will r eview all elements surrounding the adverse event to 
properly assess the causality of the event to the study device or to a study procedure.  
This review would include the subjects description of the event , study device uploads and medical records (if 
applicable) from the treating facility. These records will be m ade available to sponsor.  
Investigators should classify the relationship between the AE a nd the study device or study procedures using 
one of the five possible causality categories listed below: 
 
xNot related:  relationship to the device or procedures can be e xcluded when: 
Rthe event is not a known side effect of the product category th e device belongs to or of similar 
devices and procedures 
Rthe event has no temporal relationship with the use of the inve stigational device or the 
procedures; 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 103 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Rthe event does not follow a known response pattern to the medic al device (if the response 
pattern is previously known) and is biologically implausible; 
Rthe discontinuation of medical device application or the reduct ion of the level of 
activation/exposure - when clinically feasible ‚Äì and reintroduc tion of its use (or increase of the 
level of activation/exposure), do not impact on the serious eve nt; 
Rthe event involves a body-site or an organ not expected to be a ffected by the device or 
procedure; 
Rthe event can be attributed to another cause (e.g. an underlyin g or concurrent illness/ clinical 
condition, an effect of another device, drug, treatment or othe r risk factors); 
Rthe event does not depend on a false result given by the invest igational device used for 
diagnosis, when applicable; 
Rharms to the subject are not clearly due to use error; 
RIn order to establish the non-relatedness, not all the criteria  listed above might be met at the 
same time, depending on the type of device/procedures and the s erious event. 
 
xUnlikely: the relationship with the use of the device seems not  relevant and/or the event can be 
reasonably explained by another cause, but a relationship to th e device cannot be completely ruled 
out. 
xPossible:  the relationship with the use of the investigational  device is weak. Alternative causes are also 
possible (e.g. an underlying or concurrent illness/ clinical co ndition or/and an effect of another device, 
drug or treatment). Cases where relatedness cannot be assessed should also be classified as possible. 
 
xProbable:  the relationship with the use of the investigational  device seems relevant and/or the event 
cannot reasonably be explained by another cause. 
xCausal relationship: the event is associated with the investiga tional device or with procedures beyond 
reasonable doubt when: 
Rthe event is a known side effect of the product category the de vice belongs to or of similar 
devices and procedures; 
Rthe event has a temporal relationship with investigational devi ce use/application or 
procedures; 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 104 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Rthe event involves a body-site or organ that
¬Éthe investigational device or procedures are applied to; 
¬Éthe investigational device or procedures have an effect on; 
Rthe event follows a known response pattern to the medical devic e (if the response pattern is 
previously known); 
Rthe discontinuation of medical device application (or reduction  of the level of 
activation/exposure) and reintroduction of its use (or increase  of the level of 
activation/exposure), impact on the event (when clinically feas ible); 
Rother possible causes (e.g. an underlying or concurrent illness / clinical condition or/and an 
effect of another device, drug or treatment) have been adequate ly ruled out; 
Rharm to the subject is due to error in use; 
Rthe event depends on a false result given by the investigationa l device used for diagnosis, 
when applicable; 
RIn order to establish the relatedness, not all the criteria lis ted above might be met at the same 
time, depending on the type of device/procedures and the seriou s event. 
 
Example: A severe hyperglycemia adverse event with the followin g event description would have the 
following causality assessment for device relatedness:
Improved glucose without an infusion set/site change Not related
Changed infusion set with glucose improvement  Possible  
Infusion set fell out, bent cannula, occlusion alarm Causal relationship  
 
 
$QWLFLSDWHGRU8QDQWLFLSDWHG
If the adverse event is determined to be related to the study d evice the sponsor will then assess the event 
to determine if it is anticipated or unanticipated. 
xAnticipated:  the event is identified in the CIP; labeling; report of priors /IB or user guide. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 105 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xUnanticipated:  the event has not been previously identified in the CIP; label ing; report of priors/IB, 
Investigator brochure, or user guide
 
5HFRUGLQJ'DWD
In the Oracle Clinical Remote Data Capture (OC-RDC) database, t he investigational centers will be identified 
numerically, i.e. from 001 to 070 (depending on center number).  At the Screening visit, investigational center 
staff will assign each subject a sequential ID number that corr esponds to a pre-defined casebook in the OC-RDC 
database.   
Each case book will contain all relevant Case Report Forms for each subject. Each subject will be assigned a 
unique identifier All study documents, electronic Case Report F orms (eCRFs) and correspondence will use this 
identifier sequence in lieu of a subject‚Äôs name or initials. 
 
 'HYLDWLRQ+DQGOLQJ
A deviation is any instance(s) of failure to follow, intentiona lly or unintentionally, the requirements of the 
protocol. It is expected that the investigator will conduct thi s clinical trial in compliance with the protocol and 
all applicable regulations governing the conduct of clinical re search involving human subjects. Failure to do so 
could result in one or all of the following: 
xObservation in the monitoring report 
xDeviation to document the event 
xCorrective action plan 
xInvestigational center disqualification  
xNotification to the regulatory authorities / IRB/EC depending o n the severity of the deviation and 
reporting requirements 
The investigator is responsible for protecting the safety and w elfare of the clinical research subjects. 
 Reporting of Deviations 
USA (to Sponsor and IRB):  Any deviation from the CIP shall be recorded in eCRF together w ith an explanation 
for the deviation. Notice of deviations from the CIP to protect  the life or physical well-being of a subject in an 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 106 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
emergency shall be given as soon as possible, but no later than  5 working days after the emergency occurred. 
(21 CFR 812.150(a)(4)) 
Europe (Sponsor, Ethics Committee and Regulatory Authority): An y deviation from the CIP shall be recorded in 
eCRF together with an explanation for the deviation. Deviations  shall be reported to the sponsor who is 
responsible for analyzing them and assessing their significance .  
Note: When relevant, ECs, regulatory authorities or the appropr iate regulatory bodies should be informed. (ISO 
14155:2011)  
Notice of deviations from the CIP to protect the life or physic al well-being of a subject in an emergency shall be 
given as soon as possible, but no later than 5 working days aft er the emergency occurred.  
No waivers for deviations from CIP will be allowed.  
Canada, Australia and New Zealand (Sponsor and Ethics Committee ): Any deviation from the CIP shall be 
recorded in eCRF together with an explanation for the deviation . Notice of deviations from the CIP to protect 
the life or physical well-being of a subject in an emergency sh all be given as soon as possible, but no later than 
5 working days after the emergency occurred.  
  
6XEMHFW([LW:LWKGUDZ DORU'LVFRQWLQXDWLRQ
Subjects may choose to withdraw from the study at any time by n otifying investigational center staff of their 
intent.
If a subject chooses to end his or her study participation or i f a subject is removed from the study at the 
Investigator‚Äôs discretion, the reason for termination must be d ocumented both in source documents and on 
the appropriate eCRF. All study devices and supplies must be re turned and the return documented both in 
source documents and on the appropriate eCRF. 
Subjects may also be withdrawn from the study at the discretion  of the Investigator. A subject will be 
withdrawn from the study if: 
xIn the opinion of the Investigator, the subject‚Äôs health or saf ety would be compromised by 
continuing in the study 
xIn the opinion of the Investigator, it is in the subject‚Äôs best  interest to discontinue participation in 
the study 
xDuring the course of the study, subject begins participation in  another investigational study (drug 
or device). 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 107 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xDuring the study it becomes known that subjects are using own S MBG or system that replaces 
SMBG
xDuring the course of the study, subject begins abusing illicit drugs or marijuana. 
xDuring the course of the study subject begins abusing prescript ion drugs.  
xDuring the course of the study subject begins abusing alcohol. 
xDuring the course of the study subject begins using pramlintide  (Symlin), DPP-4 inhibitors, 
liraglutide (Victoza or other GLP-1 agonists), metformin, canag liflozin (Invokana or other SGLT2 
inhibitors). 
xDuring the course of the study, subject begins using hydroxyure a. 
xDuring the course of the study, subject receives red blood cell  transfusion or erythropoietin.       
xDuring the course of the study, the subject demonstrates that h e/she is not able to comprehend 
instructions for study procedures, as evaluated by the appropri ate research staff.  
xDuring the study, subject repeatedly activates SmartGuard when instructed otherwise (e.g. Auto 
Mode is turned on in SAP Cohort) 
xDuring the course of the study, subject is taking oral, injecta ble, or IV glucocorticoids for 3 or more 
weeks (e.g. oral prednisone daily or weekly glucocorticoid admi nistration) 
xDuring the study, (female) subject becomes pregnant. 
xDuring the study, the subject experiences two severe hypoglycem ic episodes  
xThe first episode of Severe Hypoglycemia may lead to withdrawal , if it is secondary to subject non-
compliance or other individual safety concerns:   
RSubject is not using the bolus wizard 
RSubject is not checking blood glucose using finger sticks  
RSubject is non-compliant with sensor wear 
RSubject is not following protocol procedures 
xDuring the study, the subject experiences one  episode of DKA  
xDuring the study subject has a cardiovascular event or any vasc ular event such as stroke.   
Documentation of the reason(s) leading to subject withdrawal wi ll be kept in the subject‚Äôs source file. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 108 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
For Europe only: If patient withdrawal is due to problems relate d to the device safety or performance, the 
investigator shall ask for the subject's permission to follow h is/her status/condition outside the clinical 
investigation. 
 
 
/RVWWR)ROORZXS
/RVWWR)ROORZXSUHIHUVWRDVXEMHFWZKRZDVDFWLYHO\SDUWLFLS DWLQJLQWKHVWXG\EXWLVQRORQJHUNHHSLQJ
VWXG\YLVLWDSSRLQWPHQWVDQGR UIDLOVWRUHVSRQGWRFRPPXQLFDWL RQVIURPWKHLQYHVWLJDWLYHVLWH$VXEMHFWLV
RQO\FRQVLGHUHGWREHORVWWRIROORZXSLQWKHHYHQWWKHLQYHVW LJDWLRQDOFHQWHULVXQDEOHWRGHWHUPLQHWKH
VWDWXVRIWKHVXEMHFW,WLVUHFRPPHQGHGWKDWWKH,QYHVWLJDWLYH VLWH
xDocument at least 2 separate attempts to contact subject by pho ne
xIf no response to phone contact, send the subject a registered letter with return receipt
xRequesting the subject contact the investigational center
xIf there is no response, the subject should be considered lost to follow-up and investigative site 
would withdraw the subject 
,IWKHVXEMHFWFRQWDFWVWKHLQYHVWLJDWLRQDOFHQWHUDQGZLVKHVW RZLWKGUDZWKHVXEMHFWZRXOGQRORQJHUEHORVW
WRIROORZXSEXWLQVWHDGZRXOGEHGRFXPHQWHGDVVXEMHFWZLWKGUD ZLQJFRQVHQWWRFRQWLQXHLQWKHVWXG\  
 
,QYHVWLJDWLRQDO&HQWHU'LVTXDOLILFDWLRQ
Medtronic and/or the IRB/EC retain the right to disqualify an i nvestigational center and remove all study 
materials at any time. Specific instances, which may precipitat e investigational center disqualification, include 
but are not limited to: 
xUnsatisfactory subject enrollment with regard to quality and qu antity. 
xPersistent non-compliance to protocol procedures on the part of  an Investigator/investigational 
center. Inaccurate, incomplete, and/or untimely data recording on a recurrent basis. 
xThe incidence and/or severity of adverse experiences in this or  other studies indicating a potential 
health hazard caused by the device. 
xUnsatisfactory accountability of devices. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ

CEP304DOC Revision H Page 109 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
A written statement fully documenting the reasons for such a te rmination will be provided to Medtronic, the 
Institutional Review Board (IRB) or Ethics Committee (EC) and o ther regulatory authorities, as required. 
6WRSSLQJ5XOHV
6XEMHFW6WRSSLQJ5XOHV
1.One episode of DKA or 2 episodes of severe hypoglycemia will re sult in withdrawal of subject from 
study, regardless of which a rm or period they are in. 
2.The first episode of Severe Hypoglycemia may lead to withdrawal , if it is secondary to subject non-
compliance or other individual safety concerns:   
RSubject is not using the bolus wizard 
RSubject is not checking blood glucose using finger sticks  
RSubject is non-compliant with sensor wear 
RSubject is not following protocol procedures 
 
6WRSSLQJ5XOHVIRU(QWLUH6WXG\
The study will be stopped if DMC determines that there are sign ificant safety issues. (See DMC section.)
Note: If it is decided to withdraw patients from participation in the study or if the study is stopped, subjects 
will be followed-up in accordance with standard practice. 
 
6DIHW\6XFFHVV&ULWHULD
In order to achieve safety success, the following study success  criteria must be met for the HCL Arm by the end of the 
study:
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
CEP304DOC Version H Page 110 of 182  


00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Table 14. Safety Success Criteria 
$GYHUVH(YHQW Reference 5HIHUHQFH5DWH > 25 
years old 5HIHUHQFH5DWH
15-25 years old 5HIHUHQFH5DWH <15 
years old Study Success Criteria 

DKA events per 100 
patient years STAR 3 
Bergenstal et. al  SAP arm: 0.68 
Control arm: 0 SAP arm:  2.7
Control arm: 3.6  SAP arm: 2.2 
Control arm: 0 < 4 events per 100 
patient years with HCL 
arm 
530 G Adult inhome study CEP 266 
(MDT on file) 1.27 3.4 N/A 
530 G Pediatric  
inhome study CEP 287 
(MDT on file) N/A N/A 0 
Type 1 exchange 
Weinstock et. al 4.8 N/A N/A 
Type 1 exchange Cengiz et
 al N/A 9.9
9.9 
 
  
Severe hypoglycemia per 
100 patient years STAR 3
Bergenstal et. al  
SAP  arm: 16.5
Control arm: 20.9 
SAP arm:  5.4
Control arm: 3.9 
SAP arm:  10.2
Control arm: 3.6 < 8 events per 100 
patient years with HCL 
arm 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
CEP304DOC Version H Page 111 of 182  


00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
$GYHUVH(YHQW  Reference 5HIHUHQFH5DWH > 25 
years old5HIHUHQFH5DWH
15-25 years old 5HIHUHQFH5DWH <15 
years oldStudy Success Criteria 
530 G Adult 
inhome study CEP 266 
(MDT on file) 0.85 0 N/A
530 G Pediatric  
inhome study CEP 287 
(MDT on file) N/A N/A 1.42  
Type 1 exchange 
Weinstock et. al 11.8 N/A N/A  
Type 1 exchange Cengiz et
 al N/A 6.2 6.2  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 112 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Descriptive VXPPDU\ (i.enot statistically powered) for severe hypoglycemia and DKA HYHQWV rates will be 
performed between the HCL and control arms for each age group \HDUV\HDUVDQG!\HDUV  as 
well as the overall event rates. 
Severe hypoglycemia and DKA event rates were taken from the fol lowing 
1.Richard Bergenstal et.al: Effectiveness of Sensor-Augmented Ins ulin-Pump Therapy in Type 
1Diabetes.New England Journal of Medicine, 2010; 363:311-20 
2.Weinstock et. al: Severe hypoglycemia and diabetic ketoacidosis  in adults with type 1 diabetes: results 
from the T1D Exchange clinic registry. J Clin Endocrinol Metab.  2013 Aug;98(8):3411-9. 
3.Cengiz et .al:Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the 
T1D Exchange clinic registry. Pediatr Diabetes. 2013 Sep;14(6):447-54.
4.MDT on file: Statistical Analysis Plan (SAP) for CEP304, 056-F2 86 
0HGLFDO2YHUVLJKW
In order to conduct the study, staffing with the appropriate tr aining is required: 
0HGLFDO6WDII
A physician who has managed patients on both CGM and insulin pu mp will be included in the study as the 
principal investigator.
 
4XDOLILFDWLRQ
The investigator (or designee) will need to have one of the fol lowing qualifications; Endocrinology fellowship, 
management in patients with diabetes in a clinical practice. Th e provider must be qualified to treat diabetic 
emergencies. 
 
([SHULHQFH
Investigator (or designee) must also have at least one year exp erience in managing patients with insulin 
carbohydrate ratios and insulin sensitivity ratios in his/her p ractice 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 113 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
6DIHW\0RQLWRULQJ5LVN$QDO\VLV
 *OXFRVH0RQLWRULQJ5LVN
xSubjects will be instructed to use clean fingers when performin g finger stick glucose testing.  Subjects 
will be instructed to test 4-6 times a day and also before driv ing (as applicable).  Subjects will have 
training on diabetes self-management principles.   

+\SRJO\FHPLF+\SHUJO\FHPLF5LVN
xIntervention and treatment for hypoglycemia and hyperglycemia i s addressed in Section 16. 

&DOLEUDWLRQRI&*05LVN
xWhen an erroneous glucose value is used to calibrate a CGM, the  bias is carried through until the next 
opportunity to re-calibrate the CGM. This can result in an inco rrect bias. In order to mitigate this risk, 
every new sensor will have an initial calibration.  

5HXVH5LVN
xAll study devices (including the Serter) will be single patient  use.   

6WHULOL]DWLRQ5LVN
The following devices will be supplied sterilized: 
xInfusion sets 
xInsulin reservoirs 
xGlucose sensors 

0LVXVH5LVN
xComprehensive training will take place for clinical staff regar ding the operation of the HCL, all of its 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 114 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
functional components and all other study devices to be used du ring the study at the investigational 
center initiation visit.  

5LVNRI%ORRG6DPSOH&ROOHFWLRQ&RQWDPLQDWLRQ)URP6DPSOLQJ
7HFKQLTXHV
xDetailed mitigations to blood sampling risk are provided in Sec tion 15. 

$&5LVN
xA Central laboratory will be used for A1C testing and a laborat ory manual will be provided separately. 
A1C is a primary endpoint. For subjects 2-6 years of age, Point  of Care testing is an acceptable 
alternative.
 *OXFRVHDQG*O\FHPLD0HDVXUHPHQWV
*OXFRVHDQG*O\FHPLD0HDVXUHPHQWV
During the course of the study, the subjects‚Äô blood glucose, SG  levels, A1C, and blood ketone, will be assessed 
using the following methods in this section (Section 15).
 
'DLO\%ORRG*OXFRVH
Values will be assessed during the study by all subjects using the Study Meter. The control solution test will be 
done following the manufacturer‚Äôs IFU during Home use. Subjects  will be trained on the use of the Study Meter 
per the manufacturer‚Äôs instructions for use.   
 
%ORRG.HWRQH9DOXHV
Blood ketones will be determined by all subjects using the Keto ne Meter during home use  The control solution 
test will be done following the manufacturer‚Äôs IFU during Home use. Study staff will be trained on the use of 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 115 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
the Ketone Meter per the manufacturer‚Äôs IFU. All ketone measure ments will be recorded on the appropriate 
eCRF upon entry into the Log Book section of CareLink Personal for Clinical Research/CareLink Clinical 
Software.  
Note:  In the event the blood ketone meter is not used by subjects to  collect ketone values, urine ketones must 
be measured and entered appropriately into CareLink as urine ke tones. 
 
6HQVRU*OXFRVH9DOXHV
Assessed using the following methods: 
SG data collected by subject‚Äôs Study Pump and calibrated by sub ject‚Äôs Study Meter 
 
$&
Collected at baseline, will be used as demographic information.  Also collected at various points throughout  
and at end of study.  
 
5LVNVDQG%HQHILWV
3RWHQWLDO5LVNV
Potential Risk with
 Infusion Sets Mitigation 
Potential side effects related to 
infusion sets may include:  
xLocalized infection 
xSkin irritation/redness 
xBruising 
xDiscomfort/pain 
xBleeding 
xIrritation Prevention and mitigation risks of infusion sets include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insertions and care of infusion sets. If an infusion site becomes irritated or inflamed, the infusion set should be removed and another placed in a new location.  
xIn case of hyperglycemia secondary to infusion set 
occlusion subjects will be instructed to remove current 
infusion set and replace with new infusion set and give 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 116 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xRash  
xHyperglycemia secondary 
to infusion set occlusion or site failure  
xHyperglycemia secondary 
to site falling off  correction insulin if needed with syringe. Investigational 
center staff and subjects will be instructed to follow the 
provided user guides for insulin pump management.   
xSubjects will be trained prior to study device use and 
diabetes management principles and told to call with problems.  
 
Potential Risk with Insulin 
Administration and Pump Use Mitigation 
Potential risks associated with the 
use of an insulin infusion pump include the risk of malfunction of the components of the system (pump, software, infusion set and reservoir) as well as the risk of use 
error during use of the 
system.  Device deficiencies or use 
errors can result in administration of too much or too little insulin which can lead to the following clinical consequences: 
xHypoglycemia 
xHyperglycemia 
xDiabetic ketoacidosis (DKA) 
xSevere hypoglycemia with 
or without associated seizure, coma or death 
xKinked cannula leading to 
hyperglycemia 
xInfusion set disconnection 
from pump leading to hyperglycemia 
xDislodged cannula leading 
to hyperglycemia 
xA pump error indicating 
hardware failure may lead to under delivery 
xBattery failure ‚Äì no insulin Prevention and mitigation risks of infusion sets include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insulin pump management.   
xSubjects will be trained prior to study device use and 
diabetes  management principles and told to call with problems.  
xSubjects will be required to check SMBG 4-6  times a day 
and also before driving  (as applicable).  
xSubjects will be told to have glucose on hand for 
hypoglycemia 
xSubject will be told they may need to change their infusion 
set if they suspect catheter occlusion or administer insulin with syringe with persistent hyperglycemia especially if ketones develop.   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 117 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
delivered 
xRemove a reservoir, 
without suspending and reconnecting after a while resulting in a Hypoglycemia 
xInsulin deterioration 
leading to hyperglycemia 
xIncomplete priming; Fails to 
priming tubing and/or 
cannula, leading to 
hyperglycemia 
xRemove a reservoir, 
without suspending and reconnecting after a while resulting in a Hypoglycemia 
xPatient not filling pump 
reservoir when needed 
leading to hyperglycemia 
xMagnetic Resonance 
Imaging resulting in pump /MiniLink malfunction 
xInaccurate insulin delivery 
due to sudden altitude changes. 
xHypoglycemia or 
hyperglycemia from 
manual bolus 
xHypoglycemia or 
hyperglycemia from computer hacking  
 
Risks associated with 
hyperglycemia include  
xDKA 
xSymptomatic ketosis 
xCardiovascular event  
xDehydration  Prevention and mitigation risks include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insulin pump management.   
xSubjects will be trained prior to study device use and 
diabetes management principles.  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 118 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xPotassium and sodium 
imbalance 
xShock 
xAltered mental status  
xComa  
xAcidosis  
Risks associated with hypoglycemia 
include:
xSeizure 
xComa  
xAltered mental status  
xLoss of consciousness  
xCardiovascular event  
xDeath  
xRisk of rebound 
hyperglycemia with ketosis  Prevention and mitigation risks include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insulin pump management.   
xSubjects will be trained prior to study device use device 
and diabetes management principles.  
 
Potential Risk  with Sensor  Mitigation 
Potential risks with Sensor include: 
xSkin irritation or reaction to 
adhesives 
xBruising 
xDiscomfort 
xRedness 
xBleeding 
xPain 
xRash 
xInfection 
xIrritation from tapes used 
with glucose-sensing 
products 
xRaised bump 
xAppearance of a small 
"freckle-like" dot where needle was inserted Prevention and mitigation risks of Sensor include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insertions and care of sensors. If a sensor site becomes infected or inflamed, the sensor should be removed and another placed in a new location. 
xPatients are instructed to use fingerstick glucose reading 
for diabetes management and diabetes management decisions and told to call with problems.   
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 119 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xAllergic reaction
xSyncopal episode 
secondary to needle insertion 
xSoreness or tenderness 
xSwelling at insertion site 
xSensor fracture, breakage 
or damage 
xMinimal blood splatter 
associated with sensor needle removal 
xResidual redness associated 
with adhesive and or tapes 
xScarring 
xIncorrect SG reading results 
in incorrect diabetes management 
xSubject over-treating 
secondary to alarms which can result in hyperglycemia 
or hypoglycemia   
 
Potential Risk with Serter Mitigation 
 
Potential risks with Serter use 
include: 
xSkin infection around the 
area where the Serter is 
used. 
xImproper insertion may 
result in device performance issue   
Prevention and mitigation risks of Serter include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insertions and care of Serters. The investigational centers and subjects will 
receive training on proper use of the Serter and skin 
preparation prior to insertion. 
  
Potential Risk with 
Finger Stick Mitigation 
 
Potential risks with frequent  finger  
Prevention and mitigation risks of finger stick testing include : 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 120 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
stick testing include:
xPotential risks associated 
with frequent meter testing of blood glucose and blood ketones include discomfort and ecchymosis at tips of fingers 
xPotential risks associated 
with drawing blood include 
discomfort and bruising 
xSyncopal episode can occur 
secondary to needle insertion  xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for use of meter with 
fingerstick testing. The investigational centers and subjects will receive training on proper use of the meter and fingerstick testing.  
Potential Risk with HCL Mitigation 
 
Risks for HCL include:  
xHypoglycemia 
xSevere hypoglycemia 
xHyperglycemia 
xDKA 
xUser Entry Error 
RPatient administering 
boluses by entering false carb doses leading to hypoglycemia or 
hyperglycemia 
RPatient entering false 
glucose values for any reason leading to hypo and hyperglycemia  
RPatient entering false 
BG values for 
calibration leading to 
hypo or hyperglycemia 
xSensor failure resulting 
from patient failure to 
calibrate leading to hypo or  
Mitigations specific to the HCL System:   
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insulin pump management.   
xSubjects will be trained prior to study device use and 
diabetes management principles and told to call with problems.  
xSubjects will be required to check SMBG 4-6 times a day 
and also before driving (as applicable).  
xSubjects will be told to have glucose on hand for 
hypoglycemia 
xSubjects will be asked to avoid  the use of products 
containing Acetaminophen 
xIf acetaminophen is taken, subjects will be instructed to 
use additional BG meter readings (they are not to calibrate with those readings) to verify their glucose levels.  
xSubjects will be instructed to exit AutoMode 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 121 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
hyperglycemia 
xSensor over-reading 
resulting in hypoglycemia  
xSensor under-reading 
resulting in hyperglycemia 
xSensor missed 
transmission, or any other fault resulting in no SG value, leading to hyper or 
hypoglycemia  
xVoluntary insulin delivery 
(with the pump or with a syringe) immediately prior to entering HCL may result in severe hypoglycemia despite shutting down insulin delivery by the 
algorithm 
xPatient takes insulin via 
injection while in Closed Loop  
xHypoglycemia or 
hyperglycemia related to entering or exciting closed loop 
xInsulin over-delivery due to 
Acetaminophen 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 122 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
Risks associated with 
hyperglycemia include  
 
xDKA 
xSymptomatic ketosis 
xCardiovascular event  
xDehydration  
xPotassium and sodium 
imbalance 
xShock 
xAltered mental status  
xComa  
xAcidosis  
Prevention and mitigation hyperglycemic risks include: 
 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insulin pump management.   
xSubjects and/or parent guardian will be trained on study 
device and diabetes management principles.  
xSubjects will be trained prior to study device use and 
diabetes management principles.  
xSubjects will be required to check SMBG 4 -6 times a day 
and also before driving (as applicable).  
 
 
Risks associated with 
Hypoglycemia include: 
 
xSeizure 
xComa 
xAltered mental status 
xLoss of consciousness 
xCardiovascular event  
xDeath   
xRebound hyperglycemia 
with ketosis    
Prevention and mitigation of hypoglycemia risks include: 
xInvestigational center staff and subjects will be instructed 
to follow the provided user guides for insulin pump management.   
xSubjects will be trained prior to study device use and 
diabetes management principles.  
xSubjects will be required to check SMBG 4 -6 times a day 
and also before driving (as applicable).  
xSubjects will be told to have glucose on hand for 
hypoglycemia 
 

5LVN0LQLPL]DWLRQ
Refer to Section 16.1, Potential Risks. 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 123 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
3RWHQWLDO%HQHILWV
Subjects are not expected to benefit from participation in this  study; however, they may gain increased 
awareness of emerging technologies for diabetes management as a  result of their participation. 
In Australia, inclusion of the 2-6 years of age group will expa nd our knowledge and provide specific data in this 
region. 
 
5LVN%HQHILW5DWLRQDOH
See sections 14, 16.1, 16.2 and 16.3. In Australia, the Investiga tor Brochure (IB) will be provided to sites.
 
3D\PHQWVIRU3DUWLFLSDQWV
Subjects will be compensated financially for their participatio n, as permitted by local law. 
 
$GYHUVH(YHQW$VVHVVPHQWV
'HILQLWLRQV&ODVVLILFDWLRQV
Medtronic uses the definitions provided in ISO 14155:2011 and 2 1 CFR 812 for adverse event definitions. 
Where the definition indicates ‚Äúdevice‚Äù, it refers to any devic e used in the study. This might be the device 
under investigation, or any market released component of the sy stem. Medtronic will apply causality 
definitions (Section 10.7.2)  across all events, not only serio us adverse events and definitions have been 
adapted accordingly. 
 
$GYHUVH(YHQW$(,62
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal 
laboratory findings) in subjects, users or other persons, wheth er or not related to the investigational medical 
device. 
Note 1: This definition includes events related to the investig ational medical device or the comparator. 
Note 2: This definition includes events related to the procedur es involved. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 124 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Note 3: For users or other persons, this definition is restrict ed to events related to investigational medical 
devices.  
 
 $GYHUVH'HYLFH(IIHFW$'(,62
Adverse event related to the use of an investigational medical device.  
Note 1: This definition includes adverse events resulting from insufficient or inadequate instructions for use, 
the deployment, the implantation, the installation, the operati on, or any malfunction of the investigational  
medical device. 
Note 2: This definition includes any event that is a result of a use error or intentional misuse of the 
investigational medical device.  
 6HULRXV$GYHUVH(YHQW6$(,62
Adverse event that: 
xLed to a death 
xLed to a serious deterioration in the health of the subject, th at either resulted in 
xa life-threatening illness or injury, or 
xa permanent impairment of a body structure or a body function, or 
xin-patient or prolonged hospitalization, or 
xmedical or surgical intervention to prevent life-threatening il lness or injury or permanent impairment 
to a body structure or a body function 
xLed to fetal distress, fetal death or a congenital abnormality or birth defect.  
Note 1: A planned hospitalization for pre-existing condition, o r a procedure required by the CIP, without a 
serious deterioration in health, is not considered to be a seri ous adverse event.  
For the purpose of this study,  Inpatient Hospitalization is defined as: 24 hour acute admissi on to the hospital 
based on urgent medical need rather than elective admission. 
For the purpose of this study, the term "life-threatening" in the definition of "serious" refe rs to an event in 
which the patient was at risk of death at the time of the event ; it does not refer to an event which 
hypothetically might have caused death if it were more severe. (ICH Topic E 2 A Clinical Safety Data 
Management: Definitions & Standards for Expedited Reporting. EM EA 2006) 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 125 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 6HULRXV$GYHUVH'HYLFH(IIHFW6$'(,62 
Adverse device effect that has resulted in any of the consequen ces characteristic of a serious adverse event
 
8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFW8$'(&)5V
Any serious adverse effect on health or safety or any life-thre atening problem or death caused by, or 
associated with, a device, if that effect, problem, or death wa s not previously identified in nature, severity, or 
degree of incidence in the investigational plan or application (including a supplementary plan or application), 
or any other unanticipated serious problem associated with a de vice that relates to the rights, safety, or 
welfare of subjects.
 
8QDQWLFLSDWHG6HULRXV$GYHUVH'HYLFH(IIHFW86$'(,62 

Serious adverse device effect which by its nature, incidence, s everity or outcome has not been identified in the 
current version of the risk analysis report. 
Note 1: Anticipated serious adverse device effect (ASADE) is an  effect which by its nature, incidence, severity or 
outcome has been identified in the risk analysis report 
 
6LJQLILFDQW6DIHW\,VVXH66,$XVWUDOLD1+05&6DIHW\PRQLWRU LQJDQG
UHSRUWLQJLQFOLQLFDOWULDOVLQYR OYLQJWKHUDSHXWLFJRRGV1RYHPE HU
A safety issue that could adversely affect the safety of partic ipants or materially impact on the continued 
ethical acceptability or conduct of the trial.  
 
 8UJHQW6DIHW\0HDVXUH860$XVWUDOLD1+05&6DIHW\PRQL WRULQJDQG
UHSRUWLQJLQFOLQLFDOWULDOVLQYR OYLQJWKHUDSHXWLFJRRGV1RYHPE HU
A measure required to be taken in order to eliminate an immedia te hazard to a participant‚Äôs health or safety. 
Note 1: This type of significant safety issue can be instigated  by either the investigator or sponsor and can be 
implemented before seeking approval from Human Research Ethics Committee (HRECs) or institutions  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 126 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
5HSRUWLQJRI$GYHUVH(YHQWV
The investigator or designee will record ALL adverse events whi le the Subject is enrolled in the clinical study.  
Each AE needs to be assessed for its device or procedure relate dness. A device related AE is associated with the 
use of the study/Medtronic device  (e.g. infection of sensor si te or infusion set occlusion resulting in DKA). A 
procedure related AE is associated with testing related to the study procedures specified in the CIP (e.g. IV 
insertion pain). 
Examples include: 
xDevice related (ADE): insertion site infection 
xSerious adverse device effect: cellulitis at device insertion s ite requiring hospitalization 
xProcedure related AE: bruising at IV insertion site 
xNot related to procedure or device: cold, flu, appendicitis 
Subjects participating in the study have diabetes and are expec ted to experience hypoglycemia and or 
hyperglycemia.  These normal events are not expected to be repo rted to sponsor on an AE eCRF as this is not 
considered an untoward event, but rather an expected occurrence . Any glycemic excursion that meets the 
protocol definition of Severe Hypoglycemia, Severe Hyperglycemi a or DKA is considered an untoward event 
and a worsening from the subject‚Äôs baseline and would be report ed to sponsor on an AE eCRF.  
Baseline medical conditions should only be reported to sponsor on an AE eCRF if there is a worsening from the 
subject‚Äôs baseline.  For example, a subject previously diagnose d with Asthma is hospitalized for severe asthma 
attack would be a reportable event. 
Adverse events will be documented in the subject source file an d reported to sponsor on an eCRF. The 
investigational center is responsible for documentation of adve rse events including obtaining source 
documents related to the event, such as emergency medical techn ician/paramedic reports, hospital records 
(admission summary; lab results, test results, discharge summar y) or device uploads to support the event. 
Source documents will be reviewed to determine if additional ad verse events have occurred and require 
reporting.   
Narratives gathered from completed questionnaires will not prov ide the basis of an adverse event report 
however could lead to discussions that result in the identifica tion of a reportable AE. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 127 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Adverse events that have not resolved at the time of the subjec t‚Äôs discontinuation or completion of the study 
should have an ‚Äúoutcome‚Äù of Not Recovered/Not Resolved at study  end in subject source and on an eCRF. The 
investigator should ensure that subject is aware of any follow- up or additional treatment that is required for 
any ongoing AE at end of study participation; however, there wi ll be no eCRF entry for the ongoing follow-up.  
 
Sponsor Notification: 
Investigator centers should target reporting within 24 hours of  investigator or study coordinator awareness for 
all Severe Hypoglycemia; DKA; Serious Adverse Events; and Serio us Adverse Device Effects to Medtronic. The 
AE eCRF will be completed with all known details within 24 hour s of investigational center awareness ‚Äì this will 
serve as notification to Medtronic. If the study database canno t be accessed due to technical problems, contact 
the sponsor via email at dl.diabetesclinicalresearchsafety@medt ronic.com and provide the known details of 
the event. Once the access issue has been corrected the event s hould be entered onto an AE eCRF.  
Expedited reporting by sponsor to the regulatory authorities  
xDevice related Severe Hypoglycemia events 
xThe sponsor should report device related severe hypoglycemic ev ents for those subjects > 6 
years of age to FDA following notification by investigator prio r to enrollment of subjects 2-6 
years of age and through study completion. 
xOnce enrollment commences for 2-6 year old subjects, the sponso r should report device 
related severe hypoglycemic events to the FDA within 7 days fro m sponsor notification by 
investigator 
xUnanticipated, Device related Severe Hyperglycemia events which  meet SAE criteria (SADE) 
xSponsor will assess and if event is unanticipated, complete exp edited reporting 
xSponsor will follow reporting requirements according to their r egulatory authority requirements. 
 
Expedited Safety Reporting of UADE 
 
UADE: For device studies, investigators are required to submit a report of a UADE to the sponsor and the 
reviewing IRB/EC as soon as possible, but in no event later tha n 10 working days after the investigator first 
learns of the event (21 CFR 812.150(a)(1)).  
For Canada: Investigators are required, per the TPD Investigator Agreement,  to report any incident that is 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 128 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
related to a failure of the device or deterioration in its effe ctiveness, or any inadequacy in its labeling or 
directions for use leading to death or serious deterioration in  a subject‚Äôs health within 72 hours after the 
occurrence (Canada Medical Device Regulations, SOR/98-282; 77, 59.) 
For Europe, Australia and New Zealand: It is the responsibility of the investigator to follow their IR B/EC 
reporting requirements. 
For Australia:  It is the responsibility of the investigator are to report USD AE to their HREC and institution 
without undue delay and no later than 72 hours of the Principal  Investigator becoming aware of the event. 
(NHMRC Safety monitoring and reporting in clinical trials invol ving therapeutic goods November 2016 
section C.2.g) 
 For US, Canada, Europe, Australia and New Zealand: 
The Sponsor will complete safety and vigilance reporting and no tify the investigator and IRB/EC of any event 
that results in a safety report to the regulatory authorities. Documentation of IRB/EC notification of any safety 
event must be kept at the investigational center and a copy sen t to the Sponsor. 
Reporting of Glycemic Events  
Severe Hypoglycemia  is an event requiring assistance of another person due to alte red consciousness 
to actively administer carbohydrate, glucagon, or other resusci tative actions. This means that the 
subject was impaired cognitively to the point that he/she was u nable to treat his or her self, was 
unable to verbalize his or her needs, and was incoherent, disori ented and/or combative.  
These episodes may be associated with sufficient neuroglycopeni a to induce seizure or coma. Plasma 
glucose measurements may not be available during such an event,  but neurological recovery 
attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the 
event was induced by a low plasma glucose concentration. (Adapted from American Diabetes 
Association Workgroup on Hypoglycemia, Diabetes Care 28:1245-12 49, 2005) 
Severe Hyperglycemia is defined as Hyperglycemia (blood glucose  >300 mg/dL (16.7mmol/L)) with 
blood glucose ketones >1.5mmol/L, urine ketones moderate or lar ge, or accompanied by symptoms of 
nausea, vomiting or abdominal pain. 
Diabetic Ketoacidosis/DKA diagnostic criteria: blood glucose gr eater than (>) 250 mg/dL (or greater 
than (>) 13.9 mmol/L), arterial pH less than (<) 7.3, bicarbona te less than (<) 15mEq/L, moderate 
ketonuria or ketonemia, and requiring treatment within a health  care facility. (American Diabetes 
Association-Diabetes Care, Volume 27, Supplement 1, January 200 4; S94-S102) 
Hyperglycemic events will be recorded as DKA if the event inclu des the presence of all of the following: 
xArterial blood pH less than (<)  7.30 or serum bicarbonate less  than (<) 15mEq/L 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 129 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xBlood glucose greater than (>) 250 mg/dL (or greater than (>) 1 3.9 mmol/L) 
xSerum ketones or large/moderate urine ketones 
xSymptoms such as polyuria, polydipsia, nausea, or vomiting 
xTreatment provided in a health care facility 
 
Reporting of Use Errors  
The CEC will review adverse events (AE, including: Serious Adve rse Event, Serious Adverse Device Effect, 
Unanticipated Adverse Device Effect, Severe Hypoglycemia, Diabe tic Ketoacidosis, Severe Hyperglycemia) to 
assess the aspect of critical task, user error, potential harm and severity of harm. Once the adjudication is 
completed, the internal Medtronic team (e.g. clinical, regulato ry, human factors, training and etc.) will assess 
the risk mitigation control and its evidence of effectiveness f or each AE. A use error analysis will be provided to 
FDA every 6 months (Table 15). 
 
Table 15. Use Error Report  
Adverse 
Event # Critical Task Use ErrorPotential 
Harm Severity of 
Harm Risk 
Mitigation 
Control 
(Labeling or 
TrainingEvidence for 
the 
Effectiveness 
of Risk 
Control 
Mitigation 
       
       
 
 
 'DWD5HYLHZ&RPPLWWHHV
&OLQLFDO(YHQWV&RPPLWWHH
A clinical events committee (CEC) consisting of external physic ians with an expertise in Endocrinology and 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 130 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
the management of diabetes including Insulin Pumps and CGM will  be convened. The CEC will review all 
reports of:  
xSerious Adverse Event 
xSerious Adverse Device Effect 
xUnanticipated Adverse Device Effect 
xSevere Hypoglycemia 
xDiabetic Ketoacidosis 
xSevere Hyperglycemia 
 The CEC will assess events to determine agreement or disagreeme nt with the investigator classification of an 
event. The CEC will only provide three causality assessments fo r device and procedure relatedness: Not 
Related, Possible, and Causal relationship. 
 
Causality Categories for 
Investigational Center Causality Categories for CEC: 
xNot Related 
xUnlikely 
xPossible 
xProbable 
xCausal relationship xNot Related 
xPossible 
xCausal relationship 
 
'DWD0RQLWRULQJ&RPPLWWHH
A Data Monitoring Committee (DMC) consisting of external physic ians with an expertise in Endocrinology 
and the management of insulin requiring diabetes including CGM,  along with an external statistician will be 
convened to review study progress and safety. The Board will co nvene approximately every 90 days, until 
at least 2000 Auto Mode patient days in both the 2-6 year and 7 -13 year age groups in the CEP302 and/or 
CEP304 study have been reviewed and approved by the DMC. After review of the patient day report(s), the 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 131 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
meeting cadence will transition to 180 days. The Board will als o meet when ad hoc review is required. 
In addition, the DMC will review interim analysis data, perform ed by an independent statistician, per 
Cohort at the following points in time: 
xAfter 80 subjects from Group 1 (baseline A1c > 8%) have complet ed the first 6 months of the study 
period  
xAfter 80 subjects from Group œÆÕæƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠ƒê—áœ¥–πÕø≈öƒÇ«Äƒûƒê≈Ω≈µ∆â≈Øƒû∆öƒûƒö∆ö≈öƒûƒ®≈ù∆å∆ê∆öœ≤≈µ≈Ω≈∂∆ö≈ö∆ê≈Ωƒ®∆ö≈öƒû ∆ê∆ö∆µƒö«á
period   
The DMC will perform 4 main functions:  
First: DMC will review data related to staged enrollment of sub jects 2-6years of age (Ad Hoc Review) 
xSubjects 2-6 years of age will be allowed to enroll in the post  approval study, once DMC has reviewed   
data from 10 subjects age 2-4 years who have completed particip ation in the study period of the 
CEP302 study and has  given approval to enroll   
xShould an Unanticipated Severe Hyperglycemia event which meets SAE criteria  or a device related 
Severe Hypoglycemia event occur, subjects 2-6 of age will not b e allowed to enroll, unless FDA provides 
approval to include this age group. 
Second:  DMC will track and trend the overall Safety of the study.     
Event rate, defined as number of events per 100 patient years w ill be reviewed by the DMC with respect to 
the following: 
xEvent rate of all SAEs.   
xEvent rate of severe hypoglycemia 
xEvent rate of severe hyperglycemia 
xEvent rate of DKA 
xEvent rate of device related adverse events.   
Applicable information for device related adverse events may in clude: 
xWhether or not the event was unanticipated 
xReview of sensor data from CareLink report (when applicable) 
xReview of pump data from CareLink report (when applicable) 
xMisuse of the device by the user 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 132 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Third: Based on their meetings, DMC will recommend a decision to the sp onsor regarding the following: 
xWhether or not enrollment should be halted.
xWhether or not the entire study will need to be stopped includi ng for those subjects who have 
received study devices already.  
Fourth:  During Interim analysis, independent statistician will perform  sample size re-estimation and report it to 
DMC.  DMC will then provide a recommendation: 
xWhether or not N of enrollment per Group should be increased 
xWhether or not the entire study will need to be stopped for fut ility 
 
General guidance for DMC‚Äôs recommendations to sponsor should be  based on the following:   
In general, a DMC recommendation regarding study stoppage or re sumption of enrollment should be made 
to the sponsor within 1 week of the DMC meeting where the deter mination is made. However, if more data 
i s  n e e d e d ,  t h e  D M C  m a y  m e e t  a g a i n  t o  r e - a s s e s s  t h e i r  d e c i s i o n  w ithin 2 weeks or when required data 
becomes available. 
Review of events may require the following information. Final d isposition may be delayed based on obtaining 
this information:  
xMonitoring by sponsor at site 
xDevice return and failure analysis 
xCareLink upload  and review of CareLink reports  
xSubject clarification to site regarding details about the event  
xSource documents that support event: Paramedic records; ER reco rds; Lab records; Hospital admission 
and discharge summary   
The following factors should be carefully considered in the DMC ‚Äôs recommendation to sponsor:  
Was the severe hypoglycemia or DKA related to the HCL algorithm , or was it related to a known 
insulin pump risk?  For example, a question that may be conside red in DKA would be whether the 
event was related to an infusion set issue or caused by the HCL  algorithm.  
Another important consideration would be if the severe hypoglyc emia, severe hyperglycemia or 
DKA event was related to a device malfunction versus patient no n-compliance. For example, if a 
software anomaly leading to an under-delivery of insulin is dis covered versus the subject 
repeatedly ignoring alarms prompting the subject to take action .  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 133 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Severe hypoglycemia, severe hyperglycemia or DKA caused directl y by an infusion set issue when 
the study pump is functioning as intended would likely result i n acceptance to proceed with the 
study versus severe hypoglycemia or DKA that are directly cause d by the HCL algorithm or a 
device malfunction might stop study enrollment or entire study altogether. 
It should be noted that the final determination of causality re lated to HCL System that is made by 
the DMC may include additional factors which the members consid er to be clinically relevant and 
important. 
The DMC may take into account the thresholds listed below for t he number of subjects 
experiencing hypoglycemia requiring assistance from another per son or DKA to identify when the 
number of subjects experiencing these events exceeds the number  that would be anticipated for 
the study population over the duration of this study. These thr esholds should be interpreted with 
caution due to potential differences in study populations and s tudy design. 
a.Rates taken from Type 1 exchange (Cengiz et. Al, and Weinstock et. Al), are higher than the 
clinical studies STAR 3, 530G adult in-home study (CEP266) and 530G Pediatric in-home 
study(CEP287).   
b.Reasons for lower rates of severe hypoglycemia and DKA in the c linical studies mentioned 
could be related to several factors including but not limited t o the exclusion of those with DKA 
or severe hypoglycemia, additional attention secondary to manda tory study visits, selection 
bias of motivated patients willing to perform study procedures and access to free study devices 
during the course of the study. 
c.The CL outcome study (CEP304) will include several aspects note d above including the 
provision of free study devices during the course of the study.  Therefore, the DMC should 
consider stopping study if rates of severe hypoglycemia and DKA  are significantly worse (e.g. 
higher) in HCL arm than rates provided by clinical trials menti oned in Table 16.   
d.Age consideration may also be factored in by the DMC.  For exam ple, severe hypoglycemia 
rates in those >25 years may be higher than those 25 years and below.       
e.Should DKA and/or severe hypoglycemia occur early in the study,  the DMC should consider 
that the higher event rate may not necessarily represent a sign ificant safety concern.   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
CEP304DOC Version H Page 134 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Table 16. Hyperglycemia/Hypoglycemia / DKA Threshold 
$GYHUVH(YHQW  5HIHUHQFH  5HIHUHQFH5DWH > 25 
years old 5HIHUHQFH5DWH
15-25 years old5HIHUHQFH5DWH <15 
years old 
Severe Hyperglycemia 
events per 100 patient years CER 302 
1$ 1$ 71.64 
DKA events per 100 patient 
years STAR 3 
Bergenstal et. al SAP arm: 0.68
Control arm: 0 SAP arm:  2.7
Control arm: 3.6  SAP arm: 2.2
Control arm: 0 
530 G Adult inhome study CEP 
266 
(MDT on file) 1.27 3.4 N/A 
530 G Pediatric  inhome study 
CEP 287 
(MDT on file) N/A N/A 0 
Type 1 exchange Weinstock et. 
al 4.8 N/A N/A 
Type 1 exchange Cengiz et al N/A 9.9 
9.9 
Severe hypoglycemia per 100 patient years STAR 3
Bergenstal et. al  
SAP  arm: 16.5  
Control arm: 20.9 
SAP arm:  5.4
Control arm: 3.9 
SAP arm:  10.2 
Control arm: 3.6 
530 G Adult inhome study CEP 
266 0.85 0 N/A 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
CEP304DOC Version H Page 135 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
$GYHUVH(YHQW  5HIHUHQFH  5HIHUHQFH5DWH > 25 
years old5HIHUHQFH5DWH
15-25 years old 5HIHUHQFH5DWH <15 
years old
(MDT on file) 
530 G Pediatric  inhome study 
CEP 287 
(MDT on file) N/A N/A 1.42 
Type 1 exchange Weinstock et. 
al 11.8 N/A N/A 
Type 1 exchange Cengiz et al N/A 6.2 6.2
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 136 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Descriptive VXPPDU\ (i.enot statistically powered) for severe hypoglycemia and DKA HYHQWV rates will be 
performed between the HCL and control arms for each age group \HDUV\HDUVDQG!\HDUV  as 
well as the overall event rates. 
Severe hypoglycemia and DKA event rates were taken from the fol lowing: 
1.Richard Bergenstal et.al: Effectiveness of Sensor-Augmented Ins ulin-Pump Therapy in Type 
1Diabetes.New England Journal of Medicine, 2010; 363:311-20 

2.Weinstock et. al: Severe hypoglycemia and diabetic ketoacidosis  in adults with type 1 diabetes: results 
from the T1D Exchange clinic registry. J Clin Endocrinol Metab. 2013 Aug;98(8):3411-9.

3.Cengiz et  al Severe hypoglycemia and diabetic ketoacidosis among youth with  type 1 diabetes in the 
T1D Exchange clinic registry. 3HGLDWU'LDEHWHV 6HS
4.MDT on file: Statistical Analysis Plan (SAP) for CEP304, 056-F2 86 

6WDWLVWLFDO'HVLJQDQG0HWKRGV
 6WDWLVWLFDO0HWKRGVDQG'DWD$QDO\VLV
 *HQHUDO$VSHFWVRI$QDO\VLV
All endpoints are hierarchically ordered and will be evaluated in the fixed sequence from primary endpoints to 
secondary endpoints. Unless the primary endpoints hypotheses ar e rejected, secondary endpoints will not be 
tested.   
Effectiveness endpoints will be evaluated during the 6 month st udy period by individual Cohort (CSII, MDI or 
SAP), stratified by A1C; 
 
xGroup 1: Baseline A1C > 8%  
x'∆å≈Ω∆µ∆âœÆÕóƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π  
 
The comparison of HCL arm vs. Control arm will be performed.  For SG-based comparison between HCL vs 
Control analyses, two weeks of CGM data collected at 3 month vi sit and 6 month visits will be used.   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 137 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

(QGSRLQWVDQG+\SRWKHVHV
 
Primary Safety Endpoints 
The primary safety endpoint is the event rate of severe hypogly cemia and DKA from both Groups (1 & 2) during 
the first 6 months of study phase and second 6 months of contin uation phase. The descriptive summary 
statistics will be presented by number of event and event rate (100 patient years) for severe hypoglycemia and 
DKA separately .  
Descriptive VXPPDU\ (i.e not statistically powered) for severe hypoglycemia and DKA HYHQWV rates will be 
performed between the HCL and control arms for each age group \HDUV\HDUV and !\HDUV as 
well as the overall event rates. 
 
Co-Primary Effectiveness Endpoints 
The primary effectiveness endpoints consist of one-primary endp oint for each group.  
 Group 1 ‚Äì ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—Öœ¥–πÕó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø  
The primary effectiveness endpoints for the baseline A1C > 8% g roup is change in A1C from baseline to end of 
six-month treatment period, defined as A1C measured at the six- month treatment visit minus A1C measured at 
the randomization visit. The goal is to show superiority of the  HCL Arm compared to the Control Arm in 
reducing A1C from baseline to end of six-month treatment period .  
The hypothesis is mathematically expressed as: 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the mean of change in A1C (%) with the HCL Arm,  Œº(Control) is the mean of change in A1C (%) 
with the Control Arm.   
 Group2 ‚Äì ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–πÕód≈ù≈µƒû≈ù≈∂,«á∆â≈Ω≈ê≈Ø«áƒêƒû≈µ≈ùƒêZƒÇ≈∂≈êƒû  
d≈öƒû∆â∆å≈ù≈µƒÇ∆å«áƒûƒ®ƒ®ƒûƒê∆ö≈ù«Äƒû≈∂ƒû∆ê∆êƒû≈∂ƒö∆â≈Ω≈ù≈∂∆öƒ®≈Ω∆å∆ö≈öƒûƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π≈ê∆å ≈Ω∆µ∆â≈ù∆ê∆ö≈öƒû∆ö≈ù≈µƒû«Å≈ù∆ö≈ö^'ƒèƒû≈Ø≈Ω«Åœ≥œ¨≈µ≈êÕ¨ƒö>
(3.9mmol/L) during the six-month study period, defined as perce ntage of SG below 70 mg/dL (3.9mmol/L) out 
of total number of available SG readings. The goal is to show s uperiority of the HCL Arm compared to the 
Control Arm in reducing daily time in hypoglycemic range. The h ypothesis is mathematically expressed as:
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 138 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9 mmol/L) in the HCL Arm, Œº(Control) is 
the subject mean of time with SG below 70 mg/dL (3.9 mmol/L) in  Control Arm.   
 
Key Secondary Effectiveness Endpoints  Group 1 ‚Äì Baseline A1C > 8%: Time in Hypoglycemic Range  The key secondary effectiveness endpoint for the baseline A1C >  8% group is the time with SG below 70 mg/dL 
(3.9mmol/L) during the six-month study period, defined as perce ntage of SG below 70 mg/dL (3.9mmol/L) out 
of total number of available SG readings. The goal is to show n on-inferiority (with a non-inferiority margin of 
2%) of the HCL Arm compared to the Control Arm. The hypothesis of non-inferiority is mathematically 
expressed as:
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø–ΩœÆ–π  
Ha: Œº(HCL) < Œº(Control) + 2% 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9mmol/L) in the HCL Arm, Œº(Control) is 
the subject mean of time with SG below 70 mg/dL (3.9mmol/L) in the Control Arm. 
 
Group2 ‚Äì ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–πÕó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø  
d≈öƒû≈¨ƒû«á∆êƒûƒê≈Ω≈∂ƒöƒÇ∆å«áƒûƒ®ƒ®ƒûƒê∆ö≈ù«Äƒû≈∂ƒû∆ê∆êƒû≈∂ƒö∆â≈Ω≈ù≈∂∆öƒ®≈Ω∆å∆ö≈öƒûƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—á œ¥–π≈ê∆å≈Ω∆µ∆â≈ù∆êƒê≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠ƒ®∆å≈Ω≈µƒèƒÇ∆êƒû≈Ø≈ù≈∂ƒû∆ö≈Ω
end of six-month treatment period, defined as A1C measured at t he six-month treatment visit minus A1C 
measured at the randomization visit. The goal is to show non-in feriority (with a non-inferiority margin of 0.4%) 
of the HCL Arm compared to the Control Arm in reducing A1C from  baseline to end of six-month treatment 
period. The hypothesis of non-inferiority is mathematically exp ressed as:
 
,œ¨Õó—íÕæ,>Õø—à—íÕæ Control) + 0.4% 
Ha: Œº(HCL) < Œº(Control) + 0.4% 
 
where Œº(HCL) is the mean of change in A1C (%) with the HCL Arm,  Œº(Control) is the mean of change in A1C (%) 
with the Control Arm.   
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 139 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Rest of Secondary Effectiveness Endpoints 
Group1+Group 2: Time in Hypoglycemic Range during Night The secondary effectiveness endpoint is the time with SG below 70 mg/dL (3.9mmol/L) during Night. The goal 
is to show superiority of the HCL Arm compared to the Control A rm reducing time in hypoglycemic range 
during night . The hypothesis is mathematically expressed as:
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9mmol/L) in the HCL Arm during night, 
Œº(Control) is the subject mean of time with SG below 70 mg/dL ( 3.9mmol/L) in the Control Arm during the 
night.   
 Group1+Group 2: Time in Hypoglycemic Range during Day and Night  
The endpoint of time in hypoglycemic range below 70 mg/dL (3.9m mol/L) will be evaluated for superiority in 
the combined Groups during day and night. The goal is to show s uperiority of the HCL Arm compared to the 
Control Arm in reducing time in hypoglycemic range. The hypothe sis is mathematically expressed as: 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the subject mean of time with SG below 70 mg/dL  (3.9 mmol/L) in the HCL Arm, Œº(Control) is 
the subject mean of time with SG below 70 mg/dL (3.9 mmol/L) in  the Control Arm.   
 
Group1+Group 2: Time in Target Range 70mg/dL (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) during Night 
The endpoint of time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) ‚Äì 180 
mg/dL (10.0mmol/L) during Night. The goal is to show superiorit y of the HCL Arm compared to the Control Arm 
in improving the time in target range. The hypothesis is mathem atically expressed as:
H0: Œº(HCL) ‡µë Œº(Control)   
Ha: Œº(HCL) > Œº(Control) 
where Œº(HCL) is the subject mean of time with SG between 70mg/d L (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) 
range in the HCL Arm during Night, Œº(Control) is the subject me an daily time with SG between 70mg/dL 
(3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) range in the Control Arm. 
 Group1+Group 2: Time in Target Range 70mg/dL (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) during Day and 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 140 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Night
The endpoint of time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) ‚Äì 180 
mg/dL (10.0mmol/L) during Day and Night. The goal is to show su periority of the HCL Arm compared to the 
Combined Control Arm in improving the time in target range. The  hypothesis is mathematically expressed as:  
H0: Œº(HCL) ‡µë Œº(Controls)   
Ha: Œº(HCL) > Œº(Controls) 
where Œº(HCL) is the subject mean of time with SG between 70mg/d L (3.9mmol/L) ‚Äì 180 mg/dL (10.0mmol/L) 
range in the HCL Arm during Day and Night, Œº(Control) is the su bject mean daily time with SG between 
70mg/dL (3.9mmol/L)  ‚Äì 180 mg/dL (10.0mmol/L) range in the  Con trol Arm. 
 
Group1+Group 2: Change in A1C The endpoint of change in A1C will be evaluated for superiority  in the combined groups. The goal is to show 
superiority of the HCL Arm compared to the Control Arm in reduc ing A1C from baseline to end of six-month 
treatment period. The hypothesis is mathematically expressed as : 
,œ¨Õó—íÕæ,>Õø—à—íÕæ≈Ω≈∂∆ö∆å≈Ω≈ØÕø  
Ha: Œº(HCL) < Œº(Control) 
where Œº(HCL) is the mean of change in A1C (%) with the HCL Arm,  Œº(Control) is the mean of change in A1C (%) 
with the Control Arm. 
 
 
 
 
 
 
   
 PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 141 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 142 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
   
 
5DQGRPL]DWLRQ
For each Cohort (CSII, MDI or SAP) subjects will be randomized to HCL and Control Arm with a 1:1 ratio for 
greater than 6 years of age. 2-6 years of age subjects will aut omatically enter the HCL arm at the end of the 
run-in period.  
 
The randomization will be stratified by the diabetes management  therapies at time of enrollment and baseline 
A1c categories: 
 Diabetes Management Therapies(Cohort): 
xCSII: Insulin pump therapy without CGM  
xMDI   
xSAP: Insulin pump therapy with CGM 
 Baseline A1C categories(Group): 
xƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π  
xBaseline A1C >8% 
Randomization will be based on a total of four strata per Cohor t. In each stratum, block randomization will be 
used to divide potential patients into 2m blocks of size of 2n (block size can be different for each stratum). 
Please note that MDI group will be further stratified to equal number of subjects without CGM and with CGM. 
The clinical team and investigators are blind to the block size . Equal amount of subjects will be enrolled for 
ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–π≈ê∆å≈Ω∆µ∆âƒÇ≈∂ƒöƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—Öœ¥–π≈ê∆å≈Ω∆µ∆âÕò  
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 143 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
6WXG\3RSXODWLRQV
,QWHQWLRQWR7UHDW,773RSXODWLRQ
The primary study population is the Intention to Treat (ITT) po pulation, which consists of all randomized 
subjects. 
 Per Protocol (PP) Population 
The Per Protocol (PP) population will include all randomized su bjects who complete the trial without any major 
deviations, have worn the sensor for both Arms (Control ƒÇ≈∂ƒö,>ÕøƒÇ≈∂ƒö≈öƒÇ«Äƒû∆µ∆êƒûƒö∆µ∆ö≈Ω≈µ≈ΩƒöƒûÕæ,>≈Ω≈∂≈Ø«áÕøƒ®≈Ω∆å—à
80% of the time. In addition, those subjects who take steroids after randomization will be excluded from PP 
population. Primary effectiveness endpoints and key secondary e ndpoints will be evaluated for PP Population. 
 
Safety Population The Safety Population will be all enrolled subjects. 
 
$QDO\VLVRI(QGSRLQWV
 
Primary Effectiveness Endpoints:   Test will be tested against the 0.025 (one-sided) significance level and both have to be met to claim success for 
the associated Cohort.  
 
Group1 ‚Äì ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—Öœ¥–πÕó≈öƒÇ≈∂≈êƒû≈ù≈∂œ≠Õæ—êœ≠Õø  
The initial univariate analysis for this endpoint will be an an alysis of covariance at six months.  If the computed 
F-statistic has a one-sided P<0.025 (can be computed from the t wo-sided F-statistic by taking the square root 
and comparing to a one-sided t-statistic), the null hypothesis will be rejected in favor of the alternative,  Other 
supporting analysis including multivariable modeling may also b e done to support this finding. 
 
Group2 ‚Äì ƒÇ∆êƒû≈Ø≈ù≈∂ƒûœ≠—áœ¥–πÕód≈ù≈µƒû≈ù≈∂,«á∆â≈Ω≈ê≈Ø«áƒêƒû≈µ≈ùƒêZƒÇ≈∂≈êƒû  
The initial univariate analysis for this endpoint will be an an alysis of covariance F-test at six months.  If the 
computed F-statistic has a one-sided P<0.025 (can be computed f rom the two-sided F-statistic by taking the 
square root and comparing to a one-sided t-statistic), the null  hypothesis will be rejected in favor of the 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 144 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
alternative.  Other supporting analysis including multivariable  modeling may also be done to support this 
finding. 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
  
 
 
 
    PIPIPI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 145 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
  
 

 

 
 
 
 
 
   
 
 
 
 
 
 PI
PI
PI
PI
PI
PI
PI
PI
PI PI
PIPI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 146 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH


   
  


 
  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PI
PI
PI
PI
PI
PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 147 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
    
 
 
 
 
 PI
PI
PI
PI
PI
PI
PIPI PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 148 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
    
 
 
 
 
 
 
 
 
 PI PI
PI PI
PI
PII
PI
PI
PIPI
PI
PI
PIPI
PI
PIPI
PI
PI
PIPI
PI
PI
PI
PI
PI PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 149 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 PIPI
PI
PI
PI
PI
PI
PI PI
PI
PI
PI
PI
PI PIPI
PI PIPI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 150 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PI
PI
PIPI
PI
PI
PI PI
PIPI
PI PI
PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 151 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
where    
 
 
 PI
PIPI
PI PI
PI
PI
PI
PI
PI PI PI
PI
PI
PI
PIPIPI
PI PI
PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 152 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
  
  
 
 
 
 
 
 
 
 
 

 

 
 
 
 
  
 
 
 
 
 
 
 
  
  PI
PI
PIPI
PI
PI
PI PI
PI PI
PIPI
PI PI
PI PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 153 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
  
  
  
  
 
  
  
  
  
 
  
 
 
 
 
 
 
 
 
 
 
  
 

 
 
 
 
  
 PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 154 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
 
 
 
  
 
 
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
 
 
 
 . PIPI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 155 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
  
 
 
  
 
 
  
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
   
  PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 156 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
 
 
  
  
  
 
  
   
     
    
 &RGLQJRI$GYHUVH(YHQWV
Adverse events will be coded based on the latest version of the  Medical Dictionary for Regulatory Activities 
(MedDRA) thesaurus.  
 
 
 
 (WKLFV
Risk Determination  
 
In the opinion of the sponsor, this study is considered to be a  significant risk (SR) study.  Results of an 
evaluation of the requirements per 21 CFR Part 812.3, led to th e SR determination as follows: 
xThe devices could present a potential for serious risk to subje ct health, safety or welfare. 
xThe devices are for a use of substantial importance in treating  disease, and presents potential for 
serious risk to subject health, safety or welfare. 
Therefore, for subjects 2-13 years of age, submission of an Inv estigational Device Exemption (IDE) application PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 157 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
to the United States Food and Drug Administration is required
Medtronic Inc. maintains appropriate clinical study liability i nsurance coverage as required under applicable 
laws and regulations and will comply with applicable law and cu stom concerning specific insurance coverage. If 
required, a Clinical Trial Insurance statement/certificate will  be provided to the IRB/EC. 
 
Institutional Review Board (IRB) / Ethics Committee (EC) 
This protocol, any subsequent amendments to this protocol, the Informed Consent/Assent form, subject 
material and any form of subject recruitment information (e.g. advertisements) relating to this study will be 
approved by the responsible EC/IRB in accordance with 21 CFR Pa rt 56 in the US, ISO 14155:2011, Declaration 
of Helsinki and local ethic requirements, as applicable. The st udy will not start until IRB/EC approval has been 
granted, the Sponsor has cleared the investigational center to begin the study, and the investigational clinical 
staff has been appropriately trained to conduct the study. Copi es of all relevant correspondence between the 
investigational center and the IRB/EC will be retained at inves tigational center and the Sponsor files.  
If the ethic committee imposes any additional requirements (e.g . safety reports, progress reports etc.), 
Medtronic will prepare the required documents and send them to the respective authority. 
 
Regulatory Submission
  
Where submission to the regulatory authority is required per lo cal law, no patients will be enrolled in the 
clinical study until the particular regulatory authority has ap proved the current Clinical Investigation Plan of the 
clinical study and other documents as required according to the  local requirements. 
If the regulatory authority imposes any additional requirements  (e.g. safety reports, progress reports etc.), 
Medtronic will prepare the required documents and send them to the respective authority. 
Regulatory Compliance 
In Canada, Europe, Australia and New Zealand this clinical stud y will be conducted in compliance with the 
Declaration of Helsinki 2013, the international standard ISO 14 155:2011 ('Clinical Investigation of medical 
devices for human subjects'), as well as laws and regulations o f the country/ies in which the clinical study is 
conducted (including data protection laws). Europe is also comp liant with FDA regulations 21 CRF Part 11 and 
21 CRF Part 54, and EU MDR.   
In Canada, SOR/98-282 will also be followed. 
In the US, this clinical study will be conducted in compliance with the Declaration of Helsinki 2013, the Clinical 
Investigation Agreement, the Clinical Investigation Plan, FDA r egulations CFR, Title 21, Part 54 (Financial 
Disclosure by Clinical Investigators), CFR, Title 21, Part 11 ( Electronic Records; Electronic Signatures),  21 CFR 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 158 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Part 812 (Investigational Device Exemptions), 21 CFR Part 56 (I nstitutional Review Boards) , 21 CFR Part 50 
(Informed consents) and all other applicable federal and local regulatory requirements. 
All principles of the Declaration of Helsinki have been impleme nted in this clinical study by means of the 
informed consent process, IRB/EC approval, study training, clin ical trial registration, preclinical testing, risk 
benefit assessment, publication policy, etc. 
 
Ethical Considerations 
The sponsor will avoid improper influence on, or inducement of the subject, monitor, and investigator(s) or 
other parties participating in, or contributing to, the clinica l study by implementing the informed consent 
process, Clinical Investigation Agreements and IRB/EC approval.  Pediatric patients (2-21 years) will be involved 
in this study and will be provided with assent as applicable. 
 
6WDWHPHQWVRI&RPSOLDQFH
The investigator or person designated by the investigator will document and explain any deviation from the 
approved protocol that occurs during the course of the clinical  trial. The date and reason for each deviation will 
be documented. (21 CFR 812.140 Records for US/ ISO14155:2011 9. 6g for Europe, Australia and New Zealand) 
The investigator should not implement any deviation from, or ch anges of, the protocol without agreement by 
the sponsor and prior review and documented approval/favorable opinion from the IRB/EC of an amendment, 
except where necessary to eliminate an immediate hazard(s) to t rial subjects, or when the change(s) involves 
only logistical or administrative aspects of the trial (e.g., c hange of monitor(s), change of telephone number(s)). 
The investigator may implement a deviation from, or a change in , the protocol to eliminate an immediate 
hazard(s) to trial subjects without prior IRB/EC approval/favor able opinion. As soon as possible, the 
implemented deviation or change, the reasons for it, and, if ap propriate, the proposed protocol amendment(s) 
should be submitted: 
xTo the IRB/EC for review and approval/favorable opinion 
xTo the sponsor for agreement and, if required 
xTo the regulatory authority or authorities 
Except in an emergency, prior approval by the sponsor, regulato ry authorities and IRB/EC is required for 
changes in or deviations from a plan, and if these changes or d eviations may affect the scientific soundness of 
the plan or the rights, safety, or welfare of human subjects. ( 21 CFR 812.35(a)) for US / ISO14155:2011 4.5.4 b)) 
. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 159 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
In any emergency situation the investigator shall exercise his/ her judgment to safeguard the subject‚Äôs interest. 
The investigator shall report a deviation as soon as possible t o Medtronic and the reviewing IRB/EC, according 
to IRB/EC reporting guidelines, as applicable. Medtronic will i nform the regulatory authorities, if required. 
Emergency deviations must be reported to the sponsor and IRB/EC  within 5 days. In Australia, clinical trials 
with unapproved medical devices require reporting of serious br eaches by investigator and sponsor. 
The following examples are deviations that could impact subject  safety, affect the integrity of study data 
and/or affect subject‚Äôs willingness to participate in the study . These deviations are significant and require 
immediate sponsor notification upon investigator awareness:  
xFailure to obtain informed consent, i.e., there is no documenta tion of informed consent 
xInformed consent obtained after initiation of study procedures 
xEnrollment of a subject who did not meet all inclusion/exclusio n criteria 
xPerforming study procedure not approved by the IRB/EC 
xFailure to report serious adverse event to the IRB/EC and spons or 
xInvestigational study device dispensed without obtaining inform ed consent 
Medtronic is responsible for analyzing deviations, assessing th eir significance, and identifying any additional 
corrective and/or preventive actions (e.g. amend the CIP, addit ional training, terminate the study, etc.). 
Repetitive or serious investigator compliance issues may result  in the need to initiate a corrective action plan, 
and in some cases freeze enrolment or ultimately terminate the investigator‚Äôs participation in the clinical study 
(see section 10.9). 
The investigator will propose any appropriate modification(s) o f the Clinical Investigation Plan or 
investigational device/product or investigational device/produc t use. Medtronic will review this proposal and 
decide whether the modification(s) will be implemented.  
Medtronic will submit any significant amendment to the Clinical  Investigation Plan, including a justification for 
this amendment, to the appropriate regulatory authorities and t o the investigators to obtain approval from 
their IRB/EC. The investigator will only implement the amendmen t after approval of the IRB/EC, regulatory 
authority and sponsor. Administrative amendments to the Clinica l Investigation Plan will be submitted to the 
IRB/EC for notification. Furthermore investigators shall sign a ny approved amendment for agreement: 
 'HYLFH'HILFLHQFLHVDQG7URXEOHVKRRWLQJ
The Medtronic 24-Hour Technical Support (TS) or local service p rovider will be consulted for device 
troubleshooting  (e.g. assistance is needed by subject to operate their device(s) ). When subjects call the local 
TS, they are instructed to notify the TS operator that they are  currently participating in a clinical study. All 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 160 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
device deficiencies  that are reported to the TS will be documen ted by the TS staff. 
Medtronic will review all device deficiencies and determine whe ther the deficiency requires reporting to 
regulatory agencies; vigilance reporting includes all devices t hat are CE marked in Europe. The sponsor will 
ensure timely Device Deficiency reporting to meet regulatory re quirements. 
Note: For commercially available devices, device deficiency rep orting will be documented per study and 
relevant regulatory requirements 
Depending on the country, the investigational center will be pr ovided with a copy of all TS calls for their 
subjects. The TS calls should be reviewed for investigational c enter staff awareness and for the possibility of an 
AE. If an AE is detected the investigational center staff will also complete an AE eCRF. 
In the US , all device deficiencies reported directly to the investigatio nal center staff by a subject should either 
be reported to the TS by the subject or investigational center staff.  
In Europe Canada, Australia and New Zeland  all device deficiencies reported directly to the investigation al 
center staff by a subject and should be documented on a Device Deficiency eCRF.  
A device deficiency is any communication that alleges inadequac y of a medical device with respect to its 
identity, quality, durability, reliability, safety, or performa nce. NOTE: Device deficiencies include malfunctions, 
use errors, and inadequate labeling. ( Adapted from ISO14155:2011 3.15 ) 
In the US, Canada, Europe, Australia and New Zealand: While 24-Hour TS may direct the return/replacement 
of study devices, all such transactions will be managed by inve stigational centers directly. Subjects are asked to 
call the 24-Hour TS for help with the troubleshooting of device s.  
It is the responsibility of the Investigator to follow the cent er‚Äôs IRB/EC and local regulatory authority 
reporting requirements. 
For Europe Canada, Australia and New Zealand: Device deficiencies that did not lead to an Adverse Event, but could have led to an SADE require immediate 
reporting to the sponsor via completion of the applicable CRF. In addition, follow the  IRB/EC and regulatory 
authority reporting requirements per ISO14155:2011 if any of th e  following apply: 
a) if either suitable action had not been taken, b) if intervention had not been made, or c) if circumstances had been less fortunate  
In Australia: All device deficiencies for investigational devic es with potential SADE need to be reported by 
investigator without unjustified delay (NHMRC Safety monitoring  and reporting in clinical trials involving 
therapeutic goods November 2016 section C.2.b). 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 161 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
6WXG\$GPLQLVWUDWLRQ
 0RQLWRULQJ
Monitoring will be conducted to ensure the protection and safet y of human subjects, the quality and integrity 
of the clinical data, and compliance with the protocol.  The Mo nitoring Plan will give details on how and when 
data review will be conducted by clinical monitors. It will be updated and revised as needed due to changes in 
documents or processes.  
Employees of the Sponsor, or its designees, who have received a ppropriate training, will serve as the Study 
Monitor(s). Monitoring visits will be conducted based on Medtro nic‚Äôs Standard Operating Procedures and the 
needs of the study. Quality documents will be followed for the conduct of all activities related to monitoring 
for this study.    
Site Qualification and Initiation Visits will be completed prio r to enrollment of the first subject.  On Site study 
monitoring activities will include an inspection of completed s tudy documents, source document verification 
and reporting, verification of database accuracy and completene ss.  All subjects enrolled in the trial will be 
monitored and the eCRF data verified against the subjects‚Äô sour ce documents.  Following each monitoring visit, 
a report will be prepared and submitted to the Sponsor.  From i nitiation of study to close out visit, the Study 
Monitor(s) will assume primary responsibility for communication s between the Study Investigators and the 
Sponsor. 
The Principal Investigator is responsible for ensuring that inv estigational center staff is appropriately trained to 
manage the protocol.  Initial and ongoing investigational cente r training will be provided during the Site 
Initiation Visit, subsequent monitoring visits, and regular inv estigational center contact.  All investigational 
center staff must complete and sign the Study Training Record(s ) and maintain the record(s) in the 
investigational center regulatory binder. Prior to enrollment o f the first subject, Investigators and study 
coordinators who will be participating in enrollment, eCRF comp letion, device insertion/application, device 
training, and consenting subjects must complete the Sponsor-req uired training. Investigators and staff who are 
actively engaged in the study after the start of subject enroll ment must complete all required training before 
their involvement starts. 
All monitoring visits and visits from the Sponsor to the invest igational center will be recorded using the 
Monitoring Visit Log. The log will be kept in the investigation al center regulatory binder and the original will be 
collected and submitted to the sponsor. 
 
'DWD0DQDJHPHQW
All data required for analysis will be captured on eCRFs using OC-RDC module.  Original eCRFs will not be 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 162 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
considered as source data and supporting documentation will be required.  However, in cases where center-
administered, web-based subject questionnaires are considered s ource data, said source data is electronic and 
associated systems must comply with CRF 21 Part 11 requirements .  Electronic device data will be collected 
from the MiniMed  Pump System using Medtronic CareLink Personal  for Clinical Research/CareLink Clinical 
Software. The system uses TLS technology, which encrypts all da ta it stores (21 CFR Part 11 compliant). Certain 
data points stored in the uploaded information may also be capt ured on the appropriate eCRF.  
The Investigator will ensure that all eCRFs are completed promp tly, completely, and accurately. Information on 
case report forms must conform to the information in the source  documents.  Medtronic will provide detailed 
instructions to assist with eCRF completion. In the event of da ta discrepancies, investigational centers will be 
asked to resolve queries electronically in the RDC system; othe rwise, irresolvable data-related issues will be 
routed to the Sponsor for review and final disposition. An audi t trail is maintained in OC-RDC to capture any 
corrections or changes of the eCRFs. If a person is only author ized to complete CRFs or to make changes to an 
already signed CRF, the investigator shall re-sign this CRF. Sy stem backups for data stored in the OC-RDC 
system will be consistent with Medtronic standard procedures. 
Medtronic will only consider eCRFs to be complete when all disc repancies between source data and eCRF have 
been resolved and eCRF content has been reviewed by a Study Mon itor. In addition, specific eCRFs must also 
be reviewed and electronically signed by the Investigator, indi cating his/her agreement with the accuracy of all 
recorded data. It is expected that the Investigator and his/her  staff will cooperate with the monitoring team 
and provide any missing data in a timely manner. 
 
'DWD3UHSDUDWLRQ
Prior to data extraction, all collected data will undergo a fin al verification by Data Management.  
Documentation of this verification will be maintained in the sp onsor study files.  Upon the completion of the 
verification, data will be extracted and transferred to the app ropriate personnel for analysis.  
 
6WXG\%LQGHUV
Investigator Binders will be provided by the Sponsor to be main tained by the designated investigational center 
staff. Each binder will have tabs to facilitate filing of study  documents. Examples include: 
x Medtronic Contact Information 
xCV‚Äôs & Medical Licenses 
xAgreement(s) 
xDelegation of Authority Log 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 163 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xTraining Records 
xRandomization Documentation (if applicable) 
xLaboratory Documentation 
xSubject Identification Log 
xScreening Log 
xCase Report Forms (CRFs) & Instructions  
xSponsor/Monitor Visit Log 
xInvestigator Brochure (IB) 
xProtocol and Amendments 
xDevice Instructions for Use (IFU) 
xIRB/EC Documentation & Approvals 
xIRB/EC Approved Consent Documents 
xIRB/EC approved Investigator‚Äôs Brochure/ Report of Priors 
xRegulatory Authority approval or notification 
xFinancial Disclosures  
xInsurance certificates, where applicable 
xReports  
xEssential Correspondence 
xProduct Accountability 
xRegulations and Guidance Documents 
xSite Study Materials 
xSubject Study Materials 
xNote to File 
xMiscellaneous 
xRelevant communication  
 
There will be an individual file for each subject which will in clude, but will not be limited to: 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 164 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
xSource Documents 
xSigned and dated Informed Consents/Assents 
xAdverse Event Notifications, if any 
xQuestionnaires 
xStudy Logs, if any 
 
For Europe, Australia and New Zealand: The investigator will cl early mark the clinical records to indicate that 
the subject is enrolled in this clinical study.Where copies of the original source document as well as printouts of 
original electronic source documents are retained, these shall be signed and dated by a member of the 
investigational site team with a statement that it is a true re production of the original source document. 
 
'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV
Medtronic reserves the right to conduct quality audits at the i nvestigational centers in order to verify 
adherence to external regulations as well as internal policies and procedures, to assess adequacy and 
effectiveness of clinical policies and procedures, to assure co mpliance with critical study document 
requirements, to confirm integrity and accuracy of clinical stu dy data and to protect the safety, rights and 
welfare of study subjects. 
These audits are done in addition to the regular monitoring vis its.  
Regulatory bodies may also perform inspections at participating  investigation sites. Any regulatory authority 
inspection announcements shall be forwarded immediately to the sponsor contact person. 
The investigator and/or institution shall permit Medtronic and regulatory bodies direct  access to source data 
and documents, taking into account any restrictions due to loca l law, to perform clinical study-related 
monitoring, audits, EC/IRB review, and regulatory inspections. 
 
 &RQILGHQWLDOLW\
The investigator will ensure that the subject‚Äôs anonymity is ma intained.  Subjects will not be identified in any 
publicly released reports of this study.  All records will be k ept confidential to the extent provided by federal, 
state and local law.   The study monitors and other authorized representatives of the Sponsor may inspect all 
documents and records required to be maintained by the Investig ator, including but not limited to, medical 
records.  The investigator will inform the subjects that the ab ove-named representatives will review their 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 165 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
study-related records without violating the confidentiality of the subjects. All laboratory specimens, evaluation 
forms, reports, and other records that leave the site will be i dentified only by the subject identification code in 
order to maintain subject confidentiality.  All records will be  kept locked and all computer entry and 
networking programs will be done with coded numbers only. 
 
/LDELOLW\
Medtronic maintains appropriate clinical study liability insura nce coverage as required under applicable laws 
and regulations and will comply with applicable local law and c ustom concerning specific insurance coverage. If 
required, a clinical study insurance statement/certificate will  be provided to the EC. 
 
 &,3$PHQGPHQWV
When an amendment is required, the CIP will be forwarded to FDA  and applicable regulatory authorities 
outside the United States for approval. Upon receipt of regulat ory authority approval, the document will be 
version controlled using the next version number in succession,  e.g. A to B. After the document is released by 
Medtronic‚Äôs document control system, it will be submitted to al l applicable regulatory agencies, IRBs and Ethics 
Committees for review and approval. Individual investigational centers may not enroll subjects under the 
amended investigational plan until Regulatory/IRB/Ethics approv als have been obtained including, if applicable, 
a revised Informed Consent.  
 
 5HFRUG5HWHQWLRQ
The Sponsor and Investigator will retain all records and docume nts pertaining to this study. They will be 
available for inspection by the appropriate regulatory agencies . In addition, the Investigator will retain the 
source documents from which the information entered on the eCRF  was derived. These records are to be 
retained in a secure storage facility maintained by the investi gational center until 2 years (or longer if local laws 
require) after approval of the above-listed study devices or te rmination of the study, whichever is longer. The 
Investigator should not dispose of these records without the ap proval of the Sponsor. The investigator should 
take measures to prevent accidental or early destruction of the  clinical study related materials.  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 166 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ
The contents of this protocol, the manuals pertaining to this s tudy and the results of the investigation are 
confidential and may not be published or disclosed without the written consent of Medtronic Diabetes.  The 
identity of the subjects may not be disclosed, unless required by law, to any persons not immediately involved 
in the study or the study procedures. The results of the clinic al study will be submitted for publication and 
handled according to Standard Operating Procedures. 
 
6XVSHQVLRQRU(DUO\7HUPLQDWLRQ
This study will be conducted at up to 70 investigational center s where all study-related activities will take place; 
at each center, the study will be led by a principal investigat or. Per 21 CFR 812.3(i), Investigator  means an 
individual who actually conducts a clinical investigation, i.e. , under whose immediate direction the test article 
is administered or dispensed to, or used involving, a subject, or, in the event of an investigation conducted by a 
team of individuals, is the responsible leader of that team.  
It is expected that the investigator(s) are familiar with the r egulations governing the conduct of clinical 
research on human subjects. Guidance for Industry Investigator Responsibilities ‚Äì Protecting the Rights, Safety, 
and Welfare of Study Subjects provides clarification for invest igators and sponsors. 
 FDA‚Äôs expectations concerning the investigator‚Äôs responsibilit y  
(1)to supervise a clinical study in which some study tasks are del egated to employees or colleagues of the 
investigator or other third parties and 
(2) to protect the rights, safety, and welfare of study subject s 
 The investigator‚Äôs responsibilities include: 
xEnsuring that a clinical investigation is conducted according t o the signed investigator statement for 
clinical investigations of medical devices, the investigational  plan, and applicable regulations set forth 
in 21 CFR Part 812 and all other applicable regulations, and an y conditions of approval imposed by an 
IRB/EC or regulatory requirements. 
xMedtronic contracts with participating institutions/investigato rs through a Clinical Trial Agreement 
that defines the scope and responsibilities and associated comp ensation related to carrying out the 
obligations under a clinical study sponsored by Medtronic. 
xProtecting the rights, safety, and welfare of subjects under th e investigator‚Äôs care 
RProviding reasonable medical care for study subjects for medica l problems that arise during 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 167 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
participation in the trial that are, or could be, related to th e study intervention
RProviding reasonable access to needed medical care, either by t he investigator or by another 
identified, qualified individual (e.g., when the investigator i s unavailable, when specialized care 
is needed) 
RAdhering to the protocol so that study subjects are not exposed  to unreasonable risks 
xControlling devices under investigation (21 CFR 812.100 for US / ISO14155:2011 6.9 for Europe, 
Australia & New Zealand and in accordance with Canadian regulat ions where applicable). 
xInvestigator is responsible for providing adequate supervision of those to whom tasks have been 
delegated. The investigator is accountable for regulatory viola tions resulting from failure to adequately 
supervise the conduct of a clinical study.  
xEnsuring that informed consent is obtained from each subject in  accordance with 21CFR Part 50 for the 
US, Tri-Council Policy Statement, Article 3.2 for Canada and IS O14155:2011 for Europe, Australia & 
New Zealand and that the study is not commenced until regulator y authority and IRB/EC approvals 
have been obtained.  
xSupervising the use of investigational device. In US, an invest igator shall permit an investigational 
device to be used only with subjects under the investigator‚Äôs s upervision. In US, an investigator shall 
not supply an investigational device to any person not authorize d under 21 CFR Part 812 to receive it. 
In Europe and Australia, the investigational devices shall only  be used in the clinical investigation and 
according to the protocol (ISO14155:2011 6.9). 
xDisposing of device properly. Upon completion or termination of  a clinical investigation or the 
investigator‚Äôs part of an investigation, or at the sponsor‚Äôs re quest, an investigator shall return to the 
sponsor any remaining supply of the device or otherwise dispose  of the device as the sponsor directs.  
xContinuously monitoring, assessing and documenting risks  
xAn investigator shall maintain at a minimum the following accur ate, complete and current records 
relating to the investigator‚Äôs participation in an investigatio n (21 CFR 812.140 140 for US, 
ISO14155:2011 7.4 for Europe, Australia and New Zealand):
xCorrespondence with another investigator, an IRB/EC, the sponso r, a monitor or FDA/ local regulatory 
authority in Europe, Australia and New Zealand. 
xRecords of receipt, use or disposition of study devices 
xRecords of each subject‚Äôs case history and exposure to the stud y devices 
xDocuments showing the dates of and reasons for each deviation f rom the protocol 
xAny other records the FDA/ local regulatory authority in Europe , Australia & New Zealand requires to 
be maintained by regulations or by specific requirement for a c ategory of investigations or a particular 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 168 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
investigation
xInvestigators are required to permit FDA/ local regulatory auth ority to inspect and copy any records 
pertaining to the investigation including, in certain situation s, those which identify subjects.(21 CFR 
812.145 in US / ISO14155:2011 6.7) 
xAn investigator shall prepare and submit the following complete , accurate, and timely reports 
 
Table 17. Investigator records and reporting responsibilities a pplicable to the United States 
Report  Submit To  Description/Constraints  
Withdrawal of IRB 
approval (either 
suspension or termination)  Sponsor  An investigator shall report to the sponsor, within 5 working 
days, a withdrawal of approval by the reviewing IRB of the 
investigator's part of an investigation. (21 CFR 
812.150(a)(2)).  
Progress report  Sponsor and IRB  The investigator must submit this report to the sponsor and 
IRB at regular intervals, but in no event less than yearly. (21 
CFR 812.150 (3)) .  
Study deviations  Sponsor and IRB  Notice of deviations from th e CIP to protect the life or 
physical well-being of a subject in an emergency shall be given as soon as possible, but no later than 5 working days after the emergency occurred. (21 CFR 812.150(a)(4))  
Failure to obtain IC 
prior to investigational 
device use  Sponsor and 
IRBs  If an investigator uses a device without obtaining informed 
consent, the investigator shall report such use within 5 
working days after device use. (21 CFR 812.150(a)(5))  
Final investigator 
report Sponsor, IRB s 
and Relevant 
Authorities  This report must be submitted within 3 months of study 
completion or termination of the investigation or the 
investigator‚Äôs part of the investigation. (21 CFR 
812.150(a)(6))  
Other IRB and FDA An investigator shall, upon request by a revi ewing IRB, FDA 
or any other regulatory agency, provide accurate, complete, and current information about any aspect of the investigation. (21 CFR 812.150(a)(7))  
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 169 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Table 18. Investigator Reports Applicable to Europe 
Report  Submit To  Description/Constraints  
Withdrawal of MEC 
approval Sponsor  The investigator must report a withdrawal of approval by 
the reviewing MEC of the investigator‚Äôs part of the 
investigation within 5 working days of the date of 
withdrawal. (Medtronic Requirement)  
Progress Report  Sponsor and Ethics 
Committee Provide if required by local law or EC.  
(ISO 14155:2011)  
Study Deviations  Sponsor and Ethics 
Committee and 
Regulatory Authority  Any deviation from the CIP shall be recorded together with 
an explanation for the deviation. Deviations shall be 
reported to the sponsor who is responsible for analyzing them and assessing their significance.  
Note: When relevant, ECs, regulatory authorities or the 
appropriate regulatory bodies should be informed. (ISO 
14155:2011)  
Notice of deviations from the CIP to protect the life or 
physical well-being of a subject in an emergency shall be given as soon as possible, but no later than 5 working days 
after the emergency occurred.  
Final investigator 
report Ethics Committee 
and Relevant 
Authorities  This report must be submitted within 3 months of study 
completion or termination of the investigation or the 
investigator‚Äôs part of the investigation.   
Table 19. Investigator Reports Applicable to Canada 
Report  Submit To  Description/Constraints  
Withdrawal of 
Ethics Committee approval Sponsor  The investigator must report a withdrawal of approval by 
the reviewing Ethics Committee of the investigator‚Äôs part of the investigation within 5 working days of the date of withdrawal. (Medtronic Requirement)  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 170 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Report  Submit To  Description/Constraints  
Progress Report  Sponsor and Ethics 
Committee  Provide if required by local law or EC.   
Study Deviations  Sponsor and Ethics 
Committee  Any deviation from the CIP shall be recorded together with 
an explanation for the deviation.  
Notice of deviations from the CIP to protect the life or 
physical well-being of a subject in an emergency shall be 
given as soon as possible, but no later than 5 working days 
after the emergency occurred.  ( Medtronic Requirement)  
Final investigator 
report Ethics Committee 
and Relevant Authorities  This report must be submitted within 3 months of study 
completion or termination of the investigation or the investigator‚Äôs part of the investigation. (Medtronic 
Requirement)  
 
Table 20 Investigator Reports Applicable to Australia  
Report  Submit To  Description/Constraints  
Withdrawal of 
Ethics Committee approval Sponsor  The investigator must report a withdrawal of approval by the 
reviewing Ethics Committee of the investigator‚Äôs part of the investigation within 5 working days of the date of withdrawal.   
Progress Report  Sponsor and 
Ethics Committee  Provide if required by local law or EC.   
Study Deviations  Sponsor and 
Ethics Committee Any deviation from the CIP shall be recorded together with an 
explanation for the deviation. Notice of deviations from the CIP to protect the life or physical well-being of a subject in an 
emergency shall be given as soon as possible, but no later 
than 5 working days after the emergency occurred.   
Final Investigator 
Report  Ethics 
Committee and 
Relevant Authorities  This report must be submitted within 3 months of study 
completion or termination of the investigation or the 
investigator‚Äôs part of the investigation.   
Serious Breaches by Sponsor, Investigator shall report any susp ected breaches to the 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 171 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Report  Submit To  Description/Constraints  
Investigator or 
Sponsor 
(Pre-market 
requirement) Institution‚Äôs 
Research Governance 
Office, Ethics 
Committee, or Principal Investigator as applicable sponsor and confirmed serious breaches to their institution 
(research governance office) within 72 hours of becoming aware or notified of the same; provide any follow-up 
information as required and work with the institution or 
sponsor, as appropriate, to implement any corrective and preventative actions by sponsor shall report serious breaches to the reviewing HREC and PI within 7 calendar days of confirming a serious breach has occurred and provide follow-
up reports when required 
Australia - Serious Breach: A breach of Good Clinical Practice 
or the protocol that is likely to affect to a significant degre e:  
a) The safety or rights of a trial participant,or b) The reliab ility 
and robustness of the data generated in the clinical trial. 
Significant Safety Issues
(Pre-market 
requirement) Sponsor, HREC 
and institutionUrgent Safety Measure (USMs): Within 24 hours (NHMRC 
Safety monitoring and reporting in clinical trials involving 
therapeutic goods November 2016 section C.2.c) 
All other significant safety issues: without undue delay and no  
later than 72 hours of the principal investigator becoming aware of the event (NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods November 2016 
section C.2.g) 
 
 
Table 21 Investigator Reports Applicable to New Zealand 
Report  Submit To  Description/Constraints  
Withdrawal of 
Ethics Committee 
approval Sponsor  The investigator must report a withdrawal of approval by 
the reviewing Ethics Committee of the investigator‚Äôs part of 
the investigation within 5 working days of the date of 
withdrawal. (Medtronic Requirement)  
Progress Report  Sponsor and Ethics 
Committee  Provide if required by local law or EC.   
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 172 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Report  Submit To  Description/Constraints  
Study Deviations  Sponsor and Ethics 
Committee  Any deviation from the CIP shall be recorded together with 
an explanation for the deviation.  
Notice of deviations from the CIP to protect the life or 
physical well-being of a subject in an emergency shall be 
given as soon as possible, but no later than 5 working days after the emergency occurred.   
Final investigator 
report Ethics Committee 
and Relevant Authorities  This report must be submitted within 3 months of study 
completion or termination of the investigation or the investigator‚Äôs part of the investigation.   
 
 
xTo the sponsor and IRB/EC (per their requirements): 
RAny unanticipated adverse device effect occurring during an investigation. (Due no later than 
24 hours after the investigator first learns of the effect) 
xIt is prohibited to promote and commercialize a device that has  not been first cleared or approved for 
marketing by the FDA (per IDE re gulations) or local regulatory authority in Europe,Canada, Australia or 
New Zealand.  
xThe principal investigator(s) are required to assess whether or  not to continue the clinical study at the 
respective investigation site.  
xThe principal investigator(s), his/her delegate(s) and the stud y coordinator(s) shall be accessible to 
Medtronic personnel. This accessibility is of particular import ance for reviewing data in the Case 
Report Form (CRF). Direct access to patient medical files for s ource data verification will need to be 
granted and prepared prior to any monitoring visits 
xSponsor will inform the clinical investigators of termination o r suspension and the reasons and inform 
the regulatory authorities, where required. 
The investigator‚Äôs signature on the Investigator Statement conf irms that the investigator is familiar with the 
protocol in its entirety and agrees to conduct this study in ac cordance with the provisions of the protocol and 
all applicable regulations.  The investigator, prior to the ini tiation of any study related activity, will sign the 
Investigator Statement. If the Sponsor discovers that an Invest igator is not complying with the Investigator 
Statement, investigational protocol, or other regulatory requir ements, the Sponsor shall promptly secure 
compliance or discontinue that Investigator‚Äôs participation in the study. 
 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 173 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
6WXG\&ORVXUH3URFHGXUHV
Upon completion of the study, when all subjects have completed their visit schedules (all eCRFs have been 
entered and all related queries have been resolved), all study devices, unused study materials and equipment 
will be collected and returned to Medtronic and/or its designee s. Medtronic and/or its designees will notify the 
investigational center of its intention to close out the study and a close-out visit will be conducted. The 
Monitor will ensure that the Investigator‚Äôs regulatory files ar e up-to-date and complete and that any 
outstanding issues from previous visits have been resolved. Oth er issues that will be reviewed at this visit 
include discussing retention of study files, possibility of inv estigational center audits, and notifying the IRB/EC 
of study closure. 
 
 5HIHUHQFHV
American Diabetes Association. Hyperglycemic Crises in Diabetes . Diabetes Care. 2004; 27(1) S94-S102. 
American Diabetes Association Workgroup on Hypoglycemia. Defini ng and Reporting Hypoglycemia in 
Diabetes, Diabetes Care. 2005. 28: 1245-9. 
Diabetes Research in Children Network (DirecNet) Study Group; T ype 1 Diabetes TrialNet Study Group, 
Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer  SA, DiMeglio LA, Bremer AA, Slover R, 
Cantwell M. The effects of inpatient hybrid closed-loop therapy  initiated within 1 week of type 1 diabetes 
diagnosis. Diabetes Technol Ther. 2013. May;15(5):401-8. 
Medtronic, HCL Outcomes Study Clinical Study Training Protocol. Weinzimer et. al: Fully Automated Closed 
Loop Delivery versus Semi-Automated Hybrid Control in Pediatric  Patients with Type 1 diabetes using the 
Artificial Pancreas. Diabetes Care, 2008, 31:934-939.  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 174 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
$SSHQGLFHV
$SSHQGL[$&(3&RKRUW9LVLW7DEOH+&/$UP
Refer to excel sheet labeled as ‚ÄúCEP304_ Cohort Visit Table_HCL  Arm‚Äù. 
 
$SSHQGL[%&(3&RKRUW9LVLW7DEOH&6,,$UP
Refer to excel sheet labeled as ‚ÄúCEP304_ Cohort Visit Table_CSI I Arm‚Äù. 
 
$SSHQGL[&&(3&RKRUW9LVLW7DEOH0',$UP
Refer to excel sheet labeled as ‚ÄúCEP304_ Cohort Visit Table_MDI  Arm‚Äù. 
 
$SSHQGL['&(3&RKRUW9LVLW7DEOH6$3$UP
Refer to excel sheet labeled as ‚ÄúCEP304_ Cohort Visit Table_SAP  Arm‚Äù. 
 
  
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 175 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
9HUVLRQ+LVWRU\
Version Summary of Changes Author(s)/Title
A xNot applicable, New Document  
 
B xCorrected visit schedule  
xRevised Statistical Section 
xUpdated Visit Tables 
xRevised Subject Stopping Rules 
xRevised Safety Section according to new Meddev 
regulations  
xDeleted redundancies 
xRevised Visit Schedule 
xRevised DMC Section 
xRevised Study and Continuation Period 
Summaries 
xUpdated Inclusion Criteria 
xRevised Safety Success Criteria table  
 
C xCorrected Visit Schedule Tables 
xUpdated device classifications 
xRevised inclusion/exclusion criteria 
xRevised device accountability tables 
xRevised Risk/Mitigations tables  
 
D xUpdated references of EMEA to Europe 
xAdded reference to StartRight program for HCL 
subjects  
 PI
PI
PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 176 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
xUpdated device classifications and device 
numbers 
xUpdated and corrected Visit Schedule Tables and 
transferred visit tables into Appendix. 
xUpdated study procedures (includes run-in period 
window and additional study visits for each group after Auto Mode is turned on) 
xRevised inclusion/exclusion criteria 
xUpdated subject withdrawal or discontinuation 
criterias 
xUpdated subject stopping rules 
xRevised device accountability tables 
xUpdated Adverse Events Assessment section 
xRemoved statement about regulatory submission 
in Israel 
xModified pediatric distribution for enrollment in 
CSII cohort. 
xTransferred to updated version of Medtronic 
corporate branded form CIP template (Version 3.0) 
xMoved CIP version history table to end of 
document 
xUpdated Packaging section‚Äì removed 
investigational labeling statement for US and added statement that copies of labeling for study devices will be provided under separate cover 
xUpdated device descriptions for infusion sets, 
reservoirs and infusion set serter devices 
xProvided information about subjects who are 
Freestyle Libre users at time of screening 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 177 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
xProvided information about telemedicine visits
xUpdated Product Training Requirements section 
to expand to be more generic on who supports the sites  
xAdded Liability section to align with CIP required 
elements 
xUpdated IRB/Ethics requirements  
xUpdated Device Deficiencies and Troubleshooting 
section 
E xSee ‚ÄúCEP304 Summary of Protocol Changes, 
Version D to E‚Äù  
 
F xUpdated study devices status for Canada 
xStatement updated to reflect investigational 
devices in US for subjects 2-6 years age group  
xUpdated protocol to reflect CE marked devices 
xUpdated Run-in and Study period - additional 
clarification to the blinded CGM section 
xPermitted MDI subjects with concurrent CGM to 
enroll 
xUpdated sample size number during study period 
for Cohort 2: MDI subjects 
xAdded sensor insertions should proceed with 
approved User Guide 
xInclusion criteria #6 updated 
xRemoved exclusion criteria #1 
xAdded Early withdrawal procedures  
xAdded rescreening  
xAdded exploratory analysis  
 PI
PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 178 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
xUpdated safety sections
xAdded Severe Hyperglycemia adverse event 
reference rates from the CEP302 Clinical study 
xUpdated Visit Schedule Tables 
xMade changes to Exploratory analysis section 
regarding alert performance  
xAdded statement regarding SMBG confirmation 
upon low alert 
xAdded statement regarding investigational 
labeling requirement to visit table attachments in 
each cohort 
xRe-arranged devices according to age group in 
synopsis and Table 7.2 
xFor details on protocol changes, see ‚ÄúCEP304 
Description of Protocol Changes, Version E to F‚Äù 
G xUpdated part numbers to reflect correct numbers. 
xDeleted references to the 670G system to allow 
for inclusion of the 770G system. 
xAdded 770G system and devices to reflect 770G 
system approval and use in the US and other 
geographies. 
xUpdated study duration to 6.5 years, enrollment 
completion to 54 months, Table 5 and Table 6 to account for a slow-down in pediatric enrollment. 
Deleted Chart 1 and Chart 2. 
xUpdated the minimum requirement per cohort  
xUpdated minimum eligible subjects table to 
facilitate recruiting. 
xUpdated the Inclusion criteria remove TSH  
 PI
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 179 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
requirement for subjects 2-13 years of age. 
xChanged randomization for 2-6 year olds so that 
all enrolled subjects will participate in the study group only 
xUpdated telemedicine requirements 
xUpdated Medtronic CareLink Clinical Therapy 
Management Software name to reflect the correct product name. 
xUpdated the treatment cohort statement to allow 
for transition to the 770G system in US and 
Canada. 
xAdded the Contour Next Link 2.4 Blood Glucose 
Meter to the list of investigational devices for US subjects 2-6 years. 
xUpdated product status headings and bullets for 
clarity. 
xDeleted note on StartRight program. 
xUpdated visit scheduling to avoid visit window 
overlap. 
xAdded explanation of remote monitoring for 
pediatric patients. 
xUpdated Table 7 to reflect correct numbers for 
parts distributed in Canada. Added footnotes for clarity. 
xAdded Table 8 to reflect addition of 770G to the 
study. 
xUpdated Table 9 to incorporate 770G pump and 
related devices. Split Guardian Sensor (3) into 2 rows to account for difference in disbursement to subject. 
xUpdated Table 10 to remove part numbers for 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 180 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
Canada and update device disposition. 
xUpdated Table 11 to incorporate 770G pump and 
related devices. Split Guardian Sensor (3) into 2 rows, correct part numbers and update 
disbursement to subject. 
xAdded Table 12 and 13 to reflect Australian and 
New Zealand requirements. 
xAdded Reporting of Use Errors section per FDA 
guidance. 
xUpdated document to align new EUMDR 
guidelines which includes name of the local sponsor contact, specific language related to public databases (e.g., clinicaltrials.gov), product accountability, deviations, Europe record 
retention requirement, regulatory compliance 
statement, glossary, and investigator statement. 
xUpdated Investigator Statement name to reflect 
the correct name of form. 
xUpdated trademark notation to conform with 
updated trademarking by Ascensia. Contour Next 
Link is no longer owned by Bayer. 
xUpdated Clinical Study Type for clarity. 
xUpdated Schedule of Events introduction 
xUpdated Early Withdrawal description for clarity. 
xCorrected MDI Cohort Visit 7 description.  
xUpdated document to reflect new CIP 
xtemplate requirements, including Study Site 
Requirement section, section heading titles,  Lost to Follow-up definition, Risk Minimization section, updated document footer, study binder tab list, and Aspects of Analysis section header. 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 181 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
xUpdated Causality Assessment description for 
clarity. 
xUpdated AE Assessment section headings for 
clarity. 
xUpdated AE, SAE, and ADE definitions for clarity. 
xUpdated Sponsor Notification for clarity. 
xUpdated Introduction  to include recent study 
results. 
xUpdated Blue Adapter CareLink Clinical 
Application and Guardian Link (3) descriptions for 
clarity. 
xUpdated glossary to reflect new abbreviations. 
xUpdate 24-Hour HelpLine to 24-Hour Technical 
Support. 
xUpdated Device Deficiencies and Troubleshooting 
section for clarity. 
xAdded new reference to References section. 
xUpdated Appendix section to reflect the correct 
file names. 
xUpdated the Cohort Appendices to remove the 
TSH, A1C, and c-peptide requirement for subjects 2-13 years of age.  
xCorrected small typographical errors throughout 
the document. 
xUpdated date and version number to reflect new 
version of CEP. 
xUpdated Version History. 
xFor detailed information, see ‚ÄúCEP304 Summary 
of Protocol Changes, Version F to G.‚Äù 
&(3&OLQLFDO,QYHVWLJDWLRQ3ODQ
  
CEP304DOC Revision H Page 182 of 182  

00HGWURQLF%XVLQHVV5HVWULFWHG
&21),'(17,$/ )5HY)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Version Summary of Changes Author(s)/Title
H xAdded copyright statement to Glossary. 
xUpdated sponsor contacts to correct titles. 
xRemoved sponsor contact name/title for Canada. 
xUpdated Section 1 heading to conform to 
template. 
xUpdated Primary Objective section to include 
additional detail. 
xAdded Data Collection section to conform to 
template. 
xUpdated Sample Size Considerations to include 
updated subject availability statement.  
xAdded number of subjects currently enrolled to 
synopsis and study design sections to address FDA request 
xCorrected small typographical errors throughout 
the document. 
xUpdated date, version number and document 
footer to reflect new version of CEP. 
xUpdated Version History. 
xUpdated page headers, and section titles to 
conform to corporate template updates.  
xFor detailed information, see ‚ÄúCEP304 Summary 
of Protocol Changes, Version G to H‚Äù.  
 
PI